<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001266.pub4" GROUP_ID="ARI" ID="560799081614134709" MERGED_FROM="" MODIFIED="2015-03-02 22:02:40 +0000" MODIFIED_BY="Liz Dooley" REVIEW_NO="A024" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2015-03-02 22:02:40 +0000" MODIFIED_BY="Liz Dooley">
<TITLE NOTES="&lt;p&gt;Authors used US English&lt;/p&gt;&lt;p&gt;June 2014: Copy editor's comments and Authors' replies:&lt;/p&gt;&lt;p&gt;Abstract/Results&lt;br&gt;&amp;#8220;In eight inpatient studies, there was no change in average clinical score (standardized MD (SMD) -0.14, 95% CI -0.41 to 0.12)&amp;#8230;&amp;#8221; Should this be nine? (Analysis 1.4.1). &lt;i&gt;&lt;b&gt;Karadag 2005 is one study with two bronchodilator arms (ipratropium and albuterol). Therefore it is counted as one study, leaving a total of eight inpatient studies.&lt;/b&gt; &lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&amp;#8220;In nine outpatient studies, the average clinical score decreased slightly with bronchodilators (SMD -0.42, 95% CI -0.79 to -0.06)&amp;#8230;&amp;#8221; Should this be 12? (Analysis 1.4.2). &lt;i&gt;&lt;b&gt;Anil 2010, Gadomski 1994a and Gadomski 1994b are all individual studies with two arms of bronchodilators.&lt;/b&gt;&lt;/i&gt; &lt;i&gt;&lt;b&gt;They are counted as single studies, leaving a total of nine outpatient studies.&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&amp;#8220;Sub-analyses limited to nebulized albuterol or salbutamol among outpatients (nine studies)&amp;#8230;&amp;#8221; One of the sub-analyses has 10 studies and another has eight. &lt;i&gt;&lt;b&gt;There were a total of nine outpatient studies using nebulized albuterol or salbutamol alone. All of these measured oxygen saturation. One of them, Anil 2010, had two dosing arms.&lt;/b&gt;&lt;/i&gt; &lt;i&gt;&lt;b&gt;Only eight of the albterol/salbutamol studies measured clinical score, one of them being Anil 2010. &lt;/b&gt;&lt;/i&gt;&lt;br&gt;&lt;br&gt;Characteristics of included studies&lt;br&gt;Quite a few of the &amp;#8216;Risk of bias&amp;#8217; tables have empty &amp;#8216;Support for judgement&amp;#8217; cells. Is that correct?&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;b&gt;Yes. We provided support for judgement for all &amp;#8220;unclear&amp;#8221; or &amp;#8220;high&amp;#8221; risk of bias items.&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;">Bronchodilators for bronchiolitis</TITLE>
<CONTACT MODIFIED="2015-03-02 22:02:40 +0000" MODIFIED_BY="Liz Dooley"><PERSON ID="8511" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anne</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Gadomski</LAST_NAME><POSITION>Research Scientist</POSITION><EMAIL_1>gadomski@usa.net</EMAIL_1><EMAIL_2>anne.gadomski@bassett.org</EMAIL_2><ADDRESS><DEPARTMENT>Research Institute</DEPARTMENT><ORGANISATION>Bassett Medical Center</ORGANISATION><ADDRESS_1>1 Atwell Road</ADDRESS_1><CITY>Cooperstown</CITY><ZIP>13326</ZIP><REGION>New York</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 607 5473066</PHONE_1><FAX_1>+1 607 5476914</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-03-02 22:02:40 +0000" MODIFIED_BY="Liz Dooley"><PERSON ID="8511" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anne</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Gadomski</LAST_NAME><POSITION>Research Scientist</POSITION><EMAIL_1>gadomski@usa.net</EMAIL_1><EMAIL_2>anne.gadomski@bassett.org</EMAIL_2><ADDRESS><DEPARTMENT>Research Institute</DEPARTMENT><ORGANISATION>Bassett Medical Center</ORGANISATION><ADDRESS_1>1 Atwell Road</ADDRESS_1><CITY>Cooperstown</CITY><ZIP>13326</ZIP><REGION>New York</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 607 5473066</PHONE_1><FAX_1>+1 607 5476914</FAX_1></ADDRESS></PERSON><PERSON ID="78607892404564981348100301215504" ROLE="AUTHOR"><FIRST_NAME>Melissa</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Scribani</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>melissa.scribani@bassett.org</EMAIL_1><ADDRESS><DEPARTMENT>Computing Center</DEPARTMENT><ORGANISATION>Bassett Medical Center</ORGANISATION><ADDRESS_1>1 Atwell Road</ADDRESS_1><CITY>Cooperstown</CITY><ZIP>13326</ZIP><REGION>New York</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 607 547 7635</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-01-23 22:41:23 +1000" MODIFIED_BY="Sarah Thorning">
<UP_TO_DATE>
<DATE DAY="20" MONTH="1" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="1" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="1" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2015-03-03 08:01:40 +1000" MODIFIED_BY="Liz  Dooley">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2015-03-03 08:01:40 +1000" MODIFIED_BY="Liz  Dooley">
<DATE DAY="3" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>Feedback comment published</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-02-27 07:26:55 +1000" MODIFIED_BY="Liz  Dooley">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-02-27 07:26:55 +1000" MODIFIED_BY="Liz  Dooley">
<DATE DAY="20" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>Searches updated. We included two new studies (<LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>) and excluded 17 new trials (<LINK REF="STD-Absar-2008" TYPE="STUDY">Absar 2008</LINK>; <LINK REF="STD-Alansari-2013" TYPE="STUDY">Alansari 2013</LINK>; <LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>; <LINK REF="STD-Belcastro-2010" TYPE="STUDY">Belcastro 2010</LINK>; <LINK REF="STD-Del-Vecchio-2012" TYPE="STUDY">Del Vecchio 2012</LINK>; <LINK REF="STD-Florin-2012" TYPE="STUDY">Florin 2012</LINK>; <LINK REF="STD-Frasson-2012" TYPE="STUDY">Frasson 2012</LINK>; <LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>; <LINK REF="STD-John-2006" TYPE="STUDY">John 2006</LINK>; <LINK REF="STD-Karaatmaca-2010" TYPE="STUDY">Karaatmaca 2010</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Luo-2012" TYPE="STUDY">Luo 2012</LINK>; <LINK REF="STD-Modaressi-2012" TYPE="STUDY">Modaressi 2012</LINK>; <LINK REF="STD-Ren-2011" TYPE="STUDY">Ren 2011</LINK>; <LINK REF="STD-Sezer-2010" TYPE="STUDY">Sezer 2010</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>; <LINK REF="STD-Simsek_x002d_Kiper-2011" TYPE="STUDY">Simsek-Kiper 2011</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-02-27 07:26:52 +1000" MODIFIED_BY="Liz  Dooley">
<DATE DAY="20" MONTH="1" YEAR="2014"/>
<DESCRIPTION>
<P>We expanded the sensitivity analyses to include studies using the Respiratory Distress Assessment Instrument. A subgroup analysis of albuterol and salbutamol did not change our conclusions. Four previously excluded studies of epinephrine versus placebo were omitted from this update (<LINK REF="REF-Hariprakash-2003" TYPE="REFERENCE">Hariprakash 2003</LINK>; <LINK REF="REF-Kristj_x00e1_nsson-1993" TYPE="REFERENCE">Kristjánsson 1993</LINK>; <LINK REF="REF-Lowell-1987" TYPE="REFERENCE">Lowell 1987</LINK>; <LINK REF="REF-Wainwright-2003" TYPE="REFERENCE">Wainwright 2003</LINK>), due to the Cochrane Review 'Epinephrine for bronchiolitis' (<LINK REF="REF-Hartling-2011a" TYPE="REFERENCE">Hartling 2011a</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>A new review author joined the lead author to complete this update; additional outcome measures included; conclusions changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-06-02 18:16:14 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>Searches conducted. Added to this update: five new studies were included, one previously excluded study was included and 12 new studies were excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-06 07:42:03 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-08-06 07:41:46 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="10" YEAR="2005"/>
<DESCRIPTION>
<P>This review was first published in 1998.<BR/>The update process began in 2004 and was completed in 2006. Searches of the literature were conducted during 2005. Authors of published abstracts were contacted. In the update it was decided to include pulmonary function tests as an additional measure but there were insufficient studies with this measure that met all inclusion criteria.<BR/>Five new trials were added to the update, a relatively small number given the time since the last update. For two outcomes, average clinical score and oximetry, the analyses were stratified according to treatment setting (inpatient or outpatient) rather than by drug delivery mechanism (oral or nebulized) as in the original review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-29 09:49:15 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="1" MONTH="6" YEAR="1998"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>National Prescribing Service Pty Ltd</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-06-04 08:21:20 +1000" MODIFIED_BY="Liz Dooley">
<SUMMARY MODIFIED="2014-06-02 18:26:06 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">Bronchodilators for bronchiolitis for infants with first-time wheezing</TITLE>
<SUMMARY_BODY MODIFIED="2014-06-02 18:26:06 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>What is bronchiolitis?</B>
</P>
<P>Bronchiolitis is an acute, highly contagious, viral infection of the lungs that is common in infants 0 to 12 months of age. It occurs every year in the winter months. It causes the small airways in the lungs to become inflamed and fill with debris. The airways are narrowed and this leads to blocking of the free passage of air. The infant has a harsh cough, runny nose and usually a fever. S/he can become breathless, wheezy and short of oxygen.</P>
<P>
<B>Why review bronchodilators?</B>
</P>
<P>Bronchodilators are drugs often used as aerosols to widen the air passages by relaxing the bronchial muscle. They are effective in helping older children and adults with asthma. However, unlike asthmatics, infants with bronchiolitis are usually wheezing for the first time. They are wheezing for a different reason, that is to say, because their airways are clogged with debris. Therefore, infants with bronchiolitis are less likely to respond to bronchodilators.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We reviewed the evidence about the effect of bronchodilators in infants with bronchiolitis. We found 30 trials that included a total of 1922 infants, in several countries. The evidence is current up to January 2014. We analyzed studies done in outpatient and inpatient settings separately. All bronchodilators were included in the review except for epinephrine because it is reviewed in another Cochrane review. Albuterol (otherwise known as salbutamol) is commonly used in studies, so we also reviewed this bronchodilator as a subgroup.</P>
<P>
<B>Key results</B>
</P>
<P>We found no effect of bronchodilators on oxygen saturation. Infants hospitalized for bronchiolitis showed no significant benefit of bronchodilator treatment. This review also found that bronchodilators do not reduce the need for hospitalization, do not shorten the length of stay in hospital and do not shorten the length of the illness at home. Reviewing the subgroup of studies using albuterol (salbutamol), we found no effect of this bronchodilator on oxygen saturation or clinical scores. Side effects of bronchodilators include rapid heart beat, decrease in oxygen and shakiness. Given these side effects, little evidence that they are effective and the expense associated with these treatments, bronchodilators are not helpful in the management of bronchiolitis.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>This review is limited by the small number of studies that use the same measures and methods. For example, only 22 studies included only infants wheezing for the first time. Older studies included children who had wheezed before and may have had asthma. Thus these older studies favor the use of bronchodilators. Newer studies that excluded infants with prior wheezing and had a better study design do not show a benefit of bronchodilators. This review is also limited by the small number of infants included in each study. Lastly, clinical scores used to measure the effect of the bronchodilators in some studies may vary from one observer to the next, making this measure unreliable. Studies that include more infants, use better measures and have a stronger study design are needed to define the effectiveness of these medications.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-06-04 08:21:04 +1000" MODIFIED_BY="Liz Dooley">
<ABS_BACKGROUND MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Bronchiolitis is an acute, viral lower respiratory tract infection affecting infants and is sometimes treated with bronchodilators.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-06-04 08:21:04 +1000" MODIFIED_BY="Liz Dooley">
<P>To assess the effects of bronchodilators on clinical outcomes in infants (0 to 12 months) with acute bronchiolitis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-01-24 08:45:45 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL 2013, Issue 12, MEDLINE (1966 to January Week 2, 2014) and EMBASE (1998 to January 2014).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-10-12 13:52:42 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) comparing bronchodilators (other than epinephrine) with placebo for bronchiolitis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Two authors assessed trial quality and extracted data. We obtained unpublished data from trial authors.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-06-02 18:19:28 +1000" MODIFIED_BY="[Empty name]">
<P>We included 30 trials (35 data sets) representing 1992 infants with bronchiolitis. In 11 inpatient and 10 outpatient studies, oxygen saturation did not improve with bronchodilators (mean difference (MD) -0.43, 95% confidence interval (CI) -0.92 to 0.06, n = 1242). Outpatient bronchodilator treatment did not reduce the rate of hospitalization (11.9% in bronchodilator group versus 15.9% in placebo group, odds ratio (OR) 0.75, 95% CI 0.46 to 1.21, n = 710). Inpatient bronchodilator treatment did not reduce the duration of hospitalization (MD 0.06, 95% CI -0.27 to 0.39, n = 349).</P>
<P>Effect estimates for inpatients (MD -0.62, 95% CI -1.40 to 0.16) were slightly larger than for outpatients (MD -0.25, 95% CI -0.61 to 0.11) for oximetry. Oximetry outcomes showed significant heterogeneity (I<SUP>2 </SUP>statistic = 81%). Including only studies with low risk of bias had little impact on the overall effect size of oximetry (MD -0.38, 95% CI -0.75 to 0.00) but results were close to statistical significance.</P>
<P>In eight inpatient studies, there was no change in average clinical score (standardized MD (SMD) -0.14, 95% CI -0.41 to 0.12) with bronchodilators. In nine outpatient studies, the average clinical score decreased slightly with bronchodilators (SMD -0.42, 95% CI -0.79 to -0.06), a statistically significant finding of questionable clinical importance. The clinical score outcome showed significant heterogeneity (I<SUP>2 </SUP>statistic = 73%). Including only studies with low risk of bias reduced the heterogeneity but had little impact on the overall effect size of average clinical score (SMD -0.22, 95% CI -0.41 to -0.03).</P>
<P>Sub-analyses limited to nebulized albuterol or salbutamol among outpatients (nine studies) showed no effect on oxygen saturation (MD -0.19, 95% CI -0.59 to 0.21, n = 572), average clinical score (SMD -0.36, 95% CI -0.83 to 0.11, n = 532) or hospital admission after treatment (OR 0.77, 95% CI 0.44 to 1.33, n = 404).</P>
<P>Adverse effects included tachycardia, oxygen desaturation and tremors.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-06-02 18:20:24 +1000" MODIFIED_BY="[Empty name]">
<P>Bronchodilators such as albuterol or salbutamol do not improve oxygen saturation, do not reduce hospital admission after outpatient treatment, do not shorten the duration of hospitalization and do not reduce the time to resolution of illness at home. Given the adverse side effects and the expense associated with these treatments, bronchodilators are not effective in the routine management of bronchiolitis. This meta-analysis continues to be limited by the small sample sizes and the lack of standardized study design and validated outcomes across the studies. Future trials with large sample sizes, standardized methodology across clinical sites and consistent assessment methods are needed to answer completely the question of efficacy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-06-04 08:21:20 +1000" MODIFIED_BY="Liz Dooley">
<BACKGROUND MODIFIED="2014-06-02 19:16:33 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-06-02 18:27:17 +1000" MODIFIED_BY="[Empty name]">
<P>Bronchiolitis is an acute, highly communicable lower respiratory tract infection characterized by "cough, coryza (runny nose), fever, expiratory wheezing, grunting, tachypnea (fast breathing), retractions and air trapping" (<LINK REF="REF-Welliver-1992" TYPE="REFERENCE">Welliver 1992</LINK>). Infants with bronchiolitis are wheezing for the first time, unlike asthmatics in whom bronchospasm causes recurrent wheezing. It should be emphasized that definitions of bronchiolitis vary between countries. Bronchiolitis refers to an illness starting as an upper respiratory infection followed by signs of acute respiratory distress and diffuse bilateral crepitations or rales, in addition to signs of bronchiolar obstruction such as air trapping, wheezing and high-pitched rhonchi (<LINK REF="REF-Disney-1960" TYPE="REFERENCE">Disney 1960</LINK>).</P>
<P>Largely caused by respiratory syncytial virus (RSV), bronchiolitis results in significant morbidity and mortality on a global scale (<LINK REF="REF-Nair-2010" TYPE="REFERENCE">Nair 2010</LINK>). While the average RSV hospitalization rate is 5.2 per 1000 children under 24 months old in the US, infants younger than two months of age have a much higher hospitalization rate of 17.9 per 1000 children (<LINK REF="REF-Hall-2009" TYPE="REFERENCE">Hall 2009</LINK>; <LINK REF="REF-Hall-2013" TYPE="REFERENCE">Hall 2013</LINK>). The estimated cost of hospitalization in the US increased by 24% from USD 1.2 billion in 2000 to USD 1.5 billion in 2006, despite the fact that length of stay decreased slightly from 2.4 to 2.3 days (<LINK REF="REF-Wilson-2010" TYPE="REFERENCE">Wilson 2010</LINK>). Combined with other medical encounters (outpatient and emergency department visits), the total cost of bronchiolitis in the US likely exceeds the year 2000 estimate of USD 652 million (<LINK REF="REF-Paramore-2004" TYPE="REFERENCE">Paramore 2004</LINK>), because hospitalization rates have increased both in the US and Canada (<LINK REF="REF-Langley-2003" TYPE="REFERENCE">Langley 2003</LINK>; <LINK REF="REF-Shay-1999" TYPE="REFERENCE">Shay 1999</LINK>; <LINK REF="REF-Shay-2001" TYPE="REFERENCE">Shay 2001</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-06-02 18:28:14 +1000" MODIFIED_BY="[Empty name]">
<P>Bronchodilators have been commonly used in the management of bronchiolitis. However, bronchodilator efficacy for this illness is not universally accepted and bronchodilators are seldom used to treat bronchiolitis in the United Kingdom (<LINK REF="REF-Goodman-1993" TYPE="REFERENCE">Goodman 1993</LINK>). Significant practice variation in the treatment of infants admitted for bronchiolitis or RSV pneumonia has been documented in the US (<LINK REF="REF-Christakis-2005" TYPE="REFERENCE">Christakis 2005</LINK>; <LINK REF="REF-Florin-2013" TYPE="REFERENCE">Florin 2013</LINK>; <LINK REF="REF-Wilson-2001" TYPE="REFERENCE">Wilson 2001</LINK>), Europe (<LINK REF="REF-Barben-2003" TYPE="REFERENCE">Barben 2003</LINK>; <LINK REF="REF-de-Bilderling-2003" TYPE="REFERENCE">de Bilderling 2003</LINK>), Canada (<LINK REF="REF-Plint-2004" TYPE="REFERENCE">Plint 2004</LINK>), Australia and New Zealand (<LINK REF="REF-Babl-2008" TYPE="REFERENCE">Babl 2008</LINK>; <LINK REF="REF-Vogel-2003" TYPE="REFERENCE">Vogel 2003</LINK>). Significant practice variation in emergency department bronchodilator use and bronchodilator prescription at discharge has also been documented in the US and Canada (<LINK REF="REF-Johnson-2013" TYPE="REFERENCE">Johnson 2013</LINK>; <LINK REF="REF-Plint-2004" TYPE="REFERENCE">Plint 2004</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-06-02 18:28:21 +1000" MODIFIED_BY="[Empty name]">
<P>Bronchodilators work by reversing bronchoconstriction of the airways due to bronchospasm induced by asthma triggers, viruses, exposure to toxic inhalants, etc. Infants with bronchiolitis present with wheezing, a hallmark of asthma, therefore bronchodilators have been used to manage wheezing.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-06-02 19:16:33 +1000" MODIFIED_BY="[Empty name]">
<P>Given the considerable cost of hospitalization and significant degree of practice variation documented in various parts of the world, an evidenced-based approach to bronchiolitis management is indicated. This review focuses on a broad class of bronchodilators, which includes the most commonly used agents, albuterol and salbutamol (&#946;<SUB>2</SUB>-adrenergic agonists). Epinephrine, a bronchodilator with both alpha-adrenergic and beta-adrenergic effects, is meta-analyzed in a separate Cochrane review (<LINK REF="REF-Hartling-2011a" TYPE="REFERENCE">Hartling 2011a</LINK>; <LINK REF="REF-Hartling-2011b" TYPE="REFERENCE">Hartling 2011b</LINK>). Randomized controlled trials (RCTs) of bronchodilators in bronchiolitis, whether for ambulatory or hospitalized children, have yielded variable results. Prior meta-analyses (<LINK REF="REF-Flores-1997" TYPE="REFERENCE">Flores 1997</LINK>; <LINK REF="REF-Kellner-1996" TYPE="REFERENCE">Kellner 1996</LINK>) and systematic reviews (<LINK REF="REF-Hartling-2011b" TYPE="REFERENCE">Hartling 2011b</LINK>; <LINK REF="REF-King-2004" TYPE="REFERENCE">King 2004</LINK>; <LINK REF="REF-Wainwright-2010" TYPE="REFERENCE">Wainwright 2010</LINK>) suggest that bronchodilators may improve clinical symptom scores for outpatients but they do not affect disease resolution or length of hospital stay. Some evidence-based clinical reviews and practice guidelines conflict regarding their recommendations about the use of bronchodilators. Several recommend that bronchodilators should not be used routinely to treat bronchiolitis (<LINK REF="REF-DeNicola-2013" TYPE="REFERENCE">DeNicola 2013</LINK>; <LINK REF="REF-Guia-Salud-2010" TYPE="REFERENCE">Guia Salud 2010</LINK>; <LINK REF="REF-SIGN-2006" TYPE="REFERENCE">SIGN 2006</LINK>; <LINK REF="REF-Wagner-2009" TYPE="REFERENCE">Wagner 2009</LINK>; <LINK REF="REF-Wainwright-2010" TYPE="REFERENCE">Wainwright 2010</LINK>; 
<LINK REF="REF-Zorc-2010" TYPE="REFERENCE">Zorc 2010</LINK>), while others suggest the option of a single trial of bronchodilator inhalation with careful assessment of response (<LINK REF="REF-AAP-2006" TYPE="REFERENCE">AAP 2006</LINK>; <LINK REF="REF-CCHMC-2010" TYPE="REFERENCE">CCHMC 2010</LINK>).</P>
<P>Cincinnati guidelines suggest that neither bronchodilators, steroids, antivirals nor antibacterial agents should be routinely used (<LINK REF="REF-CCHMC-2010" TYPE="REFERENCE">CCHMC 2010</LINK>). In particular, use of antibiotics and steroids should be strongly discouraged, whereas administration of bronchodilators or epinephrine are considered as an option, particularly when there is a family history for allergy, asthma or atopy.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-06-04 08:21:20 +1000" MODIFIED_BY="Liz Dooley">
<P>To assess the effects of bronchodilators on clinical outcomes in infants (0 to 12 months) with acute bronchiolitis.</P>
<P>There is widespread use of bronchodilators despite conflicting evidence regarding their efficacy, therefore we updated this systematic review of all randomized placebo-controlled trials of bronchodilators for bronchiolitis. We have reviewed the quality of studies and provided a quantitative summary of the effects of bronchodilators. The question addressed by the meta-analysis was: are bronchodilators better than placebo in the management of bronchiolitis in infants, as measured by improvement in oxygen saturation, clinical scores, admission to hospital, duration of hospitalization, pulmonary function tests or time to resolution of illness?</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-06-02 19:15:01 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-06-02 18:34:55 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-06-02 18:34:55 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trials of bronchodilators for bronchiolitis. We examined the methods and results if the title or abstract indicated that patients with bronchiolitis were studied in a prospective randomized clinical trial. Both published and unpublished studies could be included as long as the inclusion criteria were fulfilled.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Infants and young children up to 24 months with bronchiolitis. All trials used the term 'bronchiolitis' to refer to an acute lower respiratory tract infection with wheezing.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Bronchodilator therapy, including albuterol, salbutamol, terbutaline, ipratropium bromide and adrenergic agents. Studies of inhaled steroids were not included. Routes of administration were: nebulized, oral and subcutaneous. Although included in the original review, we excluded studies of epinephrine in bronchiolitis from the updates since these studies are included in the Cochrane Review 'Epinephrine for bronchiolitis' (<LINK REF="REF-Hartling-2011a" TYPE="REFERENCE">Hartling 2011a</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome measures of interest were those that assessed signs or symptoms and were, therefore, considered to have the most clinical relevance: oxygen saturation as measured by pulse oximetry, clinical score, admission to hospital, duration of hospital stay and time to resolution of illness. We added pulmonary function tests as an additional outcome in the 2006, 2010 and 2014 updates.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-12-13 12:09:53 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Oxygen saturation, as this outcome often drives the clinical decision to hospitalize an infant with bronchiolitis. This outcome is objectively measured using pulse oximetry.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Improvement in clinical scores.</LI>
<LI>Admission to hospital.</LI>
<LI>Duration of hospitalization.</LI>
<LI>Time to resolution of illness.</LI>
<LI>Pulmonary function tests.</LI>
</OL>
<P>These outcomes are more subjective and subject to interrater variability. Pulmonary function tests are objective measures of the effect of bronchodilators on airway resistance and compliance.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>For this 2014 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2013, Issue 12 (accessed 20 January 2014), which contains the Acute Respiratory Infections Group's Specialized Register, MEDLINE (January 2010 to January week 2, 2014) and EMBASE (March 2010 to January 2014). Details of previous searches are in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We used the following search strategy to search CENTRAL and MEDLINE. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision- maximizing version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We adapted these search terms to search EMBASE (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). There were no language or publication restrictions.</P>
<SUBSECTION>
<HEADING LEVEL="5">MEDLINE (OVID)</HEADING>
<P>1 exp Bronchiolitis/<BR/>2 bronchiolit*.tw.<BR/>3 1 or 2<BR/>4 exp Bronchodilator Agents/<BR/>5 bronchodilator*.tw,nm.<BR/>6 Albuterol/<BR/>7 albuterol.tw,nm.<BR/>8 salbutamol.tw,nm.<BR/>9 Terbutaline/<BR/>10 terbutaline.tw,nm.<BR/>11 Ipratropium/<BR/>12 ipratropium.tw,nm.<BR/>13 exp Adrenergic Agents/<BR/>14 adrenergic agent*.tw,nm.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>We scanned the reference lists of identified articles and contacted authors of the identified trials and other experts in the field.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-06-02 19:15:01 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-04-15 07:11:58 +1000" MODIFIED_BY="Liz Dooley">
<P>In the original review, two review authors (AG, AB) independently reviewed the articles. In the 2010 and 2014 updates, two review authors (AG, MS) reviewed the search results and independently reviewed new studies. There was complete agreement between the two review authors regarding the articles selected for inclusion in the review.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-12-13 12:15:13 +1000" MODIFIED_BY="[Empty name]">
<P>Both review authors (AG, MS) independently extracted data and achieved consensus on what data to include. We requested unpublished data from trial authors when necessary.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-06-02 18:36:45 +1000" MODIFIED_BY="[Empty name]">
<P>Both review authors (AG, MS) rated the quality of each included trial by assessing whether the following five sources of bias were adequately reported (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>): 1) sequence allocation was carried out satisfactorily; 2) allocation to treatment groups was concealed; 3) the trial was double-blinded (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>); 4) incomplete data were addressed; and 5) selective reporting was not present.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-06-02 19:15:01 +1000" MODIFIED_BY="[Empty name]">
<P>We selected oxygen saturation as measured by pulse oximetry, clinical scores based on a multi-item clinical scale and admission to hospital to measure the effect of bronchodilators on outpatients. We added duration of hospitalization as an outcome measure for inpatients. We thought these outcomes to be the most clinically relevant and to have the largest amount of experimental data reported. Two longer-term outpatient studies were published, therefore we also added time to resolution of illness as an outcome measure. Respiratory rate was not selected as an isolated measure because of many uncontrollable factors which influence respiratory rate (<LINK REF="STD-Gadomski-1994b-_x002d_-neb" TYPE="STUDY">Gadomski 1994b - neb</LINK>).</P>
<P>A number of different scoring systems were used in the included studies (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table). A summary of the components of the most widely used clinical scoring systems can be found in <LINK REF="REF-Hartling-2003" TYPE="REFERENCE">Hartling 2003</LINK>. Fourteen of 30 included studies utilized the partially validated clinical scoring system, that is to say, the Respiratory Distress Assessment Instrument (RDAI) or the Respiratory Assessment Change Score (RACS). Clinical scores were reported in two ways. In several trials, the results were reported as the proportion of infants and children with an improved score based on an a priori determination of significant clinical improvement (improvement in clinical score, a dichotomous variable). <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> defines events as the proportion of participants who did not meet pre-determined criteria for clinical score improvement. In eight inpatient and nine outpatient trials, the results were reported as the average score or change in score in each treatment group (average clinical score, a continuous variable (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>Time to resolution of illness (ROI), measured from the period of study enrollment to the time the infant returned to baseline health status, is scored by the primary caregiver at home. ROI comprises parental assessment of degree of improvement of respiratory symptoms scored on a four-point ordinal scale (worse = 1, same = 2, improved = 3, symptoms resolved = 4) (<LINK REF="REF-Cruz-1995" TYPE="REFERENCE">Cruz 1995</LINK>).</P>
<P>Duration of hospitalization was measured by length of stay, derived from the time of admission and discharge, as opposed to specific measures of improvement. The exception to this is <LINK REF="STD-Dobson-1998" TYPE="STUDY">Dobson 1998</LINK>, which defined duration as time to reach predetermined discharge criteria.</P>
<P>For the three continuous variables (oxygen saturation, average clinical score and duration of hospitalization) and the ordinal variable of ROI, we determined the effect of treatment compared with placebo using the unbiased estimate of effect size (ES), with its 95% confidence intervals (CI) (<LINK REF="REF-Bracken-1989" TYPE="REFERENCE">Bracken 1989</LINK>). For oxygen saturation, duration of hospitalization and ROI, we measured effect using the mean difference (MD) between treatment and placebo. We converted the average clinical scores to the standardized mean difference (SMD) because a variety of clinical scoring systems with different ranges were utilized by the included studies. In all scoring systems, higher scores indicate greater severity of illness.</P>
<P>For average clinical score, an ES of less than zero (that is to say, reduction of severity scores) indicates a benefit and an ES of more than zero (that is to say, increased severity scores) indicates that treatment is detrimental. Similarly, for oximetry an ES of less than zero (that is to say, lower mean oxygen saturation with placebo) indicates a beneficial effect of treatment and an ES of more than zero (that is to say, higher mean oxygen saturation with placebo) indicates a detrimental effect.</P>
<P>For the two dichotomous variables (improvement in clinical score and hospital admission), we determined the effect of treatment compared with placebo using the odds ratio (OR). An overall OR of less than one indicates that treatment is beneficial, while an OR of more than one indicates that treatment is detrimental. For improvement in clinical score, an OR of less than one indicates that the odds of not improving were lower in the treatment group compared with the placebo group. For hospital admission, an OR of less than one indicates that the odds of being hospitalized were lower in the treatment group than the placebo group.</P>
<P>Pulmonary function test (PFT) data are objective measures but changes in PFT measures may achieve statistical significance while having little clinical significance. In this update, we found one additional PFT study (<LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>), bringing the total number of PFT studies to 10. However, seven of these studies did not fulfill the inclusion criteria and only three studies could be included (<LINK REF="STD-Levin-2008" TYPE="STUDY">Levin 2008</LINK>; <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>; <LINK REF="STD-Totapally-2002" TYPE="STUDY">Totapally 2002</LINK>). However, due to the different PFT measurement techniques used, the outcomes of these studies could not be combined. Therefore, PFT data are not included as outcome measures.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-06-02 19:14:55 +1000" MODIFIED_BY="[Empty name]">
<P>We stratified results for oxygen saturation and average score (continuous) according to whether the study was conducted in an inpatient or outpatient setting. The rationale for this was that inpatients are more severely ill and, therefore, have a different response profile compared to outpatients. Also the time of outcome assessment varied according to whether the study was an inpatient or outpatient study. Inpatients were usually assessed within 24 hours of admission whereas outpatients were more consistently assessed 30 minutes to six hours after treatment was initiated. In addition, we added oral bronchodilator given at home (ascertained during a 14-day period following study enrollment) to <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK> 'Hospital admission after treatment'.</P>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over studies</HEADING>
<P>Three trials employed cross-over designs (<LINK REF="STD-Alario-1992" TYPE="STUDY">Alario 1992</LINK>; <LINK REF="STD-Ho-1991" TYPE="STUDY">Ho 1991</LINK>; <LINK REF="STD-Totapally-2002" TYPE="STUDY">Totapally 2002</LINK>). Pulse oximetry data from <LINK REF="STD-Alario-1992" TYPE="STUDY">Alario 1992</LINK>, recorded 20 minutes after either nebulized metaproterenol or 0.9% saline first among 74 outpatients (37 in each group), were included in <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>. Clinical score data for outpatients aged 12 months or younger (17 in metaproterenol group and 20 in 0.9% saline group) were available and thus included in <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> and <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>. Pulse oximetry data from <LINK REF="STD-Ho-1991" TYPE="STUDY">Ho 1991</LINK> included 30-minute readings for 13 inpatients receiving salbutamol first and eight inpatients receiving 0.9% saline first. Cross-over data were not included. The PFT results presented by <LINK REF="STD-Totapally-2002" TYPE="STUDY">Totapally 2002</LINK> were not combined with other PFT results because different PFT measurement techniques were used by the PFT studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Studies with multiple treatment groups</HEADING>
<P>Some trials had more than one bronchodilator treatment arm, either varying the mode of delivery (nebulized, oral or metered dose inhaler (MDI)) or comparing different bronchodilators (for example, salbutamol and ipratropium), or different diluents (0.9% saline versus 3% saline). In the figures depicting these analyses, the descriptive labels for these trials are annotated to indicate the arm of the trial used in the comparison. For example <LINK REF="STD-Gadomski-1994a-_x002d_-neb" TYPE="STUDY">Gadomski 1994a - neb</LINK> and <LINK REF="STD-Gadomski-1994a-_x002d_-oral" TYPE="STUDY">Gadomski 1994a - oral</LINK> are the nebulized and oral treatment arms from the same study (<LINK REF="STD-Gadomski-1994a-_x002d_-neb" TYPE="STUDY">Gadomski 1994a - neb</LINK>). In a trial that had only one placebo arm but two active treatment groups (<LINK REF="STD-Karadag-2005-_x002d_-IPR" TYPE="STUDY">Karadag 2005 - IPR</LINK>), placebo numbers were divided between comparisons to avoid double-counting of placebo participants. For <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>, the 3% saline study groups were excluded from analysis.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Given the nature of the clinical trials included in this review (short-term outpatient or longer-term inpatient studies), the reported participant drop out rates were low (see <LINK TAG="EXCLUSIONS" TYPE="SECTION">Incomplete outcome data</LINK>). We contacted the trial authors of 11 studies for missing statistics, such as standard deviations.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed statistical heterogeneity visually and with the I<SUP>2 </SUP>statistic and the Chi<SUP>2 </SUP>test. For meta-analyses including a small number of studies, we used the I<SUP>2 </SUP>statistic.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-06-02 19:15:01 +1000" MODIFIED_BY="[Empty name]">
<P>In 2006, an unpublished study was included because it was a RCT of salbutamol, ipratropium and saline that included first-time wheezing infants admitted to hospital (<LINK REF="STD-Karadag-2005-_x002d_-IPR" TYPE="STUDY">Karadag 2005 - IPR</LINK>). This study was later published (<LINK REF="STD-Karadag-2008" TYPE="STUDY">Karadag 2008</LINK>). A second unpublished inpatient study was a RCT comparing salbutamol, placebo and epinephrine (<LINK REF="STD-Gurkan-2004" TYPE="STUDY">Gurkan 2004</LINK>). We obtained data for these studies from the trialists. There were two placebo-controlled studies excluded because they were only available in abstract form (<LINK REF="STD-Ferrer-1990" TYPE="STUDY">Ferrer 1990</LINK>; <LINK REF="STD-Karaatmaca-2010" TYPE="STUDY">Karaatmaca 2010</LINK>). Pending clinical trials were sought in the Pediatric Academic Societies abstracts for 2012 and 2013 (none were found). For the original review, seven trial authors provided upon request additional data not stated in their publications (<LINK REF="STD-Alario-1992" TYPE="STUDY">Alario 1992</LINK>; <LINK REF="STD-Gadomski-1994b-_x002d_-neb" TYPE="STUDY">Gadomski 1994b - neb</LINK>; <LINK REF="STD-Ho-1991" TYPE="STUDY">Ho 1991</LINK>; <LINK REF="STD-Klassen-1991" TYPE="STUDY">Klassen 1991</LINK>; <LINK REF="STD-Lines-1992" TYPE="STUDY">Lines 1992</LINK>; <LINK REF="STD-Schuh-1990" TYPE="STUDY">Schuh 1990</LINK>; <LINK REF="STD-Schweich-1992" TYPE="STUDY">Schweich 1992</LINK>). In the 2006 update, we requested additional data and received these for inclusion from three authors for: duration of hospitalization (<LINK REF="STD-Karadag-2005-_x002d_-IPR" TYPE="STUDY">Karadag 2005 - IPR</LINK>), clinical score and oximetry outcomes at 24 hours (<LINK REF="STD-Patel-2002" TYPE="STUDY">Patel 2002</LINK>) and clinical score and oximetry (<LINK REF="STD-Gurkan-2004" TYPE="STUDY">Gurkan 2004</LINK>). In this 2014 update, we requested additional unpublished data and received these from <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>. Therefore, the likelihood of publication bias is low.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>We chose a fixed-effect model initially for the meta-analysis (<LINK REF="REF-Thompson-1991" TYPE="REFERENCE">Thompson 1991</LINK>). This model assumes that the true effect of treatment is the same in all trials and that any differences in treatment effect between trials are due to chance. We expected that there would be some heterogeneity in the data due to the different treatment settings and measurement protocols (<LINK REF="REF-Thompson-1994" TYPE="REFERENCE">Thompson 1994</LINK>). Where there was evidence of significant heterogeneity (I<SUP>2</SUP> statistic greater than 30%), we analyzed the results using both fixed-effect and random-effects models. If there was a difference in the results, we used the more conservative random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Subgroup analyses include analysis by outpatient or inpatient setting as the severity of illness differs between these two groups. We also analyzed nebulized versus oral bronchodilator studies separately, as well as outpatient versus home settings for oral bronchodilators. They are commonly used, therefore albuterol or salbutamol subgroup analysis was added in this 2014 update. Methods for investigating heterogeneity of effects include comparison of the I<SUP>2</SUP> statistic and the Chi<SUP>2 </SUP>test.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Sensitivity analysis included comparison of the estimates of the effect of bronchodilators in studies with a low risk of bias, studies that specifically included only first-time wheezers and studies that only included infants younger than or equal to 12 months of age. We defined studies with a low risk of bias as having a ranking of 'low risk' for all five items in the 'Risk of bias' table (see <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>). In this 2014 update, we included studies using the same clinical score (RDAI) in a sensitivity analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-06-02 19:15:08 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-06-02 19:15:01 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Of the 21 studies identified in the search for this 2014 update, two met the criteria for inclusion. Most of the excluded studies were excluded because they did not include a placebo group (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-06-02 19:15:01 +1000" MODIFIED_BY="[Empty name]">
<P>From a total of 30 trials (35 data sets) included in this review, 23 trials were in infants wheezing for the first time (<LINK REF="STD-Anil-2010-SAL-0.9_x0025_" TYPE="STUDY">Anil 2010 SAL 0.9%</LINK>; <LINK REF="STD-Anil-2010-SAL-3_x0025_" TYPE="STUDY">Anil 2010 SAL 3%</LINK>; <LINK REF="STD-Can-1998" TYPE="STUDY">Can 1998</LINK>; <LINK REF="STD-Chevallier-1995" TYPE="STUDY">Chevallier 1995</LINK>; <LINK REF="STD-Chowdhury-1995" TYPE="STUDY">Chowdhury 1995</LINK>; <LINK REF="STD-Dobson-1998" TYPE="STUDY">Dobson 1998</LINK>; <LINK REF="STD-Gadomski-1994a-_x002d_-neb" TYPE="STUDY">Gadomski 1994a - neb</LINK>; <LINK REF="STD-Gadomski-1994b-_x002d_-neb" TYPE="STUDY">Gadomski 1994b - neb</LINK>; <LINK REF="STD-Goh-1997" TYPE="STUDY">Goh 1997</LINK>; <LINK REF="STD-Gupta-2008" TYPE="STUDY">Gupta 2008</LINK>; <LINK REF="STD-Gurkan-2004" TYPE="STUDY">Gurkan 2004</LINK>; <LINK REF="STD-Ho-1991" TYPE="STUDY">Ho 1991</LINK>; <LINK REF="STD-Karadag-2008" TYPE="STUDY">Karadag 2008</LINK>; <LINK REF="STD-Klassen-1991" TYPE="STUDY">Klassen 1991</LINK>; <LINK REF="STD-Levin-2008" TYPE="STUDY">Levin 2008</LINK>; <LINK REF="STD-Lines-1990" TYPE="STUDY">Lines 1990</LINK>; <LINK REF="STD-Lines-1992" TYPE="STUDY">Lines 1992</LINK>; <LINK REF="STD-Patel-2002" TYPE="STUDY">Patel 2002</LINK>; <LINK REF="STD-Patel-2003" TYPE="STUDY">Patel 2003</LINK>; <LINK REF="STD-Ralston-2005" TYPE="STUDY">Ralston 2005</LINK>; <LINK REF="STD-Schuh-1990" TYPE="STUDY">Schuh 1990</LINK>; <LINK REF="STD-Tinsa-2009" TYPE="STUDY">Tinsa 2009</LINK>; <LINK REF="STD-Totapally-2002" TYPE="STUDY">Totapally 2002</LINK>; <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>). For this 2014 update, we included two new trials, both of which included first-time wheezing infants (<LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>). We also included five additional trials, in which results from participants with first-time wheezing could not be separated from those with recurrent wheezing (<LINK REF="STD-Alario-1992" TYPE="STUDY">Alario 1992</LINK>; <LINK REF="STD-Henry-1983" TYPE="STUDY">Henry 1983</LINK>; <LINK REF="STD-Mallol-1987" TYPE="STUDY">Mallol 1987</LINK>; <LINK REF="STD-Schweich-1992" TYPE="STUDY">Schweich 1992</LINK>; <LINK REF="STD-Tal-1983" TYPE="STUDY">Tal 1983</LINK>).</P>
<P>Laboratory methods to identify RSV included direct immunofluorescence microscopy, enzyme immunoassay and serum RSV titers. The range of participants who were RSV-positive was 3% to 100%, with more than 40% RSV-positive in 10 trials.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-06-02 18:46:28 +1000" MODIFIED_BY="[Empty name]">
<P>We excluded a total of 62 studies from this review (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table). We made 46 of these exclusions because the trials were not placebo-controlled (<LINK REF="STD-Absar-2008" TYPE="STUDY">Absar 2008</LINK>; <LINK REF="STD-Abu_x002d_Shukair-2001" TYPE="STUDY">Abu-Shukair 2001</LINK>; <LINK REF="STD-Alansari-2013" TYPE="STUDY">Alansari 2013</LINK>; <LINK REF="STD-Barlas-1998" TYPE="STUDY">Barlas 1998</LINK>; <LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>; <LINK REF="STD-Bentur-2003" TYPE="STUDY">Bentur 2003</LINK>; <LINK REF="STD-Bertrand-2001" TYPE="STUDY">Bertrand 2001</LINK>; <LINK REF="STD-Cengizlier-1997" TYPE="STUDY">Cengizlier 1997</LINK>; <LINK REF="STD-Chao-2003" TYPE="STUDY">Chao 2003</LINK>; <LINK REF="STD-Del-Vecchio-2012" TYPE="STUDY">Del Vecchio 2012</LINK>; <LINK REF="STD-Fernandez-2009" TYPE="STUDY">Fernandez 2009</LINK>; <LINK REF="STD-Florin-2012" TYPE="STUDY">Florin 2012</LINK>; <LINK REF="STD-Frasson-2012" TYPE="STUDY">Frasson 2012</LINK>; <LINK REF="STD-Goebel-2000" TYPE="STUDY">Goebel 2000</LINK>; <LINK REF="STD-Gomez_x002d_y_x002d_Lopez-2007" TYPE="STUDY">Gomez-y-Lopez 2007</LINK>; <LINK REF="STD-Gonzalez-1994" TYPE="STUDY">Gonzalez 1994</LINK>; <LINK REF="STD-Hammer-1995" TYPE="STUDY">Hammer 1995</LINK>; <LINK REF="STD-John-2006" TYPE="STUDY">John 2006</LINK>; <LINK REF="STD-John-2010" TYPE="STUDY">John 2010</LINK>; <LINK REF="STD-Kadir-2009" TYPE="STUDY">Kadir 2009</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Langley-2005" TYPE="STUDY">Langley 2005</LINK>; <LINK REF="STD-Luo-2003" TYPE="STUDY">Luo 2003</LINK>; <LINK REF="STD-Luo-2010" TYPE="STUDY">Luo 2010</LINK>; <LINK REF="STD-Luo-2012" TYPE="STUDY">Luo 2012</LINK>; <LINK REF="STD-Mandelberg-2003" TYPE="STUDY">Mandelberg 2003</LINK>; <LINK REF="STD-Menon-1995" TYPE="STUDY">Menon 1995</LINK>; <LINK REF="STD-Modaressi-2012" TYPE="STUDY">Modaressi 2012</LINK>; <LINK REF="STD-Modl-2005" TYPE="STUDY">Modl 2005</LINK>; <LINK REF="STD-Mull-2004" TYPE="STUDY">Mull 2004</LINK>; <LINK REF="STD-Numa-2001" TYPE="STUDY">Numa 2001</LINK>; <LINK REF="STD-Ozyurek-2002" TYPE="STUDY">Ozyurek 2002</LINK>; <LINK REF="STD-Ray-2002" TYPE="STUDY">Ray 2002</LINK>; <LINK REF="STD-Reijonen-1995" TYPE="STUDY">Reijonen 1995</LINK>; <LINK REF="STD-Sanchez-1993" TYPE="STUDY">Sanchez 1993</LINK>; <LINK REF="STD-Sarrell-2002" TYPE="STUDY">Sarrell 2002</LINK>; <LINK REF="STD-Schuh-1992" TYPE="STUDY">Schuh 1992</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>; <LINK REF="STD-Simsek-2005" TYPE="STUDY">Simsek 2005</LINK>; <LINK REF="STD-Simsek_x002d_Kiper-2011" TYPE="STUDY">Simsek-Kiper 2011</LINK>; <LINK REF="STD-Soto-1985" TYPE="STUDY">Soto 1985</LINK>; <LINK REF="STD-Springer-1990" TYPE="STUDY">Springer 1990</LINK>; <LINK REF="STD-Stokes-1983" TYPE="STUDY">Stokes 1983</LINK>; <LINK REF="STD-Torres-1997" TYPE="STUDY">Torres 1997</LINK>; <LINK REF="STD-Walsh-2008" TYPE="STUDY">Walsh 2008</LINK>; <LINK REF="STD-Zhou-2001" TYPE="STUDY">Zhou 2001</LINK>).</P>
<P>We excluded six trials because they contained limited data due to publication in abstract form only (<LINK REF="STD-Choong-1998" TYPE="STUDY">Choong 1998</LINK>; <LINK REF="STD-Ferrer-1990" TYPE="STUDY">Ferrer 1990</LINK>; <LINK REF="STD-Karaatmaca-2010" TYPE="STUDY">Karaatmaca 2010</LINK>; <LINK REF="STD-Milner-1995" TYPE="STUDY">Milner 1995</LINK>; <LINK REF="STD-Ndrepepa-1998" TYPE="STUDY">Ndrepepa 1998</LINK>; <LINK REF="STD-Zhen-2003" TYPE="STUDY">Zhen 2003</LINK>). We excluded two additional studies as abstract-only (<LINK REF="STD-Ren-2011" TYPE="STUDY">Ren 2011</LINK>; <LINK REF="STD-Sezer-2010" TYPE="STUDY">Sezer 2010</LINK>), but the data were later published as included studies in <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK> and <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>, respectively.</P>
<P>We have excluded four trials because they were not RCTs (<LINK REF="STD-Brooks-1981" TYPE="STUDY">Brooks 1981</LINK>; <LINK REF="STD-Cortes-1996" TYPE="STUDY">Cortes 1996</LINK>; <LINK REF="STD-Shu-2001" TYPE="STUDY">Shu 2001</LINK>; <LINK REF="STD-Wankum-2000" TYPE="STUDY">Wankum 2000</LINK>), one trial because it did not include nebulized delivery of bronchodilators (<LINK REF="STD-Ralston-2008" TYPE="STUDY">Ralston 2008</LINK>), two studies because they did not have clear definitions of bronchiolitis (<LINK REF="STD-Sly-1991" TYPE="STUDY">Sly 1991</LINK>; <LINK REF="STD-Tatochenko-1988" TYPE="STUDY">Tatochenko 1988</LINK>) and one study because it published a research protocol only (no outcomes data) (<LINK REF="STD-Belcastro-2010" TYPE="STUDY">Belcastro 2010</LINK>). We omitted four trials of epinephrine versus placebo, excluded in previous versions of this review (<LINK REF="REF-Hariprakash-2003" TYPE="REFERENCE">Hariprakash 2003</LINK>; <LINK REF="REF-Kristj_x00e1_nsson-1993" TYPE="REFERENCE">Kristjánsson 1993</LINK>; <LINK REF="REF-Lowell-1987" TYPE="REFERENCE">Lowell 1987</LINK>; <LINK REF="REF-Wainwright-2003" TYPE="REFERENCE">Wainwright 2003</LINK>), from this 2014 update as they have been addressed by another Cochrane Review (<LINK REF="REF-Hartling-2011a" TYPE="REFERENCE">Hartling 2011a</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>The design and methodological quality features of each study are shown in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. Generally the studies were of small size. The main problem with older studies was an inability to identify participants who were first-time wheezers versus recurrent wheezers. Other limitations to study quality included lack of standardized methods for outcome evaluation (timing of assessments, clinical scoring systems used) and lack of standardized intervention (various bronchodilators, drug dosages, routes of administration and nebulization delivery systems) used across the studies. A graphical representation of risk of bias among included studies is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. A summary of methodological quality among included studies is given in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2.</LINK>
</P>
<ALLOCATION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Methods for sequence generation and allocation concealment were not described in older studies (<LINK REF="STD-Can-1998" TYPE="STUDY">Can 1998</LINK>; <LINK REF="STD-Chevallier-1995" TYPE="STUDY">Chevallier 1995</LINK>; <LINK REF="STD-Chowdhury-1995" TYPE="STUDY">Chowdhury 1995</LINK>; <LINK REF="STD-Henry-1983" TYPE="STUDY">Henry 1983</LINK>; <LINK REF="STD-Ho-1991" TYPE="STUDY">Ho 1991</LINK>; <LINK REF="STD-Lines-1990" TYPE="STUDY">Lines 1990</LINK>; <LINK REF="STD-Lines-1992" TYPE="STUDY">Lines 1992</LINK>; <LINK REF="STD-Mallol-1987" TYPE="STUDY">Mallol 1987</LINK>), or in abstract-only studies (<LINK REF="STD-Gurkan-2004" TYPE="STUDY">Gurkan 2004</LINK>). More recent studies described methods for sequence generation, allocation concealment and use of placebo agents that were indistinguishable from bronchodilator agents. <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK> allocated infants to the study groups by consecutive order to the short stay unit.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Most medical and research staff administering treatment or assessing participants during the trial (or both) are described as being either blinded or masked during the conduct of the studies included in this review, thus reducing the potential for performance, detection or attrition bias. Only one study was described as single-blind (<LINK REF="STD-Mallol-1987" TYPE="STUDY">Mallol 1987</LINK>). Two studies were described in the abstract as being double-blind but this was not detailed in the methods (<LINK REF="STD-Can-1998" TYPE="STUDY">Can 1998</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>In the outpatient studies, there tended to be more missing data for follow-up measurements beyond 60 minutes because many patients were discharged from these settings before 90 or 120-minute assessments could be done. Bronchodilators have short-term effects, therefore some outpatient trialists did not include measurement of outcomes longer than 60 minutes post-treatment. Therefore, the outpatient results are biased towards those data measured at a shorter interval from treatment administration, so sustained outcomes may have been missed.</P>
<P>Details regarding study attrition were often not well described in the included studies. Drop out rates range from 0% to 13% (<LINK REF="STD-Gupta-2008" TYPE="STUDY">Gupta 2008</LINK>; <LINK REF="STD-Patel-2003" TYPE="STUDY">Patel 2003</LINK>; <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>). Few studies included study flow diagrams that could be used to assess differential drop out from the study groups (<LINK REF="STD-Anil-2010-SAL-0.9_x0025_" TYPE="STUDY">Anil 2010 SAL 0.9%</LINK>; <LINK REF="STD-Gupta-2008" TYPE="STUDY">Gupta 2008</LINK>; <LINK REF="STD-Patel-2003" TYPE="STUDY">Patel 2003</LINK>; <LINK REF="STD-Ralston-2005" TYPE="STUDY">Ralston 2005</LINK>). Few studies employed intention-to-treat (ITT) analysis when study participant attrition occurred (<LINK REF="STD-Patel-2002" TYPE="STUDY">Patel 2002</LINK>; <LINK REF="STD-Patel-2003" TYPE="STUDY">Patel 2003</LINK>).</P>
<P>Possible attrition bias might be a factor in three studies that excluded participants from analysis because they were 'therapeutic failures' (<LINK REF="STD-Tal-1983" TYPE="STUDY">Tal 1983</LINK>), or that withdrew participants for other reasons (<LINK REF="STD-Dobson-1998" TYPE="STUDY">Dobson 1998</LINK>; <LINK REF="STD-Goh-1997" TYPE="STUDY">Goh 1997</LINK>; <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Evidence of selective reporting of outcomes was rare as most studies presented the outcome results that were described in the methods, with one exception, that is, that few studies provided data on heart rate following treatment. Bronchodilators can increase heart rate, therefore it is an important outcome to include, although for most studies this information is included in the description of adverse effects and is not systemically addressed in all studies.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-06-08 09:57:47 +1000" MODIFIED_BY="[Empty name]">
<P>Adverse effects following treatment were often not systematically addressed in the study design and are not completely described in most studies included in this review.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-06-02 19:15:08 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Oxygen saturation</HEADING>
<P>In a random-effects analysis, bronchodilator recipients did not show a significant improvement in oxygen saturation as measured by pulse oximetry compared to placebo, as reflected by the mean difference (MD) -0.43, 95% confidence interval (CI) -0.92 to 0.06 (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>Nine outpatient studies included treatment protocols that included albuterol or salbutamol nebulization only (<LINK REF="STD-Anil-2010-SAL-0.9_x0025_" TYPE="STUDY">Anil 2010 SAL 0.9%</LINK>; <LINK REF="STD-Anil-2010-SAL-3_x0025_" TYPE="STUDY">Anil 2010 SAL 3%</LINK>; <LINK REF="STD-Can-1998" TYPE="STUDY">Can 1998</LINK>; <LINK REF="STD-Gadomski-1994a-_x002d_-neb" TYPE="STUDY">Gadomski 1994a - neb</LINK>; <LINK REF="STD-Gadomski-1994b-_x002d_-neb" TYPE="STUDY">Gadomski 1994b - neb</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Klassen-1991" TYPE="STUDY">Klassen 1991</LINK>; <LINK REF="STD-Ralston-2005" TYPE="STUDY">Ralston 2005</LINK>; <LINK REF="STD-Schuh-1990" TYPE="STUDY">Schuh 1990</LINK>; <LINK REF="STD-Schweich-1992" TYPE="STUDY">Schweich 1992</LINK>). When reduced to these nine studies, outpatient oximetry measures showed reduced heterogeneity and also reduced mean differences that were not statistically significant (I<SUP>2 </SUP>statistic = 0%; MD -0.19, 95% CI -0.59 to 0.21; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Improvement in clinical scores</HEADING>
<P>In seven trials (five inpatient and two outpatient), the clinical score of 64% of those infants treated with bronchodilators improved compared to 27% with placebo (odds ratio (OR) for no improvement = 0.18, 95% CI 0.06 to 0.50, n = 365), using a random-effects model (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Included in this analysis are three studies that were methodologically weaker than other studies and included older participants who were recurrent wheezers (<LINK REF="STD-Alario-1992" TYPE="STUDY">Alario 1992</LINK>; <LINK REF="STD-Lines-1990" TYPE="STUDY">Lines 1990</LINK>; <LINK REF="STD-Mallol-1987" TYPE="STUDY">Mallol 1987</LINK>).</P>
<P>The improvement in overall average clinical score was statistically significant (standardized MD (SMD) -0.30, 95% CI -0.54 to -0.05) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), but the small magnitude of this change limits its clinical significance. Inpatients demonstrated no improvement compared to outpatients, underscoring the short-term effect of bronchodilator treatment as most of the outpatient assessments occurred usually within one hour after treatment compared with longer time points in inpatients (see <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>). The small magnitude of difference in mean clinical score between bronchodilator and placebo groups is of questionable clinical importance, especially given the differences in scoring systems that were used.</P>
<P>We performed a sub-analysis among nine outpatient studies with treatment protocols that included albuterol or salbutamol nebulization only (<LINK REF="STD-Anil-2010-SAL-0.9_x0025_" TYPE="STUDY">Anil 2010 SAL 0.9%</LINK>; <LINK REF="STD-Anil-2010-SAL-3_x0025_" TYPE="STUDY">Anil 2010 SAL 3%</LINK>; <LINK REF="STD-Can-1998" TYPE="STUDY">Can 1998</LINK>; <LINK REF="STD-Gadomski-1994a-_x002d_-neb" TYPE="STUDY">Gadomski 1994a - neb</LINK>; <LINK REF="STD-Gadomski-1994b-_x002d_-neb" TYPE="STUDY">Gadomski 1994b - neb</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Klassen-1991" TYPE="STUDY">Klassen 1991</LINK>; <LINK REF="STD-Ralston-2005" TYPE="STUDY">Ralston 2005</LINK>; <LINK REF="STD-Schuh-1990" TYPE="STUDY">Schuh 1990</LINK>; <LINK REF="STD-Schweich-1992" TYPE="STUDY">Schweich 1992</LINK>). As shown in <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>, similar levels of heterogeneity were found but the treatment effect was not significant (I<SUP>2 </SUP>statistic = 85%; SMD -0.36, 95% CI -0.83 to 0.11, P value = 0.13).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Admission to hospital</HEADING>
<P>The rate of hospitalization was not significantly reduced in bronchodilator recipients compared with placebo recipients in outpatient studies (11.9% versus 15.9%; OR 0.75, 95% CI 0.46 to 1.21) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). Rate of hospitalization was not significantly different between oral bronchodilator or placebo groups followed in longer-term home-based studies (4.5% versus 5.2%; OR 0.86, 95% CI 0.28 to 2.64).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Duration of hospitalization</HEADING>
<P>There was no difference between bronchodilator and placebo groups in the length of stay (MD 0.06 days, 95% CI -0.27 to 0.39) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Time to resolution of illness</HEADING>
<P>There is no difference between bronchodilator and placebo groups with respect to time to resolution of illness as measured in the two longer-term home-based studies by <LINK REF="STD-Patel-2003" TYPE="STUDY">Patel 2003</LINK> and <LINK REF="STD-Gupta-2008" TYPE="STUDY">Gupta 2008</LINK> (MD 0.29, 95% CI -0.43 to 1.00, n = 269) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). Thus, oral bronchodilators do not shorten the time to resolution of illness among infants treated at home. However, only two studies examined this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Pulmonary function tests</HEADING>
<P>In this 2014 update, one placebo-controlled study utilizing PFT as an outcome met the inclusion criteria (<LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>). This study utilized tidal breathing analysis using respiratory inductive plethysmography to measure phase angle (thoracoabdominal synchrony). Changes in tidal breathing measures were compared pre- and post-albuterol or saline inhalation for 20 infants hospitalized for bronchiolitis. <LINK REF="STD-Totapally-2002" TYPE="STUDY">Totapally 2002</LINK> used tidal breathing analysis of flow-volume loops measured through close-fitting face masks to compare changes pre- and post-albuterol or saline inhalation for 20 infants with mild RSV-positive bronchiolitis. Although both studies measured peak expiratory flow to total expiratory time (Tpef/Te), the different PFT techniques used preclude merging these measurements for meta-analysis. These studies documented no significant changes in tidal breathing and Tpef/Te measures as well as clinical scores between albuterol nebulization and the 0.9% saline study groups after treatment. <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK> also documented that the RDAI clinical score did not correlate with phase angle (results included in <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). <LINK REF="STD-Levin-2008" TYPE="STUDY">Levin 2008</LINK> measured peak inspiratory pressure and inspiratory system resistance pre- and post-bronchodilator or 0.9% saline nebulization in 22 infants with severe RSV-positive bronchiolitis who were intubated and ventilated in an ICU setting. Small but statistically significant decreases in peak inspiratory pressure as well as significant increases in heart rate were observed after bronchodilator administration compared to no changes after saline. Interestingly, inspiratory resistance fell after all treatments, including saline. Differences in severity of illness, PFT methodology and outcomes (volume versus pressure) preclude merging the results of these three placebo-controlled trials that used PFT measures.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>Subgroup analysis of oximetry showed no statistically significant effects for either outpatients (MD -0.25, 95% CI -0.61 to 0.11) or inpatients (MD -0.62, 95% CI -1.40 to 0.16) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>Subgroup analyses of clinical score showed a slightly greater effect size with bronchodilators in outpatient studies, where there were shorter follow-up durations than for inpatient studies. This was shown in the analysis of average clinical score where there was a modest effect for outpatient studies (SMD -0.42, 95% CI -0.79 to -0.06) compared to the effect in inpatient studies (SMD -0.14, 95% CI -0.41 to 0.12) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>However, the magnitude of these differences between inpatient and outpatient studies is of questionable clinical importance (e.g. a MD of -0.62 in pulse oximetry is not clinically relevant) and the results of these subgroup analyses should be interpreted with caution. These differences may be due to shorter follow-up time, inclusion of participants with recurrent wheezing and lesser severity of illness among outpatients.</P>
<P>Subgroup analysis limiting bronchodilators to albuterol or salbutamol among outpatients showed no effect on oxygen saturation (MD -0.19, 95% CI -0.59 to 0.21) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Nebulized albuterol or salbutamol outpatient treatment had no effect on average clinical score (SMD -0.36, 95% CI -0.83 to 0.11, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) or hospital admission after treatment (OR 0.32, 95% CI 0.03 to 3.21, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). Oral albuterol or salbutamol given at home had no impact on hospital admission after treatment (OR 0.86, 95% CI 0.28 to 2.64, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Heterogeneity</HEADING>
<P>There was evidence of considerable heterogeneity for clinical score measures (dichotomized and average score) and oximetry, but not for hospital admission or duration of hospitalization. Where there was a difference between the effect estimate produced by the random- and fixed-effect models, we chose the more conservative random-effects model. Therefore, we used a random-effects model for oximetry and clinical score and a fixed-effect model for hospital admission, duration of hospitalization and time to resolution of illness outcomes.</P>
<P>For oximetry, use of the fixed-effect model would have resulted in a slightly larger effect estimate that was statistically significant (-0.66, 95% CI -0.82 to -0.49) than the result found with the random-effects model (-0.43, 95% CI -0.92 to 0.06). There was evidence of considerable heterogeneity with this outcome (P value &lt; 0.00001, I<SUP>2</SUP> statistic = 81%) that may be attributed to measurement differences (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The studies measured pulse oximetry at multiple time points. The points selected for pooling were based on times that were most frequently used and were either short-term, at 60 minutes in outpatient studies, or longer-term, at one or three days in inpatient studies. These variable time points for assessment reflect the nature of the studies, in that shorter times were used in outpatient studies while longer times were feasible for inpatients. These factors mean that we considered the random-effects model more appropriate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>We assessed 16 studies as being at low risk of bias (<LINK REF="STD-Alario-1992" TYPE="STUDY">Alario 1992</LINK>; <LINK REF="STD-Anil-2010-SAL-0.9_x0025_" TYPE="STUDY">Anil 2010 SAL 0.9%</LINK>; <LINK REF="STD-Anil-2010-SAL-3_x0025_" TYPE="STUDY">Anil 2010 SAL 3%</LINK>; <LINK REF="STD-Gadomski-1994a-_x002d_-neb" TYPE="STUDY">Gadomski 1994a - neb</LINK>; <LINK REF="STD-Gadomski-1994a-_x002d_-oral" TYPE="STUDY">Gadomski 1994a - oral</LINK>; <LINK REF="STD-Gadomski-1994b-_x002d_-neb" TYPE="STUDY">Gadomski 1994b - neb</LINK>; <LINK REF="STD-Gadomski-1994b-_x002d_-oral" TYPE="STUDY">Gadomski 1994b - oral</LINK>; <LINK REF="STD-Gupta-2008" TYPE="STUDY">Gupta 2008</LINK>; <LINK REF="STD-Klassen-1991" TYPE="STUDY">Klassen 1991</LINK>; <LINK REF="STD-Levin-2008" TYPE="STUDY">Levin 2008</LINK>; <LINK REF="STD-Patel-2002" TYPE="STUDY">Patel 2002</LINK>; <LINK REF="STD-Patel-2003" TYPE="STUDY">Patel 2003</LINK>; <LINK REF="STD-Ralston-2008" TYPE="STUDY">Ralston 2008</LINK>; <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>; <LINK REF="STD-Schuh-1990" TYPE="STUDY">Schuh 1990</LINK>; <LINK REF="STD-Schweich-1992" TYPE="STUDY">Schweich 1992</LINK>; <LINK REF="STD-Tinsa-2009" TYPE="STUDY">Tinsa 2009</LINK>; <LINK REF="STD-Totapally-2002" TYPE="STUDY">Totapally 2002</LINK>; <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>). Including only low risk of bias studies in the analysis significantly reduced the heterogeneity measures for oximetry (I<SUP>2</SUP> statistic = 17%; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) and average clinical score (I<SUP>2</SUP> statistic = 37%; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>), while having little impact on the overall effect size of oximetry (MD -0.38, 95% CI -0.75 to 0.00, P value = 0.05; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) and average clinical score (SMD -0.22, 95% CI -0.41 to -0.03, P value = 0.02; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). In other words, reducing the heterogeneity by removing studies with higher risk of bias did not uncover a clinically relevant treatment effect or materially change the magnitude of the effect size.</P>
<P>Low risk of bias sensitivity analysis did not significantly change the heterogeneity or effect estimates for hospital admission after treatment in an outpatient setting, duration of hospitalization or time to resolution of illness at home.</P>
<P>Fourteen studies included infants aged less than or equal to 12 months (<LINK REF="STD-Chevallier-1995" TYPE="STUDY">Chevallier 1995</LINK>; <LINK REF="STD-Chowdhury-1995" TYPE="STUDY">Chowdhury 1995</LINK>; <LINK REF="STD-Gupta-2008" TYPE="STUDY">Gupta 2008</LINK>; <LINK REF="STD-Henry-1983" TYPE="STUDY">Henry 1983</LINK>; <LINK REF="STD-Ho-1991" TYPE="STUDY">Ho 1991</LINK>; <LINK REF="STD-Karadag-2008" TYPE="STUDY">Karadag 2008</LINK>; <LINK REF="STD-Levin-2008" TYPE="STUDY">Levin 2008</LINK>; <LINK REF="STD-Mallol-1987" TYPE="STUDY">Mallol 1987</LINK>; <LINK REF="STD-Patel-2002" TYPE="STUDY">Patel 2002</LINK>; <LINK REF="STD-Patel-2003" TYPE="STUDY">Patel 2003</LINK>; <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>; <LINK REF="STD-Tal-1983" TYPE="STUDY">Tal 1983</LINK>; <LINK REF="STD-Tinsa-2009" TYPE="STUDY">Tinsa 2009</LINK>; <LINK REF="STD-Totapally-2002" TYPE="STUDY">Totapally 2002</LINK>). In this sensitivity analysis, the exclusion of several studies did not improve measures of heterogeneity but led to unstable effect size estimates.</P>
<P>Nineteen studies explicitly described inclusion of first-time wheezing infants (<LINK REF="STD-Anil-2010-SAL-0.9_x0025_" TYPE="STUDY">Anil 2010 SAL 0.9%</LINK>; <LINK REF="STD-Chevallier-1995" TYPE="STUDY">Chevallier 1995</LINK>; <LINK REF="STD-Chowdhury-1995" TYPE="STUDY">Chowdhury 1995</LINK>; <LINK REF="STD-Dobson-1998" TYPE="STUDY">Dobson 1998</LINK>; <LINK REF="STD-Gadomski-1994a-_x002d_-neb" TYPE="STUDY">Gadomski 1994a - neb</LINK>; <LINK REF="STD-Gadomski-1994a-_x002d_-oral" TYPE="STUDY">Gadomski 1994a - oral</LINK>; <LINK REF="STD-Gadomski-1994b-_x002d_-neb" TYPE="STUDY">Gadomski 1994b - neb</LINK>; <LINK REF="STD-Gadomski-1994b-_x002d_-oral" TYPE="STUDY">Gadomski 1994b - oral</LINK>; <LINK REF="STD-Goh-1997" TYPE="STUDY">Goh 1997</LINK>; <LINK REF="STD-Gupta-2008" TYPE="STUDY">Gupta 2008</LINK>; <LINK REF="STD-Ho-1991" TYPE="STUDY">Ho 1991</LINK>; <LINK REF="STD-Ipek-2011" TYPE="STUDY">Ipek 2011</LINK>; <LINK REF="STD-Karadag-2008" TYPE="STUDY">Karadag 2008</LINK>; <LINK REF="STD-Levin-2008" TYPE="STUDY">Levin 2008</LINK>; <LINK REF="STD-Patel-2002" TYPE="STUDY">Patel 2002</LINK>; <LINK REF="STD-Patel-2003" TYPE="STUDY">Patel 2003</LINK>; <LINK REF="STD-Ralston-2005" TYPE="STUDY">Ralston 2005</LINK>; <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>; <LINK REF="STD-Schuh-1990" TYPE="STUDY">Schuh 1990</LINK>; <LINK REF="STD-Tinsa-2009" TYPE="STUDY">Tinsa 2009</LINK>; <LINK REF="STD-Totapally-2002" TYPE="STUDY">Totapally 2002</LINK>). Limiting the analysis of average clinical score to first-time wheezers led to a non-significant treatment effect and also reduced heterogeneity measures and reduced mean differences (I<SUP>2</SUP> statistic = 30%, SMD - 0.10, 95% CI -0.28 to 0.08, P value = 0.13). However, no impact was observed for the other outcomes.</P>
<P>Three studies of outpatients utilized identical clinical score measurement, that is, the complete RDAI (<LINK REF="STD-Anil-2010-SAL-0.9_x0025_" TYPE="STUDY">Anil 2010 SAL 0.9%</LINK>; <LINK REF="STD-Anil-2010-SAL-3_x0025_" TYPE="STUDY">Anil 2010 SAL 3%</LINK>; <LINK REF="STD-Klassen-1991" TYPE="STUDY">Klassen 1991</LINK>; <LINK REF="STD-Ralston-2005" TYPE="STUDY">Ralston 2005</LINK>) (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). Limiting the analysis of average clinical score to these three studies showed substantially decreased heterogeneity (I<SUP>2 </SUP>statistic = 47%) when compared to all outpatient studies (I<SUP>2 </SUP>statistic = 81%). However, there was virtually no change in effect size (SMD -0.11, 95% CI -0.48 to 0.25, P value = 0.54).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>Where adverse effects were reported, we note that these were exclusively found in the study groups receiving bronchodilators and they included: tachycardia (P value less than 0.05) (<LINK REF="STD-Klassen-1991" TYPE="STUDY">Klassen 1991</LINK>; <LINK REF="STD-Lines-1990" TYPE="STUDY">Lines 1990</LINK>), decreased oxygen saturation (P value less than 0.05) (<LINK REF="STD-Ho-1991" TYPE="STUDY">Ho 1991</LINK>; <LINK REF="STD-Schweich-1992" TYPE="STUDY">Schweich 1992</LINK>), flushing (one and four participants, respectively) (<LINK REF="STD-Alario-1992" TYPE="STUDY">Alario 1992</LINK>; <LINK REF="STD-Gadomski-1994b-_x002d_-neb" TYPE="STUDY">Gadomski 1994b - neb</LINK>), hyperactivity (three participants) (<LINK REF="STD-Gadomski-1994b-_x002d_-neb" TYPE="STUDY">Gadomski 1994b - neb</LINK>), tachycardia and prolonged cough (two participants) (<LINK REF="STD-Henry-1983" TYPE="STUDY">Henry 1983</LINK>) and tremor (one participant each) (<LINK REF="STD-Tal-1983" TYPE="STUDY">Tal 1983</LINK>; <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>).</P>
<P>Amongst studies added in the 2006 update, tachycardia, mild hypertension and slight tremor were reported by <LINK REF="STD-Patel-2002" TYPE="STUDY">Patel 2002</LINK>. One infant receiving albuterol was transferred to the intensive care unit for 48 hours but did not require mechanical ventilation. No side effects were noted by <LINK REF="STD-Karadag-2005-_x002d_-IPR" TYPE="STUDY">Karadag 2005 - IPR</LINK>, except that one patient in the ipratropium group was subsequently excluded because of deteriorating clinical status. No adverse effects were described by <LINK REF="STD-Can-1998" TYPE="STUDY">Can 1998</LINK> or <LINK REF="STD-Totapally-2002" TYPE="STUDY">Totapally 2002</LINK>.</P>
<P>In the 2010 update, no adverse effects were reported in two studies (<LINK REF="STD-Anil-2010-SAL-0.9_x0025_" TYPE="STUDY">Anil 2010 SAL 0.9%</LINK>; <LINK REF="STD-Anil-2010-SAL-3_x0025_" TYPE="STUDY">Anil 2010 SAL 3%</LINK>; <LINK REF="STD-Tinsa-2009" TYPE="STUDY">Tinsa 2009</LINK>). Adverse effects including trembling, vomiting and irritability were systematically addressed in the two home studies of oral bronchodilators (<LINK REF="STD-Gupta-2008" TYPE="STUDY">Gupta 2008</LINK>; <LINK REF="STD-Patel-2003" TYPE="STUDY">Patel 2003</LINK>). While no difference was found in these symptoms between placebo and bronchodilator groups in one study (<LINK REF="STD-Patel-2003" TYPE="STUDY">Patel 2003</LINK>), more infants in the salbutamol group (six) were reported to have tremors versus the placebo group (none) in the other home study (<LINK REF="STD-Gupta-2008" TYPE="STUDY">Gupta 2008</LINK>). Significant tachycardia (sustained heart rate over 200 beats per minute for more than 30 minutes) was reported in two infants receiving albuterol nebulization (<LINK REF="STD-Ralston-2005" TYPE="STUDY">Ralston 2005</LINK>). Significant increases in heart rate were observed for all nebulized bronchodilators administered to intubated and ventilated infants compared to infants who received normal saline (<LINK REF="STD-Levin-2008" TYPE="STUDY">Levin 2008</LINK>).</P>
<P>This 2014 update includes <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>, who reported a paradoxical response to albuterol in an infant whose phase angle increased after receiving albuterol (the expected response was a decrease).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-06-02 19:14:49 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-06-02 18:57:41 +1000" MODIFIED_BY="[Empty name]">
<P>This 2014 update of the meta-analysis of trials of bronchodilators to treat infants with bronchiolitis shows no effect on oxygen saturation for outpatients or inpatients. Bronchodilators do not reduce the rate of hospital admission after outpatient treatment, do not shorten the duration of hospitalization and do not shorten the time to resolution of illness in home studies.</P>
<P>The two new studies add to the evidence that &#946;<SUB>2</SUB>-adrenergic agonists, i.e. albuterol (US) or salbutamol (as it is known elsewhere), are not effective for treating bronchiolitis. While they may produce small short-term improvements in clinical scores for infants treated as outpatients, this short-term benefit is not justified given the costs and adverse effects of these agents. These bronchodilators cause tachycardia and tremors, therefore routine use of bronchodilators for infants with bronchiolitis is not indicated.</P>
<P>
<B>What we learned from new sensitivity analysis.</B> This meta-analysis is limited by the significant heterogeneity in the analysis of trials that included oximetry and clinical score outcomes. Including only studies at low risk of bias in the meta-analysis significantly reduced the heterogeneity measures for average clinical score and oximetry, while having little impact on the overall effect size of oximetry and average clinical score outcomes.</P>
<P>Subgroup analyses showed a slightly greater effect size in outpatient studies, where there were shorter follow-up times and more recurrent wheezers and less severely ill infants included, than in inpatient studies for both oximetry and average clinical score. However, again the effect sizes are small for both settings and are of minimal clinical significance (for oximetry: outpatients mean difference (MD) -0.25 versus inpatients -0.62; for average clinical score: outpatients standardized MD (SMD) -0.42 versus inpatients -0.14). These findings may be biased toward showing a difference favoring treatment because older studies included in this analysis included older participants with recurrent wheezing and/or asthma. The inclusion of asthmatic children, who are known to respond to bronchodilators, will falsely increase the apparent level of efficacy in patients with bronchiolitis.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Increased detection of hypoxia by using pulse oximetry has been cited as one of the reasons that, in the US, hospitalization rates for bronchiolitis nearly doubled from 1988 to 1996, with no significant change in mortality during that time period (<LINK REF="REF-Shay-2001" TYPE="REFERENCE">Shay 2001</LINK>). Despite other reasons for increased hospitalization rates that include increased daycare attendance at younger ages and increased survival of premature infants (<LINK REF="REF-Shay-1999" TYPE="REFERENCE">Shay 1999</LINK>), variable pulse oximetry cut-off points for hypoxia necessitating oxygen administration probably contribute to increasing hospitalization rates as well as considerable practice variation. Clinically meaningful standardization of pulse oximetry endpoints for hospitalization and definition of what the minimal clinically important difference is for this outcome are now defined in clinical practice guidelines.</P>
<P>The lack of benefit from bronchodilators in preventing hospitalization may be difficult to interpret. In several outpatient studies, the decision to admit was made after the study was completed. This decision was made by non-study physicians and further treatment may have been given, regardless of the intervention received during the study. Thus, this outcome may reflect other treatments and social considerations, as well as the initial intervention provided in the study.</P>
<P>Similarly, the duration of hospitalization was not altered by receipt of bronchodilators. However, hospital stay is affected by multiple factors other than the clinical status of the patient. Although randomization should balance these factors, length of hospital stay may be an insensitive measure. Among Canadian hospitals, duration of hospitalization did not vary significantly despite significant variation in the types of medications used to treat infants with bronchiolitis (<LINK REF="REF-Wang-1996" TYPE="REFERENCE">Wang 1996</LINK>).</P>
<P>The widespread use of bronchodilators in bronchiolitis is likely to be due to the similarity of symptoms and signs of bronchiolitis and asthma. Bronchodilators are effective in the treatment of asthma in older children and adults, where airway obstruction is caused by inflammation, bronchospasm and bronchial hyperreactivity (<LINK REF="REF-Levison-1991" TYPE="REFERENCE">Levison 1991</LINK>). However, a Cochrane Review of short-acting &#946;<SUB>2</SUB>-adrenergic agonists for recurrent wheezing in children under two years of age showed no clear benefit of using bronchodilators in this age group (<LINK REF="REF-Chavasse-2002" TYPE="REFERENCE">Chavasse 2002</LINK>). The pathophysiology of bronchiolitis consists of terminal bronchiolar and alveolar inflammation with airway swelling and luminal debris, therefore the primary mechanism underlying wheezing is airway obstruction and plugging of the small airway diameters rather than bronchospasm (<LINK REF="REF-La-Via-1992" TYPE="REFERENCE">La Via 1992</LINK>). In addition, it may be difficult to administer the nebulization to young infants effectively. Lastly, the relative lack or immaturity of the &#946;<SUB>2</SUB>-receptor in the bronchial wall smooth muscle in infants further limits the potential effectiveness of &#946;<SUB>2</SUB>-adrenergic agonists. These factors may explain why bronchodilators are not effective for infants with bronchiolitis.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-06-02 19:14:49 +1000" MODIFIED_BY="[Empty name]">
<P>The lack of improvement in oximetry with bronchodilators and the heterogeneity of clinical scoring challenge the utility of these agents. The validity of the clinical score as an indicator of pulmonary status or relevant clinical change has not been proven (<LINK REF="REF-Hall-2007" TYPE="REFERENCE">Hall 2007</LINK>). Gadomski and colleagues have suggested that improvement in clinical scores may be due to changes in physiological state (for example, change from asleep to awake) rather than improved respiratory function with bronchodilator therapy (<LINK REF="STD-Gadomski-1994a-_x002d_-neb" TYPE="STUDY">Gadomski 1994a - neb</LINK>).</P>
<P>The clinical scoring systems used in the studies included in this review varied considerably. Few have been tested for validity, reliability or compared to a physiologic standard or proven to correlate with clinically significant improvement (<LINK REF="STD-Mull-2004" TYPE="STUDY">Mull 2004</LINK>; <LINK REF="STD-Scarlett-2012" TYPE="STUDY">Scarlett 2012</LINK>; <LINK REF="REF-Zorc-2010" TYPE="REFERENCE">Zorc 2010</LINK>), or predict the need for oxygen (<LINK REF="REF-McCallum-2013" TYPE="REFERENCE">McCallum 2013</LINK>) or hospital admission from the emergency department (<LINK REF="REF-Destino-2010" TYPE="REFERENCE">Destino 2010</LINK>). Interrater variability of current scoring methods can be high. The most commonly used score, the RDAI, has low intraclass correlation, poor construct and discriminative validity (<LINK REF="REF-Destino-2010" TYPE="REFERENCE">Destino 2010</LINK>; <LINK REF="REF-Destino-2012" TYPE="REFERENCE">Destino 2012</LINK>; <LINK REF="STD-Walsh-2008" TYPE="STUDY">Walsh 2008</LINK>). Sensitivity analysis of studies that used the RDAI show substantially decreased heterogeneity but no treatment effect (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
<P>During this 2014 update, we found few new randomized, placebo-controlled clinical trials. The adequacy of the outcome measures used to measure infant response to bronchodilators remains limited. The number of studies using similar outcome measures remains small, which limits the reliability of the effect size estimation. Most of the outcome effect estimates are small or show no difference from placebo. The estimates are imprecise as reflected by wide confidence intervals. Therefore, this meta-analysis continues to be limited by the small sample sizes and the lack of standardized study design and reliable outcome assessment across the studies. Thus, randomized controlled trials (RCTs) with large sample sizes, standardized methodology across clinical sites and consistent assessment methods are needed to answer completely the question of efficacy.</P>
<P>A more objective alternative to these outcomes is pulmonary function testing (PFT) as performed by <LINK REF="STD-Levin-2008" TYPE="STUDY">Levin 2008</LINK>, although limited to infants with severe disease. Although the number of bronchiolitis studies utilizing PFTs has increased to 10, the methods and outcomes for measuring PFTs vary, thereby precluding comparability. In addition, only three studies employed a placebo-controlled RCT design comparing measures pre- and post-treatment with a bronchodilator. Future PFT studies should employ a placebo-controlled RCT design as well as standardized methods so that outcome data can be merged.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-09-17 07:33:24 +1000" MODIFIED_BY="[Empty name]">
<P>One of the authors is a trialist and a member of the American Academy of Pediatrics Subcommittee on the Diagnosis and Management of Bronchiolitis.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>The results of this meta-analysis concur with recent reviews (<LINK REF="REF-Hartling-2011b" TYPE="REFERENCE">Hartling 2011b</LINK>; <LINK REF="REF-Wainwright-2010" TYPE="REFERENCE">Wainwright 2010</LINK>; <LINK REF="REF-Zorc-2010" TYPE="REFERENCE">Zorc 2010</LINK>), which underscore the limited effectiveness of bronchodilators, particularly as they relate to &#946;<SUB>2</SUB>-adrenergic agonists in the outpatient management of bronchiolitis. This review is also consistent with these prior reviews in the conclusion that there is no significant treatment effect of bronchodilators for infants hospitalized with bronchiolitis (<LINK REF="REF-Hartling-2011b" TYPE="REFERENCE">Hartling 2011b</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-06-02 19:02:40 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-06-02 19:02:40 +1000" MODIFIED_BY="[Empty name]">
<P>Given their high cost, adverse effects and lack of effect on oxygen saturation and other outcomes included in this meta-analysis, bronchodilators are not effective in the routine management of first-time wheezers who present with the clinical findings of bronchiolitis, in either inpatient or outpatient settings.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Prior to conducting further treatment trials, an objective outcome measure that correlates with pulmonary function tests and is independent of the level of alertness of the infant needs to be developed and validated. Measures such as need for hospital admission and duration of hospital stay, while important from a health service utilization perspective, may not be adequately sensitive to measure the improvement that may occur from treatment (<LINK REF="REF-Hall-2004" TYPE="REFERENCE">Hall 2004</LINK>; <LINK REF="REF-Hall-2007" TYPE="REFERENCE">Hall 2007</LINK>). Pulmonary function testing outcomes should be standardized so that outcome data can be merged across studies. Interrater variability as well as validity studies of the current scoring methods are needed to choose the most reliable and valid scoring system, if clinical scoring is used.</P>
<P>Treatment trials need to be conducted using placebo controls. RCTs with large sample size and standardized methodology across clinical sites are needed to answer completely the question of efficacy. Exclusion criteria must be consistently applied to exclude infants with recurrent wheezing, asthma or other pulmonary disease.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>We wish to thank Drs A Alario, T Klassen, L Landau, D Lines, S Schuh, P Schweich and C Ren for providing unpublished data from their studies. We are also grateful to Mr Derek Stephens and Ms Terri Myhr, of Toronto for their assistance with the statistical analyses performed for the original review. The original review was presented in part at the annual meeting of the Ambulatory Pediatric Association: May 1994, Seattle, Washington. The 2010 update was presented at the Pediatric Academic Societies meeting: May 2011, Denver, Colorado.</P>
<P>We would like to acknowledge the contributions of three of the original co-authors, JD Kellner, A Ohlsson and EEL Wang in conducting the original work for this review on which this update is based (<LINK REF="REF-Kellner-1998" TYPE="REFERENCE">Kellner 1998</LINK>). Drs F Gurkan, B Karadag and H Patel generously provided unpublished data from their studies for the 2006 update. Drs. Tinsa and S Ralston graciously provided unpublished data from their studies for the 2010 update. The assistance of Sarah Thorning in conducting the searches for the update is also appreciated.</P>
<P>Taixiang Wu provided invaluable assistance in assessing eligibility of trials published in the Chinese language. The support of the National Prescribing Service (NPS), Australia allowed A Bhasale to contribute to this update and is appreciated. Reviews were received with thanks from the following peer referees: Alison Thomas, Craig Mellis, Rob Ware, Juan Lozano, Amanda Young, David Isaacs, Nelcy Rodriguez-Malagon, Inge Axelsson, Conor Teljeur and Anne Lyddiatt. Finally we would like to acknowledge with thanks the support and guidance of Liz Dooley, Managing Editor for the Cochrane ARI Group, throughout the 2006, 2010 and 2014 updates.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-06-02 01:18:15 +1000" MODIFIED_BY="[Empty name]">
<P>Ann Gadomski is a trialist in included studies and is a member of the AAP Subcommittee on Diagnosis and Management of Bronchiolitis.<BR/>Melissa Scribani: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-04-15 07:14:57 +1000" MODIFIED_BY="Liz Dooley">
<P>For the 2006 update, Anne Gadomski (AG) reviewed all the searches, selected studies and contacted authors to request unpublished data. AG identified outcomes of trials relevant for inclusion, reviewed the results and wrote the discussion and conclusions. Alice Bhasale (AB) assisted with some of the searches and selection of studies, data entry and analyses.</P>
<P>For the 2010 and 2014 updates, AG and Melissa (Brower) Scribani (MS) reviewed all the searches, selected studies, reviewed the included studies for risk of bias as well as outcomes and reviewed meta-analysis results. MS performed the meta-analysis and sensitivity analysis. AG contacted authors to request unpublished data and updated the text of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-06-02 19:05:16 +1000" MODIFIED_BY="[Empty name]">
<P>Oxygen saturation was designated as the primary outcome in the 2010 update. Two review authors assessed risk of bias and completed the 'Risk of bias' table for all studies in the 2010 update. We completed sensitivity analysis for low risk of bias studies, studies including only first-time wheezers and studies including only infants less or equal to 12 months of age in the 2010 update. We completed sensitivity analysis for studies using RDAI in the 2014 update. We added subgroup analyses limited to studies using either albuterol or salbutamol in 2014.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-06-07 02:09:07 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-06-07 02:09:07 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-06-02 19:15:55 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alario-1992" MODIFIED="2010-10-14 04:49:13 +1000" MODIFIED_BY="Melissa A Brower" NAME="Alario 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-10-14 04:49:13 +1000" MODIFIED_BY="Melissa A Brower" NOTES="&lt;p&gt;Alario AJ, Lewander WJ, Dennehy P, et al. The efficacy of nebulized metaproterenol in wheezing infants and young children. Am J Dis Child 1992;146:412-8.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-10-14 04:49:13 +1000" NOTES_MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alario AJ, Lewander WJ, Dennehy P, Seifer R, Mansell AL</AU>
<TI>The efficacy of nebulized metaproterenol in wheezing infants and young children</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1992</YR>
<VL>146</VL>
<PG>412-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anil-2010-SAL-0.9_x0025_" MODIFIED="2010-05-28 01:46:30 +1000" MODIFIED_BY="Melissa A Brower" NAME="Anil 2010 SAL 0.9%" YEAR="2010">
<REFERENCE MODIFIED="2010-05-28 01:46:30 +1000" MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>See Anil 2010 SAL 3.0%</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anil-2010-SAL-3_x0025_" MODIFIED="2010-06-07 15:21:37 +1000" MODIFIED_BY="[Empty name]" NAME="Anil 2010 SAL 3%" YEAR="2010">
<REFERENCE MODIFIED="2010-06-07 15:21:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anil AB, Anil M, Saglam AB, Cetin N, Bal A, Aksu N</AU>
<TI>High volume normal saline alone is as effective as nebulized salbutamol-normal saline, epinephrine-normal saline, and 3% saline in mild bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2010</YR>
<VL>45</VL>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Can-1998" NAME="Can 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Can D, Inan G, Yendur G, Oral R, Günay I</AU>
<TI>Salbutamol or mist in acute bronchiolitis</TI>
<SO>Acta Paediatrica Japonica</SO>
<YR>1998</YR>
<VL>40</VL>
<NO>3</NO>
<PG>252-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chevallier-1995" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Chevallier 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Chevallier B, Aegerter P, Parat S, Bidat E, Renaud C, Lagardere B. Etude comparative des nebulisations de salbutamol contre placebo a la phase aigue d'une bronchiolite chez 33 nourrissons de 1 a 6 mois. Arch Pediatr. 1995;2:11-17.&lt;/p&gt;" NOTES_MODIFIED="2014-06-02 18:12:44 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chevallier B, Aegerter P, Parat S, Bidat E, Renaud C, Lagardere B</AU>
<TI>Comparative study of nebulized sambutol against placebo in the acute phase of bronchiolitis in 33 infants aged 1 to 6 months</TI>
<TO>Etude comparative des nebulisations de salbutamol contre placebo a la phase aigue d'une bronchiolite chez 33 nourrissons de 1 a 6 mois</TO>
<SO>Archives de Pédiatrie</SO>
<YR>1995</YR>
<VL>2</VL>
<NO>1</NO>
<PG>11-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chowdhury-1995" NAME="Chowdhury 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Chowdhury D, Al Howasi M, Khalil M, Al-Frayh AS, Chowdhury S, Ramia S. The role of bronchodilators in the management of bronchiolitis: a clinical trial. Annals of Tropical Paediatrics. 1995;15:77-84.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chowdhury D, Al Howasi M, Khalil M, Al-Frayh AS, Chowdhury S, Ramia S</AU>
<TI>The role of bronchodilators in the management of bronchiolitis: a clinical trial</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>1995</YR>
<VL>15</VL>
<PG>77-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dobson-1998" NAME="Dobson 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Dobson JV, Stephen-Groff SM, McMahon SR, Stemmler MM, Brallier SL, Bay C. The use of albuterol in hospitalized infants with bronchiolitis. Pediatrics. 1998;101:361-368.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dobson JV, Stephen-Groff SM, McMahon SR, Stemmler MM, Brallier SL, Bay C</AU>
<TI>The use of albuterol in hospitalized infants with bronchiolitis</TI>
<SO>Pediatrics</SO>
<YR>1998</YR>
<VL>101</VL>
<PG>361-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gadomski-1994a-_x002d_-neb" MODIFIED="2014-06-02 19:14:49 +1000" MODIFIED_BY="[Empty name]" NAME="Gadomski 1994a - neb" YEAR="1994">
<REFERENCE MODIFIED="2010-10-14 04:46:12 +1000" MODIFIED_BY="Melissa A Brower" NOTES="&lt;p&gt;Gadomski AM, Aref GH, El Din OB, et al. Oral versus nebulized albuterol in the management of bronchiolitis in Egypt. J Pediatr. 1994;124:131-138.&lt;/p&gt;" NOTES_MODIFIED="2010-10-14 04:46:12 +1000" NOTES_MODIFIED_BY="Melissa A Brower" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gadomski AM, Aref GH, El Din OB, El Sawy IH, Khallaf N, Black RE</AU>
<TI>Oral versus nebulized albuterol in the management of bronchiolitis in Egypt</TI>
<SO>Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>124</VL>
<PG>131-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gadomski-1994a-_x002d_-oral" MODIFIED="2014-06-02 19:15:44 +1000" MODIFIED_BY="[Empty name]" NAME="Gadomski 1994a - oral" YEAR="1994">
<REFERENCE MODIFIED="2014-06-02 19:15:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>See Gadomski 1994a - neb</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gadomski-1994b-_x002d_-neb" MODIFIED="2014-06-02 19:15:01 +1000" MODIFIED_BY="[Empty name]" NAME="Gadomski 1994b - neb" YEAR="1994">
<REFERENCE MODIFIED="2010-10-14 04:48:09 +1000" MODIFIED_BY="Melissa A Brower" NOTES="&lt;p&gt;Gadomski AM, Lichenstein R, Horton L, et al. Efficacy of albuterol in the management of bronchiolitis. Pediatrics 1994;93:907-12.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-10-14 04:48:09 +1000" NOTES_MODIFIED_BY="Melissa A Brower" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gadomski AM, Lichenstein R, Horton L, King J, Keane V, Permutt T</AU>
<TI>Efficacy of albuterol in the management of bronchiolitis</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>93</VL>
<PG>907-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gadomski-1994b-_x002d_-oral" MODIFIED="2014-06-02 19:15:55 +1000" MODIFIED_BY="[Empty name]" NAME="Gadomski 1994b - oral" YEAR="1994">
<REFERENCE MODIFIED="2014-06-02 19:15:55 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Gadomski AM, Lichenstein R, Horton L, et al. Efficacy of albuterol in the management of bronchiolitis. Pediatrics 1994;93:907-12.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-06-02 19:15:55 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>See Gadomski 1994b - neb</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goh-1997" NAME="Goh 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Goh A, Chay OM, Foo AL, Ong EK. Efficacy of bronchodilators in the treatment of bronchiolitis. Singapore Med J. 1997;38:326-328.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goh A, Chay OM, Foo AL, Ong EK</AU>
<TI>Efficacy of bronchodilators in the treatment of bronchiolitis</TI>
<SO>Singapore Medical Journal</SO>
<YR>1997</YR>
<VL>38</VL>
<PG>326-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gupta-2008" MODIFIED="2010-06-07 15:28:09 +1000" MODIFIED_BY="[Empty name]" NAME="Gupta 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-07 15:28:09 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gupta P, Aggarwal A, Gupta P, Sharma KK</AU>
<TI>Oral salbutamol for symptomatic relief in mild bronchiolitis: a double blind randomized placebo controlled trial</TI>
<SO>Indian Pediatrics</SO>
<YR>2008</YR>
<VL>45</VL>
<PG>547-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-04-03 05:00:45 +1000" MODIFIED_BY="Melissa A Brower"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gurkan-2004" NAME="Gurkan 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Emailed author requesting further info, 29/11/2005 fuatgurkan@hotmail.com&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gurkan F, Tuzun H, Ece A, Haspolat K, Bosnak M, Dikici B</AU>
<TI>Comparison of treatments with nebulized salbutamol and epinephrine in acute bronchiolitis [Abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>Suppl 48</NO>
<PG>344</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henry-1983" NAME="Henry 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Henry RL, Milner AD, Stokes GM. Ineffectiveness of ipratropium bromide in acute bronchiolitis. Arch Dis Child 1983;58:925-6.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henry RL, Milner AD, Stokes GM</AU>
<TI>Ineffectiveness of ipratropium bromide in acute bronchiolitis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1983</YR>
<VL>58</VL>
<PG>925-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ho-1991" NAME="Ho 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Ho L, Collis G, Landau LI, Le Souf PN. Effect of salbutamol on oxygen saturation in bronchiolitis. Arch Dis Child 1991;66:1061-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ho L, Collis G, Landau LI, Le Souf PN</AU>
<TI>Effect of salbutamol on oxygen saturation in bronchiolitis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1991</YR>
<VL>66</VL>
<PG>1061-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ipek-2011" MODIFIED="2013-12-13 09:46:29 +1000" MODIFIED_BY="[Empty name]" NAME="Ipek 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-12-13 09:46:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ipek IO, Yalcin EU, Sezer RG, Bozaykut A</AU>
<TI>The efficacy of nebulized salbutamol, hypertonic saline and salbutamol/hypertonic saline combination in moderate bronchiolitis</TI>
<SO>Pulmonary Pharmacology and Therapeutics</SO>
<YR>2011</YR>
<VL>24</VL>
<PG>633-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Karadag-2005-_x002d_-IPR" MODIFIED="2014-06-02 02:48:49 +1000" MODIFIED_BY="[Empty name]" NAME="Karadag 2005 - IPR" YEAR="2005">
<REFERENCE MODIFIED="2010-06-07 15:28:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karadag B, Ceran O, Dursun E, Guven G, Ozahi I, Karakoc F, et al</AU>
<TI>Efficacy of bronchodilators in acute bronchiolitis [Abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>Suppl 31</NO>
<PG>562</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00415977"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-07 15:28:40 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Provided by email from the Author B. Karadag. Being considered for publication October 2005.&lt;/p&gt;" NOTES_MODIFIED="2010-06-07 15:28:40 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Karadag B, Ceran O, Guven G, Dursun E, Ozahi I, Karakoc F, et al</AU>
<TI>The role of bronchodilators in the management of acute bronchiolitis</TI>
<SO>Unpublished manuscript</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-06-02 02:48:49 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Karadag B, Cerna O, Dursun E, Guven G, Ozahi I, Karakoc F, et al</AU>
<TI>Comparison of bronchodilators in acute bronchiolitis [Abstract]</TI>
<SO>European Respiratory Society Annual Congress</SO>
<YR>2002</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00429340"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Karadag-2005-_x002d_-SAL" MODIFIED="2010-04-21 23:52:30 +1000" MODIFIED_BY="Melissa A Brower" NAME="Karadag 2005 - SAL" YEAR="">
<REFERENCE MODIFIED="2010-04-21 23:52:30 +1000" MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>See Karadag 2005 - IPR</AU>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karadag-2008" MODIFIED="2010-06-07 15:29:18 +1000" MODIFIED_BY="[Empty name]" NAME="Karadag 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-07 15:29:18 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karadag B, Ceran O, Guven G, Dursun E, Ipek IO, Karakoc F, et al</AU>
<TI>Efficacy of salbutamol and ipratropium bromide in the management of acute bronchiolitis - a clinical trial</TI>
<SO>Respiration</SO>
<YR>2008</YR>
<VL>76</VL>
<PG>283-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klassen-1991" MODIFIED="2010-10-14 04:56:43 +1000" MODIFIED_BY="Melissa A Brower" NAME="Klassen 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-10-14 04:56:43 +1000" MODIFIED_BY="Melissa A Brower" NOTES="&lt;p&gt;Klassen TP, Rowe PC, Sutcliffe T, et al. Randomized trial of salbutamol in acute bronchiolitis. J Pediatr 1991;118:807-11.&lt;/p&gt;" NOTES_MODIFIED="2010-10-14 04:56:43 +1000" NOTES_MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP, Rowe PC, Sutcliffe T, Ropp LJ, McDowell IW, Li MM</AU>
<TI>Randomized trial of salbutamol in acute bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1991</YR>
<VL>118</VL>
<PG>807-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-2008" MODIFIED="2010-04-01 23:41:25 +1000" MODIFIED_BY="Melissa A Brower" NAME="Levin 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-01 23:41:22 +1000" MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin DL, Garg A, Hall LJ, Slogic S, Jarvis JD, Leiter JC</AU>
<TI>A prospective randomized controlled blinded study of three bronchodilators in infants with respiratory syncytial virus bronchiolitis on mechanical ventilation</TI>
<SO>Pediatric Critical Care Medicine</SO>
<YR>2008</YR>
<VL>9</VL>
<PG>598-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lines-1990" NAME="Lines 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Lines DR, Kattampallil JS, Liston P. Efficacy of nebulized salbutamol in bronchiolitis. Pediatr Rev Commun 1990;5:121-9.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lines DR, Kattampallil JS, Liston P</AU>
<TI>Efficacy of nebulized salbutamol in bronchiolitis</TI>
<SO>Pediatric Reviews &amp; Communications</SO>
<YR>1990</YR>
<VL>5</VL>
<PG>121-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lines-1992" MODIFIED="2010-06-07 15:30:01 +1000" MODIFIED_BY="[Empty name]" NAME="Lines 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-06-07 15:30:01 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lines DR, Bates ML, Rechtman AR, LP. S. Efficacy of nebulized ipratropium bromide in acute bronchiolitis. Pediatr Rev Commun 1992;6:161-7.&lt;/p&gt;" NOTES_MODIFIED="2010-06-07 15:30:01 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lines DR, Bates ML, Rechtman AR</AU>
<TI>Efficacy of nebulized ipratropium bromide in acute bronchiolitis</TI>
<SO>Pediatric Reviews &amp; Communications</SO>
<YR>1992</YR>
<VL>6</VL>
<PG>161-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mallol-1987" MODIFIED="2010-10-14 04:55:26 +1000" MODIFIED_BY="Melissa A Brower" NAME="Mallol 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-10-14 04:55:26 +1000" MODIFIED_BY="Melissa A Brower" NOTES="&lt;p&gt;Mallol J, Barrueto L, Girardi G, et al. Use of nebulized bronchodilators in infants under 1 year of age: analysis of four forms of therapy. Pediatr Pulmonol 1987;3:298-303.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-10-14 04:55:26 +1000" NOTES_MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallol J, Barrueto L, Girardi G, Munoz R, Puppo H, Ulloa V, et al</AU>
<TI>Use of nebulized bronchodilators in infants under 1 year of age: analysis of four forms of therapy</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1987</YR>
<VL>3</VL>
<PG>298-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Patel-2002" NAME="Patel 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Patel H, Platt RW, Pekeles GS, Ducharme FM. A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis. Journal-of-Pediatrics. 2002; 141(6): 818-824.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel H, Platt RW, Pekeles GS, Ducharme FM</AU>
<TI>A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>141</VL>
<NO>6</NO>
<PG>818-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-2003" MODIFIED="2010-04-05 23:17:48 +1000" MODIFIED_BY="Melissa A Brower" NAME="Patel 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-04-05 23:17:48 +1000" MODIFIED_BY="Melissa A Brower" NOTES="&lt;p&gt;Patel H, Gouin S, Platt RW. Randomized, double-bind, placebo-controlled trial of oral albuterol in infants with mild-to-moderate acute viral bronchiolitis. J Pediatr 2003;142:509-14&lt;/p&gt;" NOTES_MODIFIED="2010-04-05 23:17:48 +1000" NOTES_MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel H, Gouin S, Platt RW</AU>
<TI>Randomized, double-bind, placebo-controlled trial of oral albuterol in infants with mild-to-moderate acute viral bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>142</VL>
<PG>509-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ralston-2005" MODIFIED="2010-06-07 15:30:32 +1000" MODIFIED_BY="[Empty name]" NAME="Ralston 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-07 15:30:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ralston S, Hartenberger C, Anaya T, Qualls C, Kelly HW</AU>
<TI>Randomized, placebo-controlled trial of albuterol and epinephrine at equipotent beta-2 agonist doses in acute bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2005</YR>
<VL>40</VL>
<PG>292-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scarlett-2012" MODIFIED="2014-06-02 02:17:38 +1000" MODIFIED_BY="[Empty name]" NAME="Scarlett 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-06-02 02:17:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scarlett EE, Walker S, Rovitelli A, Ren CL</AU>
<TI>Tidal breathing responses to albuterol and normal saline in infants with viral bronchiolitis</TI>
<SO>Pediatric Allergy, Immunology, and Pulmonology</SO>
<YR>2012</YR>
<VL>25</VL>
<PG>220-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuh-1990" MODIFIED="2010-10-14 04:53:23 +1000" MODIFIED_BY="Melissa A Brower" NAME="Schuh 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-10-14 04:53:23 +1000" MODIFIED_BY="Melissa A Brower" NOTES="&lt;p&gt;Schuh S, Canny G, Reisman JJ, et al. Nebulized albuterol in acute bronchiolitis. J Pediatr 1990;117:633-7.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-10-14 04:53:23 +1000" NOTES_MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuh S, Canny G, Reisman JJ, Kerem E, Bentur L, Petric M, et al</AU>
<TI>Nebulized albuterol in acute bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1990</YR>
<VL>117</VL>
<PG>633-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schweich-1992" MODIFIED="2010-10-14 04:51:52 +1000" MODIFIED_BY="Melissa A Brower" NAME="Schweich 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-10-14 04:51:52 +1000" MODIFIED_BY="Melissa A Brower" NOTES="&lt;p&gt;Schweich PJ, Hurt TL, Walkley EI, et al. The use of nebulized albuterol in wheezing infants. Pediatr Emerg Care 1992;8:184-8.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-10-14 04:51:52 +1000" NOTES_MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schweich PJ, Hurt TL, Walkley EI, Mullen N, Archibald LF</AU>
<TI>The use of nebulized albuterol in wheezing infants</TI>
<SO>Pediatric Emergency Care</SO>
<YR>1992</YR>
<VL>8</VL>
<PG>184-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tal-1983" MODIFIED="2010-10-14 04:50:43 +1000" MODIFIED_BY="Melissa A Brower" NAME="Tal 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-10-14 04:50:43 +1000" MODIFIED_BY="Melissa A Brower" NOTES="&lt;p&gt;Tal A, Bavilski C, Yohai D, et al. Dexamethasone and salbutamol in the treatment of acute wheezing in infants. Pediatrics 1983;71:13-18.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-10-14 04:50:43 +1000" NOTES_MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tal A, Bavilski C, Yohai D, Bearman JE, Gorodischer R, Moses SW</AU>
<TI>Dexamethasone and salbutamol in the treatment of acute wheezing in infants</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>71</VL>
<PG>13-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tinsa-2009" MODIFIED="2010-06-07 15:31:06 +1000" MODIFIED_BY="[Empty name]" NAME="Tinsa 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-07 15:31:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tinsa F, Rhouma AB, Ghaffari H, Zouari B, Brini I, Karboul L, et al</AU>
<TI>A randomized, controlled trial of nebulized terbutaline for the first acute bronchiolitis in infants less than 12-months-old</TI>
<SO>Tunisie Medicale</SO>
<YR>2009</YR>
<VL>87</VL>
<PG>200-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Totapally-2002" NAME="Totapally 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Totapally BR, Demerci C, Zureikat G, Nolan B. Tidal breathing flow-volume loops in bronchiolitis in infancy: the effect of albuterol. Critical Care (London) 2002; 6 (2): 160-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Totapally BR, Demerci C, Zureikat G, Nolan B</AU>
<TI>Tidal breathing flow-volume loops in bronchiolitis in infancy: the effect of albuterol</TI>
<SO>Critical Care (London)</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>2</NO>
<PG>160-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1992" NAME="Wang 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Wang EEL, Milner R, Allen U, Maj H. Bronchodilators for treatment of mild bronchiolitis: a factorial randomised trial. Arch Dis Child 1992;67:289-93.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang EEL, Milner R, Allen U, Maj H</AU>
<TI>Bronchodilators for treatment of mild bronchiolitis: a factorial randomised trial</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1992</YR>
<VL>67</VL>
<PG>289-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-06-07 02:09:07 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Absar-2008" MODIFIED="2013-10-10 00:52:40 +1000" MODIFIED_BY="[Empty name]" NAME="Absar 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-10 00:52:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Absar SMN, Jahan S, Khanum S</AU>
<TI>Efficacy of nebulized ipratropium bromide versus salbutamol in infants with acute bronchiolitis</TI>
<SO>Bangladesh Medical Research Council Bulletin</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>3</NO>
<PG>112</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abu_x002d_Shukair-2001" NAME="Abu-Shukair 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Abu-Shukair M, El-Tal Y, Al-Rawabdeh E. Salbutamol versus epinephrine in the treatment of acute bronchiolitis. Journal of the Bahrain Medical Society 2001; 13(3):143-146.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abu-Shukair M, El-Tal Y, Al-Rawabdeh E</AU>
<TI>Salbutamol versus epinephrine in the treatment of acute bronchiolitis</TI>
<SO>Journal of the Bahrain Medical Society</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>3</NO>
<PG>143-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alansari-2013" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Alansari 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alansari K, Sakran M, Davidson BL, Ibrahim K, Alrefai M, Zakaria I</AU>
<TI>Oral dexamethasone for bronchiolitis: a randomized trial</TI>
<SO>Pediatrics</SO>
<YR>2013</YR>
<VL>132</VL>
<NO>1</NO>
<PG>e810-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barlas-1998" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Barlas 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barlas C, Kiper N, Gocmen A, Ozcelik U, Dilber E, Anadol D, et al</AU>
<TI>Racemic adrenaline and other treatment regimens in mild and moderate bronchiolitis</TI>
<TO>Hafif ve orta siddetteki bronsiolit vakalarinda rasemik adrenalin ve diger tedavi yontemlerinin karsilastirilmasi</TO>
<SO>Cocuk Sagligi Ve Hastaliklari Dergisi</SO>
<YR>1998</YR>
<VL>41</VL>
<PG>155&#8211;65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beck-2007" MODIFIED="2010-06-07 15:32:09 +1000" MODIFIED_BY="[Empty name]" NAME="Beck 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-07 15:32:09 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beck R, Elias N, Shoval S, Tov N, Talmon G, Godfrey S, et al</AU>
<TI>Computerized acoustic assessment of treatment efficacy of nebulized epinephrine and albuterol in RSV bronchiolitis</TI>
<SO>BMC Pediatrics</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcastro-2010" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Belcastro 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcastro MR, Backes CR, Chila AG</AU>
<TI>Bronchiolitis: a pilot study of osteopathic manipulative treatment, bronchodilators, and other therapy</TI>
<SO>Journal of the American Osteopathic Association</SO>
<YR>2010</YR>
<VL>83</VL>
<NO>9</NO>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bentur-2003" NAME="Bentur 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Bentur L, Beck R, Shoval S, Elias N, Naveh T, Godfrey S. Nebulized epinephrine versus albuterol for treatment of RSV bronchiolitis [abstract]. SO: American Thoracic Society 99th International Conference. 2003. C093 Poster 703.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bentur L, Beck R, Shoval S, Elias N, Naveh T, Godfrey S</AU>
<TI>Nebulized epinephrine versus albuterol for treatment of RSV bronchiolitis</TI>
<SO>American Thoracic Society 99th International Conference</SO>
<YR>2003</YR>
<PG>C093 Poster 703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bertrand-2001" MODIFIED="2013-12-03 02:14:28 +1000" MODIFIED_BY="[Empty name]" NAME="Bertrand 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-12-03 02:14:28 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bertrand P, Aranibar H, Castro E, Sanchez I. Efficacy of nebulized ephinephrine versus salbutamol in hospitalized infants with bronchiolitis. Pediatr Pulmonol 2001; 31:284-288.&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 02:14:28 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bertrand P, Aranibar H, Castro E, Sanchez I</AU>
<TI>Efficacy of nebulized epinephrine versus salbutamol in hospitalized infants with bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2001</YR>
<VL>31</VL>
<PG>284-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brooks-1981" NAME="Brooks 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Brooks LJ, Cropp GJA. Theophylline therapy in bronchiolitis. Am J Dis Child 1981;135:934-6.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brooks LJ, Cropp GJA</AU>
<TI>Theophylline therapy in bronchiolitis</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1981</YR>
<VL>135</VL>
<PG>934-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cengizlier-1997" NAME="Cengizlier 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Cengizlier R, Saraclar Y, Adalioglu G, Tuncer A. Effect of oral and inhaled salbutamol in infants with bronchiolitis. Acta Paediatrica Japonica. 1997;39:61-63.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cengizlier R, Saraclar Y, Adalioglu G, Tuncer A</AU>
<TI>Effect of oral and inhaled salbutamol in infants with bronchiolitis</TI>
<SO>Acta Paediatrica Japonica</SO>
<YR>1997</YR>
<VL>39</VL>
<PG>61-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chao-2003" NAME="Chao 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chao LC, Lin YZ, Wu WF, Huang FY</AU>
<TI>Efficacy of nebulized budesonide in hospitalized infants and children younger than 24 months with bronchiolitis</TI>
<SO>Acta Paediatrica Taiwanica</SO>
<YR>2003</YR>
<VL>44</VL>
<NO>6</NO>
<PG>332-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choong-1998" MODIFIED="2010-06-24 14:54:26 +1000" MODIFIED_BY="[Empty name]" NAME="Choong 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-24 14:54:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choong CS, Huang YF, Liew KL, Liu PN, Tsai DH, Cheng IY, et al</AU>
<TI>The efficacy of nebulized beta-2 agonist bronchodilator therapy in the treatment of acute bronchiolitis</TI>
<SO>Tsu Chi Medical Journal</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>2</NO>
<PG>95-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cortes-1996" NAME="Cortes 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cortes ME, Graniel GJ</AU>
<TI>Administration of nebulized salbutamol versus placebo in infants with bronchiolitis</TI>
<SO>Practica Pediatrica</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>7</NO>
<PG>18-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Del-Vecchio-2012" MODIFIED="2014-06-02 02:20:18 +1000" MODIFIED_BY="[Empty name]" NAME="Del Vecchio 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-06-02 02:20:18 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Vecchio MT, Doerr LE, Gaughan JP</AU>
<TI>The use of albuterol in young infants hospitalized with acute RSV bronchiolitis</TI>
<SO>Interdisciplinary Perspectives on Infectious Diseases</SO>
<YR>2012</YR>
<VL>2012</VL>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-2009" MODIFIED="2010-06-07 15:32:54 +1000" MODIFIED_BY="[Empty name]" NAME="Fernandez 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-07 15:32:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez CI, Fernandez BH, Navarro CM, Soler MG, Lopez PV, Pardillo RM</AU>
<TI>Heliox-driven bronchodilator nebulization in the treatment of infants with bronchiolitis</TI>
<SO>Annals of Pediatrics</SO>
<YR>2009</YR>
<VL>70</VL>
<PG>40-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrer-1990" MODIFIED="2010-06-07 15:33:01 +1000" MODIFIED_BY="[Empty name]" NAME="Ferrer 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-06-07 15:33:01 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Ferrer C, Gaig P, Marin A, et al. Bromuro de ipratropio en las bronquiolitis. Rev Esp Alergol Immunol Clin 1990;5 (Suppl 1):83-4.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-06-07 15:33:01 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrer C, Gaig P, Marin A, et al</AU>
<TI>Bromuro de ipratropio en las bronquiolitis</TI>
<SO>Revista Espanola de Alergologia e Immunologia Clinica</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>83-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Florin-2012" MODIFIED="2014-01-21 06:56:54 +1000" MODIFIED_BY="[Empty name]" NAME="Florin 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-01-21 06:56:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Florin TA, Kittick M, Shaw KN, Zorc JJ</AU>
<TI>A randomized trial of nebulized hypertonic saline for bronchiolitis in the emergency department</TI>
<SO>Pediatric Emergency Care</SO>
<YR>2012</YR>
<VL>28</VL>
<NO>9</NO>
<PG>1096</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frasson-2012" MODIFIED="2013-12-13 09:53:19 +1000" MODIFIED_BY="[Empty name]" NAME="Frasson 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-12-13 09:53:19 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frasson T, Nascimento-Junior G, Frasson F, Rossi M, Rodrigues A, Goncalves W, et al</AU>
<TI>Increase in induced expiratory flow reduces peripheral hypoxemia in children with acute bronchiolitis</TI>
<SO>Pediatric Critical Care Medicine</SO>
<YR>2012</YR>
<VL>13</VL>
<NO>5</NO>
<PG>618</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goebel-2000" NAME="Goebel 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Goebel J, Estrada B, Quinonez J, Nagji N, Sanford D, Boerth RC. Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis. Clinical Pediatrics 2000; 39 (4): 213-20.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goebel J, Estrada B, Quinonez J, Nagji N, Sanford D, Boerth RC</AU>
<TI>Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis</TI>
<SO>Clinical Pediatrics</SO>
<YR>2000</YR>
<VL>39</VL>
<NO>4</NO>
<PG>213-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomez_x002d_y_x002d_Lopez-2007" MODIFIED="2010-06-07 15:33:30 +1000" MODIFIED_BY="[Empty name]" NAME="Gomez-y-Lopez 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-07 15:33:30 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomez-y-Lopez RE, Hernandez-Sierra JF, Torres-Ruvalcaba BA, Martinez-Puente E, del Carmen Martinez-Garcia M</AU>
<TI>Comparative clinical study of dexamethasone vs. nebulized salbutamol in acute bronchiolitis</TI>
<SO>Gaceta Medica de Mexico</SO>
<YR>2007</YR>
<VL>142</VL>
<NO>3</NO>
<PG>189-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez-1994" MODIFIED="2013-12-13 09:53:38 +1000" MODIFIED_BY="[Empty name]" NAME="Gonzalez 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-12-13 09:53:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez PYE, Ruiz BA, Garate AJ, Romero IC, Bone CJ, Arranz AL, et al</AU>
<TI>A multicenter randomized, open, parallel group study comparing different treatments for hospitalized infants with acute wheezy bronchitis</TI>
<SO>Anales Espanoles de Pediatria</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>5</NO>
<PG>315-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hammer-1995" MODIFIED="2010-10-12 14:04:07 +1000" MODIFIED_BY="[Empty name]" NAME="Hammer 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-10-12 14:04:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hammer J, Numa A, Newth CJL</AU>
<TI>Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection</TI>
<SO>Pediatric Pharmacology and Therapeutics</SO>
<YR>1995</YR>
<VL>127</VL>
<NO>3</NO>
<PG>485-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-John-2006" MODIFIED="2013-12-13 09:54:00 +1000" MODIFIED_BY="[Empty name]" NAME="John 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-12-13 09:54:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>John BM, Patnaik SK, Prasad PL</AU>
<TI>Efficacy of nebulized epinephrine versus salbutamol in hospitalized children with bronchiolitis</TI>
<SO>Medical Journal Armed Forces India</SO>
<YR>2006</YR>
<VL>62</VL>
<PG>354-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-John-2010" MODIFIED="2010-04-01 22:39:39 +1000" MODIFIED_BY="Melissa A Brower" NAME="John 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-04-01 22:39:39 +1000" MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>John BM, Singh D</AU>
<TI>Comparison of nebulised salbutamol and L-epinephrine in first time wheezy children</TI>
<SO>Medical Journal Armed Forces India</SO>
<YR>2010</YR>
<VL>66</VL>
<PG>9-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kadir-2009" MODIFIED="2010-06-07 15:34:41 +1000" MODIFIED_BY="[Empty name]" NAME="Kadir 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-07 15:34:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kadir MA, Mollah AH, Basak R, Choundhury AM, Ahmed S</AU>
<TI>Comparative efficacy of combined nebulized salbutamol with ipratropium bromide and nebulized adrenaline to treat children with acute bronchiolitis</TI>
<SO>Mymensingh Medical Journal</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>2</NO>
<PG>208-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karaatmaca-2010" MODIFIED="2014-06-02 02:22:14 +1000" MODIFIED_BY="[Empty name]" NAME="Karaatmaca 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-06-02 02:22:14 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karaatmaca B, Aydogan M, Piraneci R, Bicer S</AU>
<TI>Comparison of the effectiveness of nebulized budesonide, salbutamol and adrenaline in the treatment of acute bronchiolitis: a randomized double blind placebo controlled clinical trial</TI>
<SO>Allergy</SO>
<YR>2010</YR>
<VL>65</VL>
<NO>Suppl 92</NO>
<PG>716</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2011" MODIFIED="2013-12-13 09:54:23 +1000" MODIFIED_BY="[Empty name]" NAME="Kim 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-12-13 09:54:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kim IK, Phrampus E, Sikes K, Pendleton J, Saville A, Corcoran T, et al</AU>
<TI>Helium-oxygen therapy for infants with bronchiolitis: a randomized controlled trial</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>2011</YR>
<VL>165</VL>
<NO>12</NO>
<PG>1115-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langley-2005" MODIFIED="2010-06-07 15:35:04 +1000" MODIFIED_BY="[Empty name]" NAME="Langley 2005" YEAR="May 5, 2005">
<REFERENCE MODIFIED="2010-06-07 15:35:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langley JM, Smith MB, LeBlanc JC, Joudrey H, Ojah CR, Pianosi P</AU>
<TI>Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial</TI>
<SO>BMC Pediatrics</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2003" NAME="Luo 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Published in Chinese language. Author contacted by Chinese-speaking colleague. Study 'quasi' randomized, no placebo group.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo AW, Ma HH, Zhou W, Xie XA</AU>
<TI>The clinical observation of budesonide and terbutaline aerosol on the treatment of bronchiolitis</TI>
<SO>Chinese Journal of Hospital Pharmacy</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>9</NO>
<PG>549-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2010" MODIFIED="2010-08-27 04:38:22 +1000" MODIFIED_BY="[Empty name]" NAME="Luo 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-08-27 04:38:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo A, Lui E, Luo J, Li S, Zeng F, Yang X, et al</AU>
<TI>Nebulized hypertonic saline/salbutamol solution treatment in hospitalized children with mild to moderate bronchiolitis</TI>
<SO>Pediatrics International</SO>
<YR>2010</YR>
<VL>52</VL>
<PG>199-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2012" MODIFIED="2013-12-13 09:54:46 +1000" MODIFIED_BY="[Empty name]" NAME="Luo 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-12-13 09:54:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo Z, Liu E, Luo J, Li S, Zeng F, Yang X, et al</AU>
<TI>Nebulized hypertonic saline/salbutamol solution treatment in hospitalized children with mild to moderate bronchiolitis</TI>
<SO>Pediatrics International</SO>
<YR>2010</YR>
<VL>52</VL>
<NO>2</NO>
<PG>199-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandelberg-2003" MODIFIED="2010-06-07 15:35:39 +1000" MODIFIED_BY="[Empty name]" NAME="Mandelberg 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-07 15:35:39 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mandelberg A, Tal G, Witzling M, Someck E, Houri S, Balin A, Priel IE. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest 2003; 123: 481-7.&lt;/p&gt;" NOTES_MODIFIED="2010-06-07 15:35:39 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandelberg A, Tal G, Witzling M, Someck E, Houri S, Balin A, et al</AU>
<TI>Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis</TI>
<SO>Chest</SO>
<YR>2003</YR>
<VL>123</VL>
<PG>481-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menon-1995" NAME="Menon 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menon K, Sutcliffe T, Klassen TP</AU>
<TI>A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1995</YR>
<VL>126</VL>
<NO>6</NO>
<PG>1004-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milner-1995" NAME="Milner 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Milner, A. Role des anticholinergiques dans la bronchiolite aigue du nourisson. Arch Pediatr 1995; 2Suppl 2: 159s-162s&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milner A</AU>
<TO>Role des anticholinergiques dans la bronchiolite aigue du nourisson</TO>
<SO>Archives de Pédiatrie</SO>
<YR>1995</YR>
<VL>2</VL>
<NO>Suppl 2</NO>
<PG>159-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Modaressi-2012" MODIFIED="2013-12-13 09:55:07 +1000" MODIFIED_BY="[Empty name]" NAME="Modaressi 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-12-13 09:55:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Modaressi MR, Asadian A, Faghihinia J, Arashpour M, Mousavinasab F</AU>
<TI>Comparison of epinephrine to salbutamol in acute bronchiolitis</TI>
<SO>Iranian Journal of Pediatrics</SO>
<YR>2012</YR>
<VL>22</VL>
<PG>241-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Modl-2005" MODIFIED="2014-06-07 02:09:07 +1000" MODIFIED_BY="[Empty name]" NAME="Modl 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-06-07 02:09:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Modl M, Eber E, Malle-Scheid D, Weinhandl E, Zach MS</AU>
<TI>Does bronchodilator responsiveness in infants with bronchiolitis depend on age?</TI>
<SO>Journal of Pediatrics</SO>
<YR>2005</YR>
<VL>147</VL>
<NO>5</NO>
<PG>617-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mull-2004" MODIFIED="2010-06-07 15:36:17 +1000" MODIFIED_BY="[Empty name]" NAME="Mull 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-07 15:36:17 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mull CC; Scarfone RJ; Ferri LR; Carlin T; Salvaggio C; Bechtel KA; Hanes-Trephan MA; Rissman RL; Gracely EJ. A Randomized Trial of Nebulized Epinephrine vs Albuterol in the Emergency Department Treatment of Bronchiolitis. Archives of Pediatrics and Adolescent Medicine 2004; 158(2): 113-118&lt;/p&gt;" NOTES_MODIFIED="2010-06-07 15:36:17 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mull CC, Scarfone RJ, Ferri LR, Carlin T, Salvaggio C, Bechtel KA, et al</AU>
<TI>A randomized trial of nebulized epinephrine vs albuterol in the emergency department treatment of bronchiolitis</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2004</YR>
<VL>158</VL>
<NO>2</NO>
<PG>113-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ndrepepa-1998" MODIFIED="2010-06-24 14:55:23 +1000" MODIFIED_BY="[Empty name]" NAME="Ndrepepa 1998" YEAR="1998;12(Suppl28):4085">
<REFERENCE MODIFIED="2010-06-24 14:55:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ndrepepa A, Sinamti J, Vevcka E, Kote L</AU>
<TI>Comparative study of inhaled bronchodilators in infants less than 18 months old with acute bronchiolitis</TI>
<SO>European Respiratory Journal</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>Suppl 28</NO>
<PG>4085</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Numa-2001" NAME="Numa 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Numa AH, Williams GD, Dakin CJ</AU>
<TI>The effect of nebulized epinephrine on respiratory mechanics and gas exchange in bronchiolitis</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>164</VL>
<NO>1</NO>
<PG>86-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozyurek-2002" NAME="Ozyurek 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Ozyurek H, Uyan AP, Keskin M, Afsar Y, Kocabay K. Comparison of two different bronchodilators in the treatment of acute bronchiolitis. COCUK-SAGLIGI-HAST-DERG. Cocuk-Sagligi-ve-Hastaliklari-Dergisi. 2002; 45(4): 298-303.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozyurek H, Uyan AP, Keskin M, Afsar Y, Kocabay K</AU>
<TI>Comparison of two different bronchodilators in the treatment of acute bronchiolitis</TI>
<SO>Cocuk Sagligi ve Hastaliklari Dergisi</SO>
<YR>2002</YR>
<VL>45</VL>
<NO>4</NO>
<PG>298-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ralston-2008" MODIFIED="2010-06-07 15:36:40 +1000" MODIFIED_BY="[Empty name]" NAME="Ralston 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-07 15:36:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ralston S, Roohi M</AU>
<TI>A randomized, controlled trial of nasal phenylephrine in infants hospitalized for bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2008</YR>
<VL>153</VL>
<PG>795-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ray-2002" NAME="Ray 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Ray MS, Singh V. Comparison of nebulized adrenaline versus salbutamol in wheeze associated respiratory tract infection in infants. Indian Pediatrics 2002;39:12-22&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ray MS, Singh V</AU>
<TI>Comparison of nebulized adrenaline versus salbutamol in wheeze associated respiratory tract infection in infants</TI>
<SO>Indian Pediatrics</SO>
<YR>2002</YR>
<VL>39</VL>
<PG>12-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reijonen-1995" NAME="Reijonen 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Reijonen T, Korppi M, Pitkakangas S, Tenhola S, Remes K. The clinical efficacy of nebulized racemic epinephrine and albuterol in acute bronchiolitis. Arch Pediatr Adolesc Med. 1995;149:686-692.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reijonen T, Korppi M, Pitkakangas S, Tenhola S, Remes K</AU>
<TI>The clinical efficacy of nebulized racemic epinephrine and albuterol in acute bronchiolitis</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>1995</YR>
<VL>149</VL>
<PG>686-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ren-2011" MODIFIED="2014-01-24 09:02:32 +1000" MODIFIED_BY="[Empty name]" NAME="Ren 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-01-24 09:02:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ren CL, Scarlett EE</AU>
<TI>Effect of inhaled albuterol on tidal breathing patterns in infants hospitalized for viral bronchiolitis</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2011</YR>
<VL>183</VL>
<PG>A1889</PG>
<IDENTIFIERS MODIFIED="2014-01-24 08:57:58 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-24 08:57:58 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A1889A1889"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez-1993" NAME="Sanchez 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Sanchez I, De Koster J, Powell RE, Wolstein R, Chernick V. Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis. J Pediatr 1993;122:145-51.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez I, De Koster J, Powell RE, Wolstein R, Chernick V</AU>
<TI>Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1993</YR>
<VL>122</VL>
<PG>145-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarrell-2002" MODIFIED="2010-06-07 15:37:18 +1000" MODIFIED_BY="[Empty name]" NAME="Sarrell 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-07 15:37:18 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sarrell EM, Tal G, Witzling M, Someck E, Houri S, Cohen HA, Mandelberg A. Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms. Chest 2002; 122:2015-2020&lt;/p&gt;" NOTES_MODIFIED="2010-06-07 15:37:18 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sarrell EM, Tal G, Witzling M, Someck E, Houri S, Cohen HA, et al</AU>
<TI>Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>2015-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuh-1992" MODIFIED="2010-10-14 04:59:54 +1000" MODIFIED_BY="Melissa A Brower" NAME="Schuh 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-10-14 04:59:54 +1000" MODIFIED_BY="Melissa A Brower" NOTES="&lt;p&gt;Schuh S, Johnson D, Canny G, et al. Efficacy of adding nebulized ipratropium bromide to nebulized albuterol therapy in acute bronchiolitis. Pediatrics 1992;90:920-3.&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-10-14 04:59:54 +1000" NOTES_MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuh S, Johnson D, Canny G, Reisman J, Shields M, Kovesi T, et al</AU>
<TI>Efficacy of adding nebulized ipratropium bromide to nebulized albuterol therapy in acute bronchiolitis</TI>
<SO>Pediatrics</SO>
<YR>1992</YR>
<VL>90</VL>
<PG>920-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sezer-2010" MODIFIED="2013-12-25 06:02:45 +1000" MODIFIED_BY="[Empty name]" NAME="Sezer 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-25 06:02:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sezer GR, Bozaykut A, Ipek IO, Uyur E, Seren PL, Paketci C</AU>
<TI>The efficacy of nebulized salbutamol, hypertonic saline and salbutamol/hypertonic saline combination in first bronchiolitis attack</TI>
<SO>Acta Paediatrica, International Journal of Paediatrics</SO>
<YR>2010</YR>
<VL>99</VL>
<PG>114</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2013" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Sharma 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma BS, Gupta MK, Rafik SP</AU>
<TI>Hypertonic (3%) saline vs 0.9% saline nebulization for acute viral bronchiolitis: a randomized controlled trial</TI>
<SO>Indian Pediatrics</SO>
<YR>2013</YR>
<VL>50</VL>
<NO>14</NO>
<PG>743-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shu-2001" NAME="Shu 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;In Chinese language, copy not available&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shu L, Long Z, Pi GX</AU>
<TI>Therapeutic effect of ipratropine combined with heparin aerosol inhalation on children with bronchiolitis</TI>
<SO>Chinese Journal of Contemporary Pediatrics</SO>
<YR>2001</YR>
<VL>3</VL>
<NO>5</NO>
<PG>555-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Simsek-2005" MODIFIED="2010-06-24 14:56:06 +1000" MODIFIED_BY="[Empty name]" NAME="Simsek 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-24 14:56:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Simsek PO, Aslan AT, Kiper N, Yalcin E, Dogru D, Ozcelic U, et al</AU>
<TI>A randomized trial of the effectiveness of nebulized therapy with epinephrine compared with salbutamol in the treatment of acute viral bronchiolitis [Abstract]</TI>
<SO>European Respiratory Society Annual Congress</SO>
<YR>18 September 2005</YR>
<PG>Poster P865</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simsek_x002d_Kiper-2011" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Simsek-Kiper 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simsek-Kiper PO, Kiper N, Hascelik G, Dolgun A, Yalcin E, Dogru-Ersoz D, et al</AU>
<TI>Emergency room management of acute bronchiolitis: a randomized trial of nebulized epinephrine</TI>
<SO>Turkish Journal of Pediatrics</SO>
<YR>2011</YR>
<VL>6</VL>
<PG>651-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sly-1991" NAME="Sly 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Sly PD, Lanteri CJ, Raven JM. Do wheezy infants recovering from bronchiolitis respond to inhaled salbutamol? Pediatr Pulmonol 1991;10:36-9.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sly PD, Lanteri CJ, Raven JM</AU>
<TI>Do wheezy infants recovering from bronchiolitis respond to inhaled salbutamol?</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>36-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soto-1985" MODIFIED="2010-06-07 15:39:06 +1000" MODIFIED_BY="[Empty name]" NAME="Soto 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-06-07 15:39:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soto ME, Sly PD, Uren E, Taussig LM, Landau LI</AU>
<TI>Bronchodilator response during acute viral bronchiolitis in infancy</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1985</YR>
<VL>1</VL>
<NO>2</NO>
<PG>85-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Springer-1990" MODIFIED="2010-10-14 05:02:20 +1000" MODIFIED_BY="Melissa A Brower" NAME="Springer 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-10-14 05:02:20 +1000" MODIFIED_BY="Melissa A Brower" NOTES="&lt;p&gt;Springer C, Bar-Yishay E, Uwayyed K, et al. Corticosteroids do not affect the clinical or physiological status of infants with bronchiolitis. Pediatr Pulmonol 1990;9:181-5.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-10-14 05:02:20 +1000" NOTES_MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Springer C, Bar-Yishay E, Uwayyed K, Avital A, Vilozni D, Godfrey S</AU>
<TI>Corticosteroids do not affect the clinical or physiological status of infants with bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1990</YR>
<VL>9</VL>
<PG>181-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stokes-1983" NAME="Stokes 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Stokes GM, Milner AD, Hodges IGC, Henry RL, Elphick MC. Nebulised therapy in acute severe bronchiolitis in infancy. Arch Dis Child 1983;58:279-83.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stokes GM, Milner AD, Hodges IGC, Henry RL, Elphick MC</AU>
<TI>Nebulised therapy in acute severe bronchiolitis in infancy</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1983</YR>
<VL>58</VL>
<PG>279-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tatochenko-1988" MODIFIED="2010-06-07 15:39:25 +1000" MODIFIED_BY="[Empty name]" NAME="Tatochenko 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-06-07 15:39:25 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Tatochenko VK, Shiryaeva IS, Dorokhova NF, et al. Effectiveness of spasmolytic aerosols in infants with obstructive bronchitis. Vop Okhrany Meterin Det 1988;33:31-3.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-06-07 15:39:25 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tatochenko VK, Shiryaeva IS, Dorokhova NF, et al</AU>
<TI>Effectiveness of spasmolytic aerosols in infants with obstructive bronchitis</TI>
<SO>Voprosy Okhrany Materinstva i Detstva</SO>
<YR>1988</YR>
<VL>33</VL>
<PG>31-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torres-1997" NAME="Torres 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Torres Jr., A., Anders, M., Anderson, P., Heulitt, M. J. Efficacy of metered-dose inhaler administration of albuterol in intubated infants. Chest 1997; 112: 484-490.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torres Jr A, Anders M, Anderson P, Heulitt MJ</AU>
<TI>Efficacy of metered-dose inhaler administration of albuterol in intubated infants</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>112</VL>
<PG>484-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walsh-2008" MODIFIED="2010-06-07 15:40:03 +1000" MODIFIED_BY="[Empty name]" NAME="Walsh 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-06-07 15:40:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh P, Caldwell J, McQuillan KK, Friese S, Robbins D, Rothenberg SJ</AU>
<TI>Comparison of nebulized epinephrine to albuterol in bronchiolitis</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>4</NO>
<PG>305-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-03-26 01:34:33 +1000" MODIFIED_BY="Melissa A Brower"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wankum-2000" NAME="Wankum 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wankum P, Graff GR, Tobias J</AU>
<TI>A comparison of the effects of nebulized albuterol, L-epinephrine, and saline on the pulmonary mechanics in RSV bronchiolitis [Abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>Suppl 3</NO>
<PG>A340</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00428970"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhen-2003" MODIFIED="2010-06-15 04:56:55 +1000" MODIFIED_BY="Melissa A Brower" NAME="Zhen 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-06-15 04:56:55 +1000" MODIFIED_BY="Melissa A Brower" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhen KJ, Xiong MH, Wang JH, Lu XX, Wang WW, Lin RM</AU>
<TI>Fog-inhalation therapy of Ventolin for bronchiolitis in babies</TI>
<SO>Medical Journal of Qilu</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>2</NO>
<PG>180-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2001" NAME="Zhou 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Paper could not be retrieved&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou XH, Lu M</AU>
<TI>Clinical outcomes observation of inspiring budesonide and salbutamol on children bronchiolitis</TI>
<SO>Journal of Nanjing Railway Medical College</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>2</NO>
<PG>120-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-06-09 05:17:28 +1000" MODIFIED_BY="Melissa A Brower"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AAP-2006" MODIFIED="2010-06-07 15:41:29 +1000" MODIFIED_BY="[Empty name]" NAME="AAP 2006" TYPE="JOURNAL_ARTICLE">
<AU>American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis</AU>
<TI>Diagnosis and management of bronchiolitis</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>118</VL>
<PG>1774-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Babl-2008" MODIFIED="2013-12-13 09:57:28 +1000" MODIFIED_BY="[Empty name]" NAME="Babl 2008" TYPE="JOURNAL_ARTICLE">
<AU>Babl FE, Sheriff N, Neutze J, Borland M, Oakley E</AU>
<TI>Bronchiolitis management in pediatric emergency departments in Australia and New Zealand: a PREDICT study</TI>
<SO>Pediatric Emergency Care</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>10</NO>
<PG>656-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barben-2003" MODIFIED="2013-12-04 06:10:38 +1000" MODIFIED_BY="[Empty name]" NAME="Barben 2003" TYPE="JOURNAL_ARTICLE">
<AU>Barben J, Hammer J</AU>
<TI>Current management of acute bronchiolitis in Switzerland</TI>
<SO>Swiss Medical Weekly</SO>
<YR>2003</YR>
<VL>133</VL>
<NO>1-2</NO>
<PG>9-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bracken-1989" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Bracken 1989" TYPE="BOOK_SECTION">
<AU>Bracken MB</AU>
<TI>Statistical methods for analysis of effects of treatment in overviews of randomized trials</TI>
<SO>Effective Care in Pregnancy and Childbirth</SO>
<YR>1989</YR>
<PG>13-8</PG>
<ED>Chalmers I, Enkin M, Keirse MJNC</ED>
<PB>Oxford University Press</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CCHMC-2010" MODIFIED="2014-06-02 02:48:24 +1000" MODIFIED_BY="[Empty name]" NAME="CCHMC 2010" TYPE="OTHER">
<AU>Cincinnati Children's Hospital Medical Center (CCHMC)</AU>
<TI>Evidence-based care guideline for management of first time episode bronchiolitis in infants less than 1 year of age</TI>
<SO>Cincinnati (OH): Cincinnati Children's Hospital Medical Center</SO>
<YR>2010</YR>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chavasse-2002" MODIFIED="2010-10-12 14:04:31 +1000" MODIFIED_BY="[Empty name]" NAME="Chavasse 2002" TYPE="COCHRANE_REVIEW">
<AU>Chavasse RJPG, Seddon P, Bara A, McKean MC</AU>
<TI>Short acting beta2 agonists for recurrent wheeze in children under two years of age</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-10-08 05:38:22 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-10-08 05:38:22 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002873"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Christakis-2005" MODIFIED="2013-12-13 09:58:26 +1000" MODIFIED_BY="[Empty name]" NAME="Christakis 2005" TYPE="JOURNAL_ARTICLE">
<AU>Christakis DA, Cowan CA, Garrison MM, Molteni R, Marcuse E, Zerr DM</AU>
<TI>Variation in inpatient diagnostic testing and management of bronchiolitis</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>4</NO>
<PG>878-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cruz-1995" MODIFIED="2010-06-07 15:44:16 +1000" MODIFIED_BY="[Empty name]" NAME="Cruz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cruz MN, Stewart G, Rosenberg N</AU>
<TI>Use of dexamethasone in the outpatient management of acute laryngotracheitis</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>96</VL>
<PG>220-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Bilderling-2003" MODIFIED="2013-12-04 06:10:58 +1000" MODIFIED_BY="[Empty name]" NAME="de Bilderling 2003" TYPE="JOURNAL_ARTICLE">
<AU>de Bilderling G, Bodart E</AU>
<TI>Bronchiolitis management by the Belgian paediatrician: discrepancies between evidence-based medicine and practice</TI>
<SO>Acta Clinica Belgica</SO>
<YR>2003</YR>
<VL>58</VL>
<NO>2</NO>
<PG>98-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeNicola-2013" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="DeNicola 2013" TYPE="OTHER">
<AU>DeNicola LK</AU>
<TI>Bronchiolitis treatment &amp; management</TI>
<SO>Medscape (http://emedicine.medscape.com/article/961963-treatment)</SO>
<YR>2013 (accessed 12 September 2013)</YR>
<IDENTIFIERS MODIFIED="2013-12-13 09:58:52 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-13 09:58:52 +1000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Accessed September 12, 2013.http://emedicine.medscape.com/article/961963-treatment"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Destino-2010" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Destino 2010" TYPE="CONFERENCE_PROC">
<AU>Destino L, Soung P, Weisgerber M, Bakalarski D, Yan K, Rehborg R, et al</AU>
<TI>The reliability and validity of the respiratory distress assessment instrument (RDAI) and Children's Hospital of Wisconsin Respiratory Score (CHWRS) in infants with bronchiolitis</TI>
<SO>Pediatric Academic Societies Meeting, Vancouver, Canada; 2010 May 4</SO>
<YR>2010</YR>
<PG>Abstract #4403.187</PG>
<IDENTIFIERS MODIFIED="2014-06-02 02:31:30 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Destino-2012" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Destino 2012" TYPE="JOURNAL_ARTICLE">
<AU>Destino L, Weisgerber MC, Soung P, Bakalarski D, Yan K, Rehborg R, et al</AU>
<TI>Validity of respiratory scores in bronchiolitis</TI>
<SO>Hospital Pediatrics</SO>
<YR>2012</YR>
<VL>2</VL>
<NO>4</NO>
<PG>202-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Disney-1960" MODIFIED="2013-12-04 06:11:03 +1000" MODIFIED_BY="[Empty name]" NAME="Disney 1960" TYPE="JOURNAL_ARTICLE">
<AU>Disney ME, Sandiford BR, Cragg J, Wolff J</AU>
<TI>Epidemic bronchiolitis in infants</TI>
<SO>British Medical Journal</SO>
<YR>1960</YR>
<VL>1</VL>
<PG>1407-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Flores-1997" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Flores 1997" TYPE="JOURNAL_ARTICLE">
<AU>Flores G, Horwitz RI</AU>
<TI>Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>100</VL>
<PG>233-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Florin-2013" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Florin 2013" TYPE="CONFERENCE_PROC">
<AU>Florin TA, Byczkowski T, Ruddy R, Zorc J, Test M, Sha SS</AU>
<TI>Variation in the management of infants hospitalized for bronchiolitis persists after the 2006 AAP Bronchiolitis Guidelines</TI>
<SO>Pediatrics Academic Societies Meeting</SO>
<YR>2013</YR>
<PG>Abstract 1150.5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodman-1993" NAME="Goodman 1993" TYPE="JOURNAL_ARTICLE">
<AU>Goodman BT, Chambers TL</AU>
<TI>Bronchodilators for bronchiolitis?</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<PG>1380</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guia-Salud-2010" MODIFIED="2013-12-03 03:20:29 +1000" MODIFIED_BY="[Empty name]" NAME="Guia Salud 2010" TYPE="OTHER">
<AU>Giua Salud</AU>
<TI>Clinical practice guideline on acute bronchiolitis</TI>
<SO>Catalan Agency for Health Information, Assessment and Quality - State/Local Government Agency [Non-U.S.]</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-2004" MODIFIED="2014-06-02 02:34:11 +1000" MODIFIED_BY="[Empty name]" NAME="Hall 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hall CB</AU>
<TI>Managing bronchiolitis and respiratory syncytial virus</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>2004</YR>
<VL>158</VL>
<PG>111-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-2007" MODIFIED="2010-06-07 15:45:04 +1000" MODIFIED_BY="[Empty name]" NAME="Hall 2007" TYPE="JOURNAL_ARTICLE">
<AU>Hall CB</AU>
<TI>Therapy for bronchiolitis: when some becomes none</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<NO>4</NO>
<PG>402-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-2009" MODIFIED="2013-12-13 10:01:29 +1000" MODIFIED_BY="[Empty name]" NAME="Hall 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al</AU>
<TI>The burden of respiratory syncytial virus infection in young children</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>6</NO>
<PG>588-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-2013" MODIFIED="2013-12-13 10:02:00 +1000" MODIFIED_BY="[Empty name]" NAME="Hall 2013" TYPE="JOURNAL_ARTICLE">
<AU>Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, et al</AU>
<TI>Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age</TI>
<SO>Pediatrics</SO>
<YR>2013</YR>
<VL>132</VL>
<NO>2</NO>
<PG>e341-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hariprakash-2003" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Hariprakash 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hariprakash S, Alexander J, Carroll W, Ramesh P, Randell T, Turnbull F, et al</AU>
<TI>Randomized controlled trial of nebulized adrenaline in acute bronchiolitis</TI>
<SO>Pediatric Allergy and Immunology</SO>
<YR>2003</YR>
<VL>14</VL>
<PG>134-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hartling-2003" MODIFIED="2014-04-15 07:20:38 +1000" MODIFIED_BY="Liz Dooley" NAME="Hartling 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hartling L, Wiebe N, Russell K, Patel H, Klassen TP</AU>
<TI>A meta-analysis of randomized controlled trials evaluating the efficacy of epinephrine for the treatment of acute viral bronchiolitis</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2003</YR>
<VL>157</VL>
<NO>10</NO>
<PG>957-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hartling-2011a" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Hartling 2011a" TYPE="COCHRANE_REVIEW">
<AU>Hartling L, Bialy LM, Vandermeer B, Tjosvold L, Johnson DW, Plint AC</AU>
<TI>Epinephrine for bronchiolitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2013-12-13 10:02:20 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-13 10:02:20 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003123.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hartling-2011b" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Hartling 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Hartling L, Fernandes RM, Bialy L, Milne A, Johnson D, Plint A</AU>
<TI>Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d1714</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-01-16 15:05:59 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG, Sterne JAC</AU>
<TI>Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2013-12-25 06:58:05 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-2013" MODIFIED="2013-12-13 10:02:43 +1000" MODIFIED_BY="[Empty name]" NAME="Johnson 2013" TYPE="JOURNAL_ARTICLE">
<AU>Johnson LW, Robles J, Hudgins A, Osburn S, Martin D, Thompson A</AU>
<TI>Management of bronchiolitis in the emergency department: impact of evidence-based guidelines?</TI>
<SO>Pediatrics</SO>
<YR>2013</YR>
<VL>131</VL>
<NO>Suppl 1</NO>
<PG>103-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-King-2004" MODIFIED="2013-12-04 06:11:26 +1000" MODIFIED_BY="[Empty name]" NAME="King 2004" TYPE="JOURNAL_ARTICLE">
<AU>King VJ, Viswanathan M, Bordley C, Jackman AM, Sutton SF, Lohr KN, et al</AU>
<TI>Pharmacologic treatment of bronchiolitis in infants and children. A systematic review</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2004</YR>
<VL>158</VL>
<PG>127-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kristj_x00e1_nsson-1993" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Kristjánsson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kristjánsson S, Lodrup Carlson KC, Wennergren G, Strannegård I-L, Carlsen K-H</AU>
<TI>Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1993</YR>
<VL>69</VL>
<PG>650-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-La-Via-1992" MODIFIED="2013-12-04 06:11:30 +1000" MODIFIED_BY="[Empty name]" NAME="La Via 1992" TYPE="JOURNAL_ARTICLE">
<AU>La Via WV, Marks MI, Stutman HR</AU>
<TI>Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention</TI>
<SO>Journal of Pediatrics</SO>
<YR>1992</YR>
<VL>121</VL>
<PG>503-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Langley-2003" MODIFIED="2013-12-13 10:03:09 +1000" MODIFIED_BY="[Empty name]" NAME="Langley 2003" TYPE="JOURNAL_ARTICLE">
<AU>Langley JM, LeBlanc JC, Smith B, Wang EE</AU>
<TI>Increasing incidence of hospitalization for bronchiolitis among Canadian children, 1980-2000</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2003</YR>
<VL>188</VL>
<NO>11</NO>
<PG>1764-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2014-01-24 08:52:52 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levison-1991" MODIFIED="2013-12-04 06:11:33 +1000" MODIFIED_BY="[Empty name]" NAME="Levison 1991" TYPE="JOURNAL_ARTICLE">
<AU>Levison H</AU>
<TI>Canadian consensus on the treatment of asthma in children</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1991</YR>
<VL>145</VL>
<PG>1449-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lowell-1987" MODIFIED="2013-12-25 05:49:18 +1000" MODIFIED_BY="[Empty name]" NAME="Lowell 1987" TYPE="JOURNAL_ARTICLE">
<AU>Lowell DI, Lister G, Von Koss H, McCarthy P</AU>
<TI>Wheezing in infants: the response to epinephrine</TI>
<SO>Pediatrics</SO>
<YR>1987</YR>
<VL>79</VL>
<PG>939-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCallum-2013" MODIFIED="2013-12-13 10:03:48 +1000" MODIFIED_BY="[Empty name]" NAME="McCallum 2013" TYPE="JOURNAL_ARTICLE">
<AU>McCallum GB, Morris PS, Wilson CC, Versteegh LA, Ward LM, Chatfield MD, et al</AU>
<TI>Severity scoring systems: are they internally valid, reliable and predictive of oxygen use in children with acute bronchiolitis?</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2013</YR>
<VL>48</VL>
<NO>8</NO>
<PG>797-803</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nair-2010" MODIFIED="2013-12-13 10:04:08 +1000" MODIFIED_BY="[Empty name]" NAME="Nair 2010" TYPE="JOURNAL_ARTICLE">
<AU>Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al</AU>
<TI>Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>375</VL>
<NO>9725</NO>
<PG>1545-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paramore-2004" MODIFIED="2013-12-13 10:04:24 +1000" MODIFIED_BY="[Empty name]" NAME="Paramore 2004" TYPE="JOURNAL_ARTICLE">
<AU>Paramore LC, Ciuryla V, Ciesla G, Liu L</AU>
<TI>Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases</TI>
<SO>Pharmacoeconomics</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>275-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plint-2004" MODIFIED="2013-12-13 10:04:45 +1000" MODIFIED_BY="[Empty name]" NAME="Plint 2004" TYPE="JOURNAL_ARTICLE">
<AU>Plint AC, Johnson DW, Wiebe N, Bulloch B, Pusic M, Joubert G, et al</AU>
<TI>Practice variation among pediatric emergency departments in the treatment of bronchiolitis</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>4</NO>
<PG>353-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shay-1999" NAME="Shay 1999" TYPE="JOURNAL_ARTICLE">
<AU>Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ</AU>
<TI>Bronchiolitis-associated hospitalizations among US children, 1980-1996</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>15</NO>
<PG>1440-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shay-2001" NAME="Shay 2001" TYPE="JOURNAL_ARTICLE">
<AU>Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ</AU>
<TI>Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2001</YR>
<VL>183</VL>
<NO>1</NO>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SIGN-2006" MODIFIED="2013-12-13 11:00:47 +1000" MODIFIED_BY="[Empty name]" NAME="SIGN 2006" TYPE="JOURNAL_ARTICLE">
<AU>Scottish Intercollegiate Guidelines Network (SIGN)</AU>
<TI>Bronchiolitis in children. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN)</TI>
<SO>SIGN publication</SO>
<YR>2006</YR>
<VL>91</VL>
<PG>41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1991" NAME="Thompson 1991" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SG, Pocock SJ</AU>
<TI>Can meta-analyses be trusted?</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<PG>1127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-1994" NAME="Thompson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SG</AU>
<TI>Why sources of heterogeneity in meta-analysis should be investigated?</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1351-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vogel-2003" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Vogel 2003" TYPE="JOURNAL_ARTICLE">
<AU>Vogel AM, Lennon DR, Harding JE, Pinnock RE, Graham DA, Grimwood K, et al</AU>
<TI>Variations in bronchiolitis management between five New Zealand hospitals: can we do better?</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2003</YR>
<VL>39</VL>
<NO>1</NO>
<PG>40-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wagner-2009" MODIFIED="2013-12-13 11:00:53 +1000" MODIFIED_BY="[Empty name]" NAME="Wagner 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wagner T</AU>
<TI>Bronchiolitis</TI>
<SO>Pediatrics in Review</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>10</NO>
<PG>386-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wainwright-2003" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Wainwright 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wainwright C, Altamirano L, Cheney M, Cheney J, Barber S, Price D</AU>
<TI>A multicenter, randomized, double blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>1</NO>
<PG>27-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wainwright-2010" MODIFIED="2010-10-12 14:05:47 +1000" MODIFIED_BY="[Empty name]" NAME="Wainwright 2010" TYPE="JOURNAL_ARTICLE">
<AU>Wainwright C</AU>
<TI>Acute viral bronchiolitis in children - a very common condition with few therapeutic options</TI>
<SO>Paediatric Respiratory Review</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>1</NO>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-1996" MODIFIED="2010-06-07 15:53:16 +1000" MODIFIED_BY="[Empty name]" NAME="Wang 1996" TYPE="JOURNAL_ARTICLE">
<AU>Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S, et al</AU>
<TI>Pediatric Investigators Collaborative Network in Infections in Canada (PICNIC) study of admissions and management variation in patients hospitalized with respiratory syncytial virus lower respiratory tract infection</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>1996</VL>
<PG>390-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Welliver-1992" MODIFIED="2013-12-04 06:11:46 +1000" MODIFIED_BY="[Empty name]" NAME="Welliver 1992" TYPE="BOOK_SECTION">
<AU>Welliver RC, Cherry JD</AU>
<TI>Bronchiolitis and infectious asthma</TI>
<SO>Textbook of Pediatric Infectious Diseases</SO>
<YR>1992</YR>
<PG>245-54</PG>
<EN>Third</EN>
<ED>Feigin RD, Cherry JD</ED>
<PB>WB Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-2001" MODIFIED="2013-12-04 06:11:49 +1000" MODIFIED_BY="[Empty name]" NAME="Wilson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wilson DF, Horn SD, Hendley JO, Smout R, Gassaway J</AU>
<TI>Effect of practice variation on resource utilization in infants hospitalized for viral lower respiratory illness</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>108</VL>
<PG>851-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-2010" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Wilson 2010" TYPE="UNPUBLISHED">
<AU>Wilson KM, Blumkin AK, Rauch DA, Szilagyi PG</AU>
<TI>Trends in cost and length of stay for children hospitalized for bronchiolitis: 2000-2006</TI>
<SO>Pediatric Academic Societies Meeting; 2010 May 2; Vancouver, Canada</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zorc-2010" MODIFIED="2010-10-12 14:06:03 +1000" MODIFIED_BY="[Empty name]" NAME="Zorc 2010" TYPE="JOURNAL_ARTICLE">
<AU>Zorc JJ, Hall CB</AU>
<TI>Bronchiolitis: recent evidence on diagnosis and management</TI>
<SO>Pediatrics</SO>
<YR>2010</YR>
<VL>125</VL>
<NO>2</NO>
<PG>342-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Gadomski-2006" MODIFIED="2013-12-10 05:20:59 +1000" MODIFIED_BY="[Empty name]" NAME="Gadomski 2006" TYPE="COCHRANE_REVIEW">
<AU>Gadomski AM, Bhasale AL</AU>
<TI>Bronchodilators for bronchiolitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-12-10 05:20:59 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-10 05:20:59 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001266.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gadomski-2010" MODIFIED="2013-12-13 11:07:12 +1000" MODIFIED_BY="[Empty name]" NAME="Gadomski 2010" TYPE="COCHRANE_REVIEW">
<AU>Gadomski AM, Brower MA</AU>
<TI>Bronchodilators for bronchiolitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2013-12-13 11:07:12 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-13 11:07:12 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001266.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kellner-1996" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Kellner 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kellner JD, Ohlsson A, Gadomski AM, Wang EEL</AU>
<TI>Efficacy of bronchodilator therapy in bronchiolitis: a meta-analysis</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>1996</YR>
<VL>150</VL>
<PG>1166-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kellner-1998" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Kellner 1998" TYPE="COCHRANE_REVIEW">
<AU>Kellner JD, Ohlsson A, Gadomski AM, Wang EEL</AU>
<TI>Bronchodilator therapy in bronchiolitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-10-08 05:45:44 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-10-08 05:45:44 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001266.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-06-09 10:11:34 +1000" MODIFIED_BY="Liz Dooley">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-06-09 10:11:34 +1000" MODIFIED_BY="Liz Dooley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alario-1992">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients less than 36 months old with acute wheezing and or respiratory distress less than 48 hours. N = 73. Mean age 16.1 months, 68% male, no underlying cardiac or lung disease<BR/>Country: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: metaproterenol sulfate 10 mg (0.2 ml of a 5% solution). Group 2: 0.2 ml normal saline. Both diluted in 2 ml normal saline administered by nebulizer without oxygen via face mask. 20 to 25 minutes after initial treatment, participants crossed over. Children received nebulized metaproterenol, either as an initial treatment or after a control treatment with normal saline solution. Only initial treatment results are included</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory rate, RDI score (color, wheezing, accessory muscle use, flaring, grunting, distress), oxygen saturation, side effects (tremors, vomiting, extreme irritability). RDI results were available for 37 infants aged <U>&lt;</U> 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Included asthmatic participants or recurrent wheezers. &#8220;Responders to metaproterenol therapy&#8221; included 40% of those aged 12 months or younger versus 52% of those aged 24 months or older</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:43 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Enrolled 186 children ages 1.5 to 24 months, treated as outpatients in a pediatric ED. Mean age 9.5 months, 65.1% male. Inclusion criterion was mild bronchiolitis (clinical score between 1 and 9). Exclusions were prior history of wheezing, previous treatment with bronchodilators and/or steroids and lung or cardiac disease<BR/>Country: Turkey</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>All groups were pre-treated with 8 ml of nebulized normal saline. Treatment was 2.5 mg of salbutamol in 4 ml of 0.9% saline at 0 and 30 minutes. The placebo group received a 4 ml 0.9% saline solution nebulization. 2 other study groups received epinephrine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score (RDAI), pulse oximetry and heart rate at 0, 30, 60 and 120 minutes, and hospital admission</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-08 08:25:12 +1000" MODIFIED_BY="[Empty name]">
<P>All participants were reassessed for recurrent wheezing attacks in the following 6 months (by phone)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anil-2010-SAL-3_x0025_">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Enrolled 186 children ages 1.5 to 24 months, treated as outpatients in a pediatric ED. Mean age 9.5 months, 65.1% male. Inclusion criterion was mild bronchiolitis (clinical score between 1 and 9). Exclusions were prior history of wheezing, previous treatment with bronchodilators and/or steroids and lung or cardiac disease<BR/>Country: Turkey</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>All groups were pre-treated with 8 ml of normal saline. Treatment was 2.5 mg of salbutamol in 4 ml of 3% saline at 0 and 30 minutes. The placebo group received a 4 ml 0.9% saline solution nebulization. 2 other study groups received epinephrine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score (RDAI), pulse oximetry and heart rate at 0, 30, 60 and 120 minutes, and hospital admission</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>All participants were reassessed for recurrent wheezing attacks in the following 6 months (by phone)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Can-1998">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-08 01:44:06 +1000" MODIFIED_BY="Melissa A Brower">
<P>Outpatient (emergency department) study of 156 infants with acute bronchiolitis. Mean age 7.1 months. Excluded infants who were pre-term, had chronic disease, prior bronchodilator treatment, history of previous attack, symptoms for more than 1 week, HR more than 200 beats per minute, lethargy or RDS score more than 5<BR/>Country: Turkey</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-16 09:29:56 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: salbutamol nebulized 0.15 mg/kg in 2 ml saline<BR/>Group 2: saline nebulized<BR/>Group 3: mist tent<BR/>Intervention was repeated at 30 minutes if RDS score more than 5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-16 09:29:58 +1000" MODIFIED_BY="[Empty name]">
<P>Outcomes: heart rate, oximetry, RDS score at 0, 30 and 60 minutes and percentage of participants with RDS score more than 5 at 30 and 60 minutes. Chest X-ray and laboratory studies (hemoglobin, hematocrit, leucocyte, neutrophils, eosinophils and IgE) were also compared<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis of infants less than 6 months versus those more than 6 months showed similar changes in RDS at 30 and 60 minutes. No differences in laboratory values noted among the 3 study groups. Chest X-ray findings consistent with bronchiolitis higher in Group 1 (88%) compared with 69% in Group 2 and 73% in Group 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chevallier-1995">
<CHAR_METHODS MODIFIED="2014-04-15 03:32:15 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients aged 1 to 6 months hospitalized with first episode of bronchiolitis. N = 104. Mean age 3.1 months, 67% male, no underlying lung/cardiac disease, preceding bronchodilator/steroids in the past 48 hours also excluded. 78% RSV-positive<BR/>Country: France</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-12 13:52:44 +1000" MODIFIED_BY="[Empty name]">
<P>Nebulized salbutamol (0.15 mg/kg/dose) or saline placebo administered using oxygen propellant 3 times at intervals of 1 hour</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory rate, clinical scoring system (4-point score for each of retractions and wheezing), oximetry (used value taken at 30 minutes)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-08 08:20:34 +1000" MODIFIED_BY="[Empty name]">
<P>All participants less than 12 months of age</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chowdhury-1995">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients aged 23 days to 11 months, admitted with moderate bronchiolitis. Mean age 3.85 months, 73% male. No previous history of wheeze or bronchodilator use, no underlying lung/cardiac disease. 58% RSV-positive<BR/>Country: Saudi Arabia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 01:29:32 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: salbutamol respiratory solution (ventolin 5 mg/ml) 0.15 mg/kg; Group 2: ipratropium bromide (0.025% solution) 12.5 micrograms/kg; Group 3: combination of above two at doses stated; Group 4: normal saline 0.3 ml/kg. All mixed with 2 ml normal saline and delivered with 100% oxygen at 6 to 7 L/min using nebulizer. 6 hourly for 36 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Modified RDAI Clinical Score (5-point score for each of wheezing: expiratory, inspiratory, location; retraction: supraclavicular, intercostal, subcostal; respiratory rate)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-08 08:21:14 +1000" MODIFIED_BY="[Empty name]">
<P>All participants less than 12 months of age</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dobson-1998">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients aged less than 24 months admitted to inpatient unit with first episode of wheezing with moderately severe bronchiolitis defined as pulse oximetry &lt; 94% and clinical score &gt; 1. Mean age 5.6 months, 48% male, no underlying lung/cardiac disease. 81% RSV-positive<BR/>Country: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-14 01:14:48 +1000" MODIFIED_BY="Melissa A Brower">
<P>Albuterol: 1.25 mg for patients less than 10 kg and 2.5 mg for patients more than 10 kg in normal saline for total volume of 3 ml or normal saline: 3 ml. Both administered with nebulized aerosol every 2 hours for first 24 hours, then every 4 hours for next 48 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Oxygen saturation, clinical score (5-point score for general appearance, 4-point score for each of accessory muscle use and wheezing), duration of hospitalization (defined as time to each predetermined discharge criteria)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-03 02:11:06 +1000" MODIFIED_BY="[Empty name]">
<P>86% of the study population is less than 12 months of age. Adverse effects were compared between study groups. 3 participants were withdrawn from the albuterol group due to worsening hypoxemia. Subgroup analysis of results for infants less than 12 months was done but results not published</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gadomski-1994a-_x002d_-neb">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients and emergency department participants less than 18 months old with first-time wheezing. Mean age 5.9 months. No underlying lung/cardiac disease<BR/>Country: Egypt</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: nebulized salbutamol (0.15 mg/kg/dose), Group 2: nebulized saline solution, Group 3: orally administered salbutamol (0.15 mg/kg/dose), Group 4: orally administered placebo. Nebulized groups received 2 treatments 30 minutes apart and oral-treated groups received 1 treatment. Nebulization performed within 10 to 12 minutes with flow rate 4 to 6 L/min using a foot-pump nebulizer, with room air, up-mist nebulizer and pediatric face mask</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory rate, oxygen saturation, change in state of infant, study-specific clinical score (34-point scale for each of degree of grunting, nasal flaring, supraclavicular retractions, intercostal retraction, chest indrawing, air entry, air hunger, wheezing, general appearance)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Nebulized treatment group: in order to represent the results from the 2 bronchodilator treatment arms (nebulized and oral), this study is listed twice. Each treatment group had its own placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gadomski-1994a-_x002d_-oral">
<CHAR_METHODS MODIFIED="2010-06-08 08:22:29 +1000" MODIFIED_BY="[Empty name]">
<P>See Gadomski 1994a - neb</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Oral treatment group: in order to represent the results from the 2 bronchodilator treatment arms (nebulized and oral), this study is listed twice. Each treatment group had its own placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients less than 15 months old, with first episode of wheezing. Median age 5.5 months, 56% male, no underlying lung/cardiac disease. 48% RSV-positive<BR/>Country: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: nebulized salbutamol in 3 ml saline, Group 2: nebulized saline placebo in 3 ml saline, Group 3: oral salbutamol, Group 4: oral saline placebo. Dose of salbutamol 0.15 mg/kg/dose. Nebulized group received 2 nebulizations 30 minutes apart and oral groups received 1 dose. Nebulization with compressed air at 6 L/min via Up-mist nebulizer with pediatric face mask. Infants 7 kg or less received 1 unit dose of 1 mg salbutamol solution for inhalation (5 mg/ml) or 1 oral dose of 2.5 ml</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory rate, heart rate, clinical score (4-point score for each of grunting, nasal flaring, supraclavicular and intercostal retractions, air entry, air hunger, duration of wheeze in respiratory cycle, location of wheeze, general appearance), oxygen saturation, infant's state. Side effects: flushing of face, hyperactivity, increased coughing, tremors</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Nebulized treatment group: in order to represent the results from the 2 bronchodilator treatment arms (nebulized and oral), this study is listed twice. Each treatment group had its own placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gadomski-1994b-_x002d_-oral">
<CHAR_METHODS MODIFIED="2010-06-08 08:23:07 +1000" MODIFIED_BY="[Empty name]">
<P>Oral arm - see Gadomski 1994b - neb</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Oral treatment group: in order to represent the results from the 2 bronchodilator treatment arms (nebulized and oral), this study is listed twice. Each treatment group had its own placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goh-1997">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, blinded trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients less than 24 months old admitted for signs and symptoms consistent with clinical diagnosis of bronchiolitis. Mean age 5.2 to 7.4 months, 72% male. No history of previous wheezing, no underlying lung/cardiac disease. 42% RSV-positive<BR/>Country: Singapore</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: salbutamol 2.5 mg/ml; Group 2: ipratropium bromide 250 µg/ml; Group 3: normal saline; Group 4: humidified oxygen without nebulization. Administered over 10 to 15 minutes by face masks driven by oxygen flow rate of 6 to 8 L/min. Nebulized at 4 to 6-hourly intervals. Less than 6 months: 0.3 ml solution, more than 6 months: 0.6 ml solution in 2 ml saline for nebulizations</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Duration of hospitalizations, clinical score (5-point score for each of respiratory rate, subcostal retractions, presence of wheeze and 2-point score for each of presence of crepitations, oxygen requirement, nebulization, intravenous infusion). Used day 3 clinical scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gupta-2008">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients less than 1 year of age, with clinical diagnosis of acute bronchiolitis defined as first episode of wheezing with evidence of an acute viral respiratory tract infection. Included only if mild disease (RR &lt;= 70 breaths/min, SpO<SUB>2</SUB> &gt;= 95% in room air, no or mild accessory muscle use and RDAI score &lt;= 10). Exclusions: dehydration, lethargy, chronic cardiopulmonary disease, or prior bronchodilator use<BR/>Country: (North) India</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: oral salbutamol (0.1 mg/kg/dose) 3 times daily for a maximum of 7 days or until symptoms resolved. Group 2: oral placebo given 3 times daily for a maximum of 7 days or until symptoms resolved</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-13 13:56:43 +1000" MODIFIED_BY="[Empty name]">
<P>Time to resolution of illness (ROI), defined as time from study enrolment to the time the infant returned to baseline health status, as determined by the principal caregiver on a 4-point scale. Time to resolution of individual symptoms that comprised the ROI also included. Outcomes were determined at 3, 7 and 14 days. Hospitalization was also reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>RDAI was used only at baseline. A total of 10 participants were lost to follow-up, 7 (10%) in the salbutamol group and 3 (4.3%) in the placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gurkan-2004">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:45 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients aged between 2 and 24 months, with moderate acute viral bronchiolitis. Mean age 7.2 months, 68% male. 1. Diagnostic criteria were: an acute infection of the lower respiratory tract preceded by or accompanied by fever and/or rhinitis and characterized by tachypnea, expiratory wheezing and increased respiratory effort, as per <LINK REF="STD-Dobson-1998" TYPE="STUDY">Dobson 1998</LINK>. Exclusions: infants with history of more than 1 hospitalization from wheezing; history of personal or familial atopy or presence of atopic dermatitis; chronic cardiac or pulmonary diseases; diagnosed immune deficiency disorder; recent use of corticosteroid or bronchodilator agent; concomitant severe diseases (pneumonia, meningitis, sepsis, etc.)<BR/>Country: Turkey</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: salbutamol 0.15 mg/kg dose. Group 2: adrenaline 0.5 mg (1 ml). Group 3: nebulized saline placebo - 4 ml. All groups received routine supportive management</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score (adapted from <LINK REF="STD-Schuh-1990" TYPE="STUDY">Schuh 1990</LINK>), heart rate, respiratory rate and oxygen saturation, temperature. (Clinical score included 4-point scale for each of general appearance, accessory muscle use, wheezing). Evaluations were conducted at admission and 30 minutes, 1, 3, 12, 24 and 48 hours. 24-hour data were used to be as consistent as possible with other data</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished data and study details provided by e-mail from author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henry-1983">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:45 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients less than 1 year old with acute bronchiolitis. Mean age 4.3 months, 61% male, 68% RSV-positive<BR/>Country: UK</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>6-hourly nebulized solutions of 250 µg of ipratropium bromide in 2 ml saline (n = 34) or normal saline alone (n = 32)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-13 13:56:43 +1000" MODIFIED_BY="[Empty name]">
<P>Day to improvement in study specific clinical score. 4-point score for each of heart rate, respiratory rate, cough, rhinitis, nasal flaring, cyanosis, hyperinflation, tracheal tug, intercostal recession, subcostal recession, respiratory distress, crepitations and rhonchi. Side effects: increased heart rate, persistent coughing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ho-1991">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Setting: inpatients<BR/>Hospitalized participants less than 6 months old with first episode of cough and wheeze due to acute bronchiolitis. Mean age 3 months, 52% male, no underlying heart/lung disease. All RSV-positive<BR/>Country: Australia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-12 13:52:45 +1000" MODIFIED_BY="[Empty name]">
<P>Nebulized salbutamol (2 to 5 mg/2ml) or normal saline placebo (2 ml). Administered with nebulizer run from compressed gas supply with flow of 6 L/min. 30 to 40 minutes after initial treatment, participants crossed over</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Oxygen saturation up to 30 minutes after each treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-12 13:52:45 +1000" MODIFIED_BY="[Empty name]">
<P>Short follow-up after intervention</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ipek-2011">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Setting: short-stay unit of a pediatric emergency department<BR/>Infants between 1 and 23 months of age, seen for moderate bronchiolitis, first episode of wheezing. Patients with history of preceding viral URI, followed by wheezing and crackles on auscultation and a clinical bronchiolitis severity score (CBSS) of 4 to 8. Mean age 7.96 ± 3.91 months. Exclusion criteria were: prematurity; birth weight &lt; 2500 g; chronic neurological or cardiopulmonary disease, including asthma; infants younger than 1 month old and greater than 2 years; proven immune deficiency, consolidation or atelectasis on CXR; oxygen saturation &lt; 85% on room air<BR/>Country: Turkey</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-13 11:24:33 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: nebulized salbutamol 0.15 mg/kg plus normal saline (NS) every 20 minutes for 3 doses</P>
<P>Group 2: nebulized salbutamol 0.15 mg/kg plus hypertonic saline (HS) every 20 minutes for 3 doses<BR/>Group 3: hypertonic saline every 20 minutes for 3 doses</P>
<P>Group 4: normal saline every 20 minutes for 3 doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-15 03:32:21 +1000" MODIFIED_BY="[Empty name]">
<P>Changes in CBSS, respiratory rate, oxygen saturation, heart rate assessed at 0, 20, 40 and 60 minutes; corticosteroid need, hospitalization ratios</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-13 11:24:40 +1000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Sezer-2010" TYPE="STUDY">Sezer 2010</LINK> was a published abstract using the same trial data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karadag-2005-_x002d_-IPR">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Setting: inpatients<BR/>Infants less than 1 year of age, hospitalized for moderate to severe bronchiolitis, first episode of wheezing. Chest X-ray compatible with bronchiolitis. Mean age 5.1 ± 2.7 months. No prematurity; chronic neurological or cardiopulmonary disease, including asthma; proven or suspected acute bacterial infection; previous treatment with bronchodilators or corticosteroids; infants younger than 4 weeks old and who needed ventilation at neonatal period; symptoms present for more than 7 days; fever higher than 38.5 °C; or infants with mild bronchiolitis.<BR/>Country: Turkey</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: nebulized salbutamol solution (Ventolin, Glaxo) plus saline solution (0.9%) 2.5 ml every 6 hours. Group 2: ipratropium bromide (Atrovent, Boehringer Ingelheim) 250 µg/2 ml plus 3 ml saline solution every 6 hours<BR/>Group 3: normal saline received 5 ml every 6 hours<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Changes in the oxygen saturation rates, clinical scores and duration of hospital stay. Adverse effects were recorded, i.e. tachycardia and tremor after nebulization of each medication<BR/>The clinical score system was based on respiratory rate, degree of wheezing, degree of accessory muscle use and general condition, described by <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>. Improvement was defined as a decrease by 2 points in the total clinical score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-08 08:30:04 +1000" MODIFIED_BY="[Empty name]">
<P>Ipratropium (IPR) treatment group: in order to represent the results from the 2 bronchodilator treatment arms (ipratropium and salbutamol), this study is listed twice. The placebo group was divided between comparisons to avoid double-counting of placebo participants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-08 08:30:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karadag-2005-_x002d_-SAL">
<CHAR_METHODS>
<P>See Karadag 2005 - IPR</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2010-06-08 08:30:27 +1000" MODIFIED_BY="[Empty name]">
<P>Salbutamol (SAL) treatment group: in order to represent the results from the 2 bronchodilator treatment arms (ipratropium and salbutamol), this study is listed twice. The placebo group was divided between comparisons to avoid double-counting of placebo participants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-08 08:30:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karadag-2008">
<CHAR_METHODS MODIFIED="2010-06-08 08:30:17 +1000" MODIFIED_BY="[Empty name]">
<P>Same as Karadag 2005</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2010-06-08 08:30:37 +1000" MODIFIED_BY="[Empty name]">
<P>This published manuscript describes the same study as Karadag 2005 that was published as an abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klassen-1991">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:45 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-08 02:33:23 +1000" MODIFIED_BY="Melissa A Brower">
<P>Outpatients treated in emergency department, aged less than 24 months old, with first episode of wheezing. Mean age 7.2 months, 57% male, no underlying lung/cardiac disease or previous bronchodilator use<BR/>Country: Canada</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>2 treatments at 30-minute intervals of either nebulized salbutamol (0.10 mg/kg in 2 ml normal saline) or similar volume (0.02 ml/kg) normal saline placebo. Administered for 5 to 8 minutes through updraft nebulizer with continuous flow of oxygen for 5 to 6 L/min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-08 08:30:53 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory rate, heart rate, oxygen saturation, RDAI score (5-point score for each of wheezing: expiration, inspiration, location; retractions: supraclavicular, intercostal, subcostal)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levin-2008">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:45 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, blinded prospective study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>22 infants with respiratory syncytial virus bronchiolitis who were in respiratory failure and intubated and ventilated in a pediatric ICU. Only first-time wheezers were included. Mean age 8.1 weeks, 64% male, with no underlying lung or cardiac disease<BR/>Country: United States</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized to 4 groups: albuterol (3 ml of 0.083%, 2.5 mg/3 ml), levalbuterol (3 ml of 1.25 mg/3 ml), norepinephrine (0.5 ml of 2.25% solution) and normal saline. Nebulized every 6 hours by the endotracheal tube. Each participants acted as their own control</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-13 13:56:43 +1000" MODIFIED_BY="[Empty name]">
<P>Peak inspiratory pressure, inspiratory respiratory system resistance and heart rate measured before and 20 minutes after treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-08 08:32:01 +1000" MODIFIED_BY="[Empty name]">
<P>Participants recruited from December 2001 to March 2007. Study documented a significant increase in heart rate for all 3 bronchodilator treatment groups but not for the placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lines-1990">
<CHAR_METHODS>
<P>Double-blind, controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inpatients less than 18 months old admitted to hospital with bronchiolitis. Mean age 6.2 months, 73% male, no underlying lung/cardiac disease<BR/>Country: Australia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>2 doses given at 2-hour intervals. Either 0.2 ml salbutamol (5 mg/ml) or 0.2 ml saline in 4 ml of physiological saline given over 10 minutes with oxygen at 8 L/min through a Hudson mask<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>RDAI, oximetry, RACS (wheezing, retraction, respiratory rate), pulse rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lines-1992">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:45 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, controlled, prospective clinical study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inpatients less than 18 months old admitted with acute bronchiolitis. No underlying lung/cardiac disease<BR/>Country: Australia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>2 doses (with 2-hour interval) of nebulized ipratropium bromide 1 ml (250 µg) in 4 ml saline or 5 ml saline placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Oxygen saturation, RACS, respiratory rate, heart rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mallol-1987">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:46 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inpatients less than 1 year old admitted with acute wheezing. Mean age 5.9 months, 67% male, no underlying lung/cardiac disease<BR/>Country: Chile</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: nebulized fenoterol plus ipratropium bromide. Group 2: fenoterol. Group 3: fenoterol plus steroids. Group 4: aminophylline, IV, plus steroids and oral fenoterol (FNT). Group 5: nebulized normal saline (control). Pediatric nebulizers used with the bronchodilator and saline amounting to 4 ml. A flow of 6 L/min of compressed air, or occasionally, oxygen was used. Warm saline used. Dosage of drugs: nebulized FNT - 0.04 ml/kg/dose every 6 hours (0.5% solution), nebulized IB - 250 µg/dose every 6 hours (0.025% solution), oral or IV aminophylline - less than 6 months (age in weeks *0.3 + 8 = mg/kg/day, 4 equal doses every 6 hours) or more than 6 months (15 mg/kg/day, 4 equal doses every 6 hours), steroids: dexamethasone (IV or IM, 0.3 mg/kg/dose initially, 0.3 mg/kg/day, 3 equal doses every 8 hours) or prednisone (oral 2 mg/kg/day, 3 equal doses every 8 hours)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical score same as with <LINK REF="STD-Tal-1983" TYPE="STUDY">Tal 1983</LINK>. No adverse side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-12 13:52:46 +1000" MODIFIED_BY="[Empty name]">
<P>No distinction made between asthma and bronchiolitis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 19:08:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patel-2002">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, parallel-group, controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients less than 12 months old with clinical diagnosis of bronchiolitis. Mean age 4 months. No previous wheeze or bronchodilator use, prematurity, underlying chronic disease, immunocompromise, RSV immunoprophylaxis or parents not fluent in English or French<BR/>Country: Canada<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-08 04:30:11 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: epinephrine (0.03 ml/kg/dose of a 2.25% solution)<BR/>Group 2: nebulized albuterol (0.03 ml/kg of a 5 mg/ml solution)<BR/>Group 3: saline (0.03 ml/kg/dose of 0.9% solution of 0.9% sodium chloride)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Duration of hospitalization (LOS) was defined as time between study entry and time that infant left the inpatient ward, time from admission to normal hydration, oxygenation and minimal respiratory distress<BR/>RDAI (Lowell 17-point categorical score)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 19:08:21 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patel-2003">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>129 infants, mean age 5.3 months, 60% male, seen in an emergency department setting for mild to moderate bronchiolitis, defined as first episode of wheezing in an infant with evidence of URI. Upon discharge, randomized to receive either oral albuterol or placebo. Exclusions were age older than 12 months, prior wheezing, prior bronchodilator use, underlying lung or cardiac disease, or admission to hospital<BR/>Country: Canada</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>First dosage of medication was given in the ED before discharge. Oral albuterol was dosed at 0.1 mg/kg per dose given 3 times per day for 7 days. Placebo was also given 3 times per day for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-12 13:52:46 +1000" MODIFIED_BY="[Empty name]">
<P>Time to resolution of illness (ROI), measured on a daily basis by telephone interview until the score of 4 was documented. Secondary outcomes included time to normal feeding, normal sleeping, quiet breathing, resolved cough and resolved coryza. Hospitalization was also recorded</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>RDAI was used only at baseline. More infants in the albuterol group who did not complete 7 days of therapy as compared to placebo (8 in albuterol and 2 in placebo). There were 2 withdrawals from each study group. Total drop out for this study was 10.8%</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ralston-2005">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>65 participants ages 6 weeks to 24 months, outpatients with acute bronchiolitis seen in an urgent care setting. Mean age 7.6 months, 55% male. Inclusion criteria were RDAI score between 4 and 14. Exclusion criteria were prior wheezing or asthma, lung or cardiac disease, systemic steroid use or physiologic instability at presentation</P>
<P>Country: United States, high altitude (5000 feet)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-12 13:52:46 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment was 5 mg of racemic albuterol in 3 ml of normal saline administered at 0 and 30 minutes, compared to 3 ml placebo nebulization of 0.9% saline. (A third group received 5 mg racemic epinephrine)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-15 03:32:24 +1000" MODIFIED_BY="[Empty name]">
<P>Need for hospitalization or home oxygen. RDAI and oxygen saturation at 60 minutes were included as unpublished data</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-08 08:35:09 +1000" MODIFIED_BY="[Empty name]">
<P>Participants recruited from January 2000 to March 2004</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scarlett-2012">
<CHAR_METHODS MODIFIED="2013-08-23 02:01:37 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients younger than or equal to 12 months of age with a first episode of wheezing due to RSV bronchiolitis. Mean age in placebo group 8.8 weeks, albuterol 20.1 weeks (despite randomization, albuterol-treated infants were significantly older than placebo-treated infants, P value &lt; 0.0001). Excluded preterm infants, underlying chronic lung disease, previous history of wheezing or treatment with bronchodilators before current illness, previous treatment with RSV prophylaxis therapy, history of respiratory infection 3 weeks before enrollment, hemodynamically significant congenital heart disease, immune-compromised state, albuterol therapy within 6 hours of administration of the study drug, gastro-esophageal reflux requiring medical therapy, neurodevelopmental delay, severe bronchiolitis requiring admission to pediatric intensive care</P>
<P>Country: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-13 11:22:32 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: albuterol nebulized (0.1 mg/kg in 3 ml saline). Group 2: saline (3 ml)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-13 11:22:33 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory inductive plethysmography (RIP) for a total of 30 breaths, ratio of time to peak expiratory flow to total expiratory time (Tpef/Te), RDAI, oxygen saturation, respiratory rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-13 11:22:54 +1000" MODIFIED_BY="[Empty name]">
<P>Only infants with a 10% increase in heart rate were included in the final analysis. 3 participants excluded because they did not maintain quiet sleep. <LINK REF="STD-Ren-2011" TYPE="STUDY">Ren 2011</LINK> was a published poster abstract using the same trial data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 19:12:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schuh-1990">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-08 08:35:18 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients in emergency department, 6 weeks to 24 months old. Mean age 5.7 months. No prior history of wheeze or bronchodilators, no underlying lung/cardiac disease<BR/>Country: Canada</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 19:12:09 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: 3 doses of 0.5% nebulized salbutamol, 0.15 mg/kg/dose at 1-hour intervals, Group 2: 2 doses of nebulized saline solution, followed by 1 dose of 0.5% nebulized salbutamol, 0.15 mg/kg/dose, 1 hour apart. All doses suspended in 3 ml normal saline solution and delivered for 15 minutes by face mask and nebulizer, driven by oxygen at flow rate of 6 to 7 L/min<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Respiratory rate, heart rate, accessory muscle score, wheezing score, transcutaneous oxygen saturation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 19:12:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schweich-1992">
<CHAR_METHODS>
<P>Double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 19:12:30 +1000" MODIFIED_BY="[Empty name]">
<P>Outpatients admitted to emergency department, aged less than 24 months old with wheezing. Mean age 7.35 months old, 48% male, no underlying cardiac/lung disease. 3 infants in each study group had prior wheezing<BR/>Country: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-03 02:13:23 +1000" MODIFIED_BY="[Empty name]">
<P>2 doses of nebulized salbutamol (0.15 mg/kg in 3 ml normal saline) or placebo (0.03 ml/kg normal saline in 3 ml normal saline). Both administered with continuous-flow oxygen at 6 liters/min at interval of about 30 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-08 08:37:42 +1000" MODIFIED_BY="[Empty name]">
<P>Respiratory rate, heart rate, wheeze score (5-point score for each of expiration, inspiration, location), retraction score (5 point score for each of supraclavicular, intercostal, subcostal), oxygen saturation)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Included recurrent wheezers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tal-1983">
<CHAR_METHODS MODIFIED="2010-10-12 13:52:46 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-15 03:32:24 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients aged 1 to 12 months, hospitalized with bronchiolitis, asthma or WARI. Mean age 5.4 months, 62.5% male<BR/>Country: USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-08 08:38:08 +1000" MODIFIED_BY="[Empty name]">
<P>Intramuscular dexamethasone or placebo (double-blind) and salbutamol (oral and inhaled) or none (open) in all 4 possible combinations. Dexamethasone (4 mg/ml) or placebo (normal saline) administered intramuscularly, 0.075 ml/kg on admission and 0.025 ml/kg every 8 hours for next 3 days. Also, half of these patients were given salbutamol (via 2 routes simultaneously) or no additional treatment. Salbutamol: inhalation (0.5 ml salbutamol respiratory solution with 2 ml water) given on admission and subsequently every 6 hours, oral (salbutamol syrup, 0.15 mg/kg) every 8 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Study-specific clinical scoring system (4-point scale for each of respiratory rate, wheezing, cyanosis, use of accessory muscles). Measurements of arterial blood gases, blood pressure. Side effects: tremors</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Included asthmatic patients and recurrent wheezers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tinsa-2009">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomized, placebo-controlled, double-blind clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>36 first-time wheezing infants ages 3 to 12 months admitted to hospital for moderate severity bronchiolitis. Inclusion criterion was RDAI score between 4 and 15. Excluded were children with underlying lung or cardiac disease, concurrent bronchodilator or corticosteroid treatment and recurrent wheezing<BR/>Country: Tunisia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-16 09:30:04 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment was nebulized terbutaline at 0.15 mg/kg in 4 ml of normal saline every 4 hours. Placebo group received 4 ml of normal saline nebulized</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-15 03:32:24 +1000" MODIFIED_BY="[Empty name]">
<P>RDAI score, respiratory rate, pulse oximetry and heart rate at 0, 30, 60 and 120 minutes after the first treatment and duration of hospitalization</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-08 08:39:09 +1000" MODIFIED_BY="[Empty name]">
<P>1 participant withdrawn from placebo group due to worsening clinical status, necessitating transfer to the ICU</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Totapally-2002">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients less than 12 months old with a first episode of wheezing due to RSV bronchiolitis. Mean age 5.8 months. Excluded preterm infants, underlying chronic disease or infants with grunting<BR/>Country: USA<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-08 04:30:29 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: albuterol nebulized (0.15 mg/kg in 3 ml saline). Group 2: saline (3 ml). All infants treated first with chloral hydrate. Participants crossed over at 6-hour intervals in random order<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-23 02:11:49 +1000" MODIFIED_BY="[Empty name]">
<P>Tidal breathing flow loops, wheeze score, heart rate, respiratory rate, pulse oximetry, ratio of time to peak expiratory flow to total expiratory time (Tpef/Te)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Wheeze score was:<BR/>0 for none<BR/>1 for end exp<BR/>2 for audible with stethoscope<BR/>3 for audible without stethoscope<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-1992">
<CHAR_METHODS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, factorial trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Setting: inpatients<BR/>Infants 2 to 24 months of age hospitalized for the first time with mild bronchiolitis. 55% male, no underlying cardiac/lung disease<BR/>Country: Canada</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Group 1: salbutamol at 0.15 mg/kg/dose in 2 ml saline followed 1 hour later by 0.5 ml or 1 ml saline placebo. Group 2: 0.03 ml/kg saline in 2 ml saline followed by either 125 µg ipratropium bromide if less than 6 months old or 250 µg ipratropium bromide if older than 6 months. Group 3: both salbutamol and ipratropium bromide in doses indicated. Group 4: saline placebos in same volumes indicated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-08 08:40:00 +1000" MODIFIED_BY="[Empty name]">
<P>Oxygen saturation, study-specific clinical assessment (4-point score for each of respiratory rate, wheezing, retractions, general condition)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Infants with prior use of bronchodilators were included (1 in salbutamol, 2 in ipratropium, 4 in saline). 4 participants withdrawn from trial due to worsening: 1 in Group 1, 2 in Group 3 and 1 in Group 4</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CBSS = clinical bronchiolitis severity score<BR/>CXR = chest X-ray<BR/>ED = emergency department<BR/>HR = heart rate<BR/>hr = hour<BR/>HS = hypertonic saline<BR/>ICU = intensive care unit<BR/>IM = intramuscular<BR/>IV = intravenous<BR/>L/min = liters per minute<BR/>MDI = metered dose inhaler<BR/>NS = normal saline<BR/>RACS = Respiratory Assessment Change Score<BR/>RDAI = Respiratory Distress Assessment Instrument<BR/>RDI = Respiratory Distress Index<BR/>RDS = Respiratory Distress Score<BR/>RR = respiratory rate<BR/>RSV = respiratory syncytial virus<BR/>SpO<SUB>2</SUB> = oxygen saturation<BR/>URI = upper respiratory infection<BR/>WARI = wheeze associated acute respiratory infection<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-10-10 00:52:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Absar-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-10 00:52:51 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Abu_x002d_Shukair-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-21 06:58:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alansari-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-21 06:58:33 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-30 07:02:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barlas-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-30 07:02:13 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-05 04:09:59 +1000" MODIFIED_BY="Melissa A Brower" STUDY_ID="STD-Beck-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-05 04:09:59 +1000" MODIFIED_BY="Melissa A Brower">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-30 06:48:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Belcastro-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-30 06:48:48 +1000" MODIFIED_BY="[Empty name]">
<P>Research protocol only - no patient outcomes data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bentur-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bertrand-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-16 09:30:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brooks-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-16 09:30:05 +1000" MODIFIED_BY="[Empty name]">
<P>Not a randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cengizlier-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Control group was not given placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 02:11:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chao-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 02:11:01 +1000" MODIFIED_BY="[Empty name]">
<P>Groups were stratified by age but no equivalent aged placebo group for the bronchodilator (terbutaline) group, therefore no comparison could be made</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-15 04:58:57 +1000" MODIFIED_BY="Melissa A Brower" STUDY_ID="STD-Choong-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-15 04:58:57 +1000" MODIFIED_BY="Melissa A Brower">
<P>Poster abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-16 09:30:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cortes-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-16 09:30:05 +1000" MODIFIED_BY="[Empty name]">
<P>Not clearly randomized, insufficient information provided in brief report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-21 00:57:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Del-Vecchio-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-21 00:57:48 +1000" MODIFIED_BY="[Empty name]">
<P>Not a randomized controlled trial, no placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-08 08:42:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fernandez-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-08 08:42:23 +1000" MODIFIED_BY="[Empty name]">
<P>Study compared heliox versus oxygen to drive albuterol or epinephrine. No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ferrer-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only available in abstract form</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-21 06:58:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Florin-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-21 06:58:16 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frasson-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only; testing method of nebulization; no placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goebel-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-05 04:10:10 +1000" MODIFIED_BY="Melissa A Brower" STUDY_ID="STD-Gomez_x002d_y_x002d_Lopez-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-05 04:10:10 +1000" MODIFIED_BY="Melissa A Brower">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-30 06:59:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonzalez-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-30 06:59:17 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hammer-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT; no placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-10 00:56:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-John-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-10 00:56:41 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-12 13:52:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-John-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-12 13:52:46 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-12 13:52:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kadir-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-12 13:52:46 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group and not blinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karaatmaca-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-30 07:37:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-30 07:37:39 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-20 06:45:47 +1000" MODIFIED_BY="Melissa A Brower" STUDY_ID="STD-Langley-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-20 06:45:47 +1000" MODIFIED_BY="Melissa A Brower">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luo-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group; quasi-experimental; not fully randomized<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-08 08:42:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luo-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-08 08:42:35 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-10 00:40:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luo-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-10 00:40:43 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mandelberg-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Menon-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Milner-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data not provided</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-21 01:35:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Modaressi-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-21 01:35:03 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Modl-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Not randomized or placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mull-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-15 04:58:30 +1000" MODIFIED_BY="Melissa A Brower" STUDY_ID="STD-Ndrepepa-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-15 04:58:30 +1000" MODIFIED_BY="Melissa A Brower">
<P>Poster abstract only, available only in Turkish</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Numa-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT; no placebo group; epinephrine only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ozyurek-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-12 13:52:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ralston-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-12 13:52:46 +1000" MODIFIED_BY="[Empty name]">
<P>Nasal phenylephrine, not used as a bronchodilator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ray-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reijonen-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-21 01:38:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ren-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-21 01:38:43 +1000" MODIFIED_BY="[Empty name]">
<P>Poster abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanchez-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT; no placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sarrell-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schuh-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-10 00:48:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sezer-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-10 00:48:48 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-21 06:58:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-21 06:58:22 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-16 09:30:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shu-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-16 09:30:05 +1000" MODIFIED_BY="[Empty name]">
<P>Not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simsek-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>No placebo group; abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-13 11:18:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simsek_x002d_Kiper-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-13 11:18:31 +1000" MODIFIED_BY="[Empty name]">
<P>Nebulized epinephrine versus salbutamol; no placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sly-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients did not clearly have bronchiolitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Soto-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Not a RCT; salbutamol only - no placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Springer-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Results and analysis focused on pulmonary function tests</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stokes-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Excluded from original review as results and analysis focused on pulmonary function tests. Excluded from update as not clearly randomized and water not a valid placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tatochenko-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Criteria for diagnosis unclear</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Torres-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Walsh-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>Compared 3 doses of albuterol to 1 dose of epinephrine plus 2 saline nebulizers and therefore was not placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wankum-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Results and analysis focused on pulmonary function tests. Only 3 infants studied. Author contacted but no response</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-15 04:58:00 +1000" MODIFIED_BY="Melissa A Brower" STUDY_ID="STD-Zhen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-15 04:58:00 +1000" MODIFIED_BY="Melissa A Brower">
<P>Poster abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhou-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomized controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-06-09 05:17:28 +1000" MODIFIED_BY="Melissa A Brower" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-01-10 20:37:57 +1000" MODIFIED_BY="Melissa A Brower" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 01:13:43 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Alario-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 01:15:07 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 01:35:37 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Anil-2010-SAL-3_x0025_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:35:11 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Can-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:34:58 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Chevallier-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:19:42 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Chowdhury-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:20:32 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Dobson-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 01:55:28 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994a-_x002d_-neb">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 01:59:16 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994a-_x002d_-oral">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:00:45 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:06:08 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994b-_x002d_-oral">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:21:41 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Goh-1997">
<DESCRIPTION>
<P>Not described </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:11:31 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gupta-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:21:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gurkan-2004">
<DESCRIPTION>
<P>Unclear; not published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:22:26 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Henry-1983">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:37:57 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Ho-1991">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:28:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ipek-2011">
<DESCRIPTION>
<P>Consecutive patients enrolled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:30:17 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Karadag-2005-_x002d_-IPR">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:30:30 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Karadag-2005-_x002d_-SAL">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:27:53 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Karadag-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:31:04 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Klassen-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:33:51 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Levin-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:31:16 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Lines-1990">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:31:26 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Lines-1992">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:31:44 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Mallol-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:49:08 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Patel-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:50:28 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Patel-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:30:11 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Ralston-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-13 11:22:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scarlett-2012">
<DESCRIPTION>
<P>Performed by research pharmacy (unpublished information)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:34:42 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Schuh-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:38:22 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Schweich-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:43:00 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Tal-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:45:55 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Tinsa-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:51:36 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Totapally-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:57:15 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Wang-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-01-10 20:43:36 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:36:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alario-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:36:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:36:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010-SAL-3_x0025_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:35:16 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Can-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:34:51 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chevallier-1995">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:37:10 +1000" MODIFIED_BY="Melissa A Brower" RESULT="UNKNOWN" STUDY_ID="STD-Chowdhury-1995">
<DESCRIPTION>
<P>Unclear; insufficient detail provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:37:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dobson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:37:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gadomski-1994a-_x002d_-neb">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:00:09 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994a-_x002d_-oral">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:37:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:06:18 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994b-_x002d_-oral">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-08 08:23:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goh-1997">
<DESCRIPTION>
<P>Fourth study group receiving humidified oxygen was studied 1 year later without blinding or allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:37:36 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gupta-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:37:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gurkan-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:22:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henry-1983">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:43:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ho-1991">
<DESCRIPTION>
<P>Unclear; insufficient detail provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:42:25 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ipek-2011">
<DESCRIPTION>
<P>Consecutive allocation to treatment groups; insufficient detail provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:30:27 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Karadag-2005-_x002d_-IPR">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:30:33 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Karadag-2005-_x002d_-SAL">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:27:55 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Karadag-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:37:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klassen-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:38:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Levin-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:42:09 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Lines-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:42:23 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Lines-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:31:49 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Mallol-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:38:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:38:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:38:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-17 23:20:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scarlett-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:35:01 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Schuh-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:38:30 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Schweich-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:45:26 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Tal-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:38:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tinsa-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-22 08:39:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Totapally-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:57:38 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Wang-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 01:13:56 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Alario-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 01:15:12 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 01:35:39 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Anil-2010-SAL-3_x0025_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-10 20:35:26 +1000" MODIFIED_BY="Melissa A Brower" RESULT="UNKNOWN" STUDY_ID="STD-Can-1998">
<DESCRIPTION>
<P>No detail provided in the methods section of the manuscript; but abstract mentions "double blind" in the methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 01:46:24 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Chevallier-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chowdhury-1995">
<DESCRIPTION>
<P>Investigators blinded up to 36 hours, single-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 01:51:34 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Dobson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 01:56:11 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994a-_x002d_-neb">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 01:59:22 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994a-_x002d_-oral">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:01:17 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:06:20 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994b-_x002d_-oral">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goh-1997">
<DESCRIPTION>
<P>For 3 treatment groups (salbutamol, ipratropium and normal saline)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:11:42 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gupta-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:13:17 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gurkan-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:18:34 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Henry-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:21:43 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Ho-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-10 20:28:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ipek-2011">
<DESCRIPTION>
<P>Insufficient detail provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:30:21 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Karadag-2005-_x002d_-IPR">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:30:34 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Karadag-2005-_x002d_-SAL">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:27:56 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Karadag-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:31:08 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Klassen-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:33:54 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Levin-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:36:04 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Lines-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:42:34 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Lines-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:47:09 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Mallol-1987">
<DESCRIPTION>
<P>Single blinding only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:49:16 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Patel-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-08 02:50:32 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Patel-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 04:30:13 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Ralston-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-17 23:20:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scarlett-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 04:34:56 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Schuh-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 04:38:31 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Schweich-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 04:43:09 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Tal-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 04:48:14 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Tinsa-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 04:51:47 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Totapally-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-12 04:57:38 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Wang-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-01-10 20:36:51 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 01:15:23 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Alario-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 01:15:15 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 01:35:40 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Anil-2010-SAL-3_x0025_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-10 20:18:59 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Can-1998">
<DESCRIPTION>
<P>Incomplete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 01:47:41 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Chevallier-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 04:18:15 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Chowdhury-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 01:53:40 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Dobson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 01:57:10 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994a-_x002d_-neb">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 01:59:23 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994a-_x002d_-oral">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:03:04 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:06:21 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994b-_x002d_-oral">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-08 08:23:41 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goh-1997">
<DESCRIPTION>
<P>10 participants excluded without information about which group they were assigned to</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:11:51 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gupta-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-10 20:36:51 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gurkan-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-10 20:24:58 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Henry-1983">
<DESCRIPTION>
<P>Incomplete data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:22:44 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Ho-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-13 11:24:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ipek-2011">
<DESCRIPTION>
<P>Complete data; no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:30:22 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Karadag-2005-_x002d_-IPR">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:30:35 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Karadag-2005-_x002d_-SAL">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:28:55 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Karadag-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:32:26 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Klassen-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:34:07 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Levin-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:41:56 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Lines-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:43:29 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Lines-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-06-08 08:33:18 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mallol-1987">
<DESCRIPTION>
<P>Participants whose scores did not decrease at 24 hours were excluded from the study as "failures"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:49:29 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Patel-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-08 02:51:30 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Patel-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-12 13:52:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005">
<DESCRIPTION>
<P>Intention-to-treat analysis was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-17 23:20:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scarlett-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 04:36:49 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Schuh-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 04:40:15 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Schweich-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 04:44:34 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Tal-1983">
<DESCRIPTION>
<P>10 relative therapeutic failures and 2 complete therapeutic failures were excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 04:48:52 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Tinsa-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 04:55:06 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Totapally-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-12 04:58:27 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Wang-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 01:14:06 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Alario-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 01:33:20 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 01:35:41 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Anil-2010-SAL-3_x0025_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:18:55 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Can-1998">
<DESCRIPTION>
<P>Non-significant findings on heart rate not presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 01:47:53 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Chevallier-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:18:18 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Chowdhury-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 01:53:45 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Dobson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 01:58:34 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994a-_x002d_-neb">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 01:59:24 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994a-_x002d_-oral">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:03:38 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:06:22 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gadomski-1994b-_x002d_-oral">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goh-1997">
<DESCRIPTION>
<P>Length of hospitalization not provided for the randomized groups; oximetry data not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:12:01 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Gupta-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:22:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gurkan-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:24:45 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Henry-1983">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:21:52 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Ho-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-17 23:17:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ipek-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:43:03 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Karadag-2005-_x002d_-IPR">
<DESCRIPTION>
<P>Data on heart rate mentioned but not presented in results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:30:39 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Karadag-2005-_x002d_-SAL">
<DESCRIPTION>
<P>See Karadag 2005 - IPR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-10 20:30:23 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Karadag-2008">
<DESCRIPTION>
<P>See Karadag 2005 - IPR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:32:38 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Klassen-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:34:23 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Levin-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:36:22 +1000" MODIFIED_BY="Melissa A Brower" RESULT="NO" STUDY_ID="STD-Lines-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:43:31 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Lines-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:48:12 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Mallol-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:49:36 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Patel-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-08 02:51:34 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Patel-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-08 08:35:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005">
<DESCRIPTION>
<P>Clinical scores and oximetry data that were not published were obtained from the author for the 2010 update</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-17 23:20:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scarlett-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:36:58 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Schuh-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:40:44 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Schweich-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:44:48 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Tal-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:48:57 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Tinsa-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:52:41 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Totapally-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 04:58:44 +1000" MODIFIED_BY="Melissa A Brower" RESULT="YES" STUDY_ID="STD-Wang-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-05-08 01:32:50 +1000" MODIFIED_BY="Melissa A Brower" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-12-04 05:36:31 +1000" MODIFIED_BY="Melissa A Brower"/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-06-09 10:13:51 +1000" MODIFIED_BY="Liz Dooley">
<COMPARISON ID="CMP-001" MODIFIED="2014-06-09 10:13:51 +1000" MODIFIED_BY="Liz Dooley" NO="1">
<NAME>Bronchodilators compared to placebo for treatment of acute bronchiolitis</NAME>
<CONT_OUTCOME CHI2="128.83339995778988" CI_END="0.061783178607129785" CI_START="-0.9178370493872634" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4280269353900668" ESTIMABLE="YES" I2="81.37129035804132" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2014-05-09 06:39:44 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.551115123125783E-16" P_Q="0.3994182347705697" P_Z="0.08676038159008419" Q="0.7100784623927714" RANDOM="YES" SCALE="6.780021786111718" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.9455103515965588" TOTALS="YES" TOTAL_1="576" TOTAL_2="666" UNITS="" WEIGHT="100.00000000000001" Z="1.712740006390283">
<NAME>Oxygen saturation measured by pulse oximetry: inpatient and outpatient settings</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Bronchodilator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="112.8942849196455" CI_END="0.15614638436957484" CI_START="-1.401680507773034" DF="11" EFFECT_SIZE="-0.6227670617017297" ESTIMABLE="YES" I2="90.25637125224767" ID="CMP-001.01.01" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-4.440892098500626E-16" P_Z="0.11710159584763441" STUDIES="12" TAU2="1.355221805592734" TOTAL_1="219" TOTAL_2="276" WEIGHT="52.110019817835685" Z="1.5670560289461042">
<NAME>Inpatient studies</NAME>
<CONT_DATA CI_END="-0.9269258438543677" CI_START="-1.473074156145638" EFFECT_SIZE="-1.2000000000000028" ESTIMABLE="YES" MEAN_1="93.2" MEAN_2="94.4" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" ORDER="128" SD_1="0.4" SD_2="0.4" SE="0.13932610920384722" STUDY_ID="STD-Chevallier-1995" TOTAL_1="17" TOTAL_2="16" WEIGHT="6.4724254125372696"/>
<CONT_DATA CI_END="4.182307502662741" CI_START="-3.5823075026627476" EFFECT_SIZE="0.29999999999999716" ESTIMABLE="YES" MEAN_1="93.5" MEAN_2="93.2" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" ORDER="129" SD_1="6.04" SD_2="7.83" SE="1.980805531778079" STUDY_ID="STD-Dobson-1998" TOTAL_1="29" TOTAL_2="23" WEIGHT="1.28265701344776"/>
<CONT_DATA CI_END="0.7376925088647635" CI_START="-1.1376925088647691" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" MEAN_1="95.6" MEAN_2="95.8" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" ORDER="130" SD_1="1.2" SD_2="1.4" SE="0.4784233364802441" STUDY_ID="STD-Gurkan-2004" TOTAL_1="12" TOTAL_2="18" WEIGHT="5.317941472861972"/>
<CONT_DATA CI_END="2.851465521327565" CI_START="1.5485344786724125" EFFECT_SIZE="2.1999999999999886" ESTIMABLE="YES" MEAN_1="97.6" MEAN_2="95.4" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="0.7" SD_2="0.8" SE="0.3323864757037645" STUDY_ID="STD-Ho-1991" TOTAL_1="8" TOTAL_2="13" WEIGHT="5.914241420687463"/>
<CONT_DATA CI_END="0.6703610484487341" CI_START="-3.8703610484487228" EFFECT_SIZE="-1.5999999999999943" ESTIMABLE="YES" MEAN_1="92.2" MEAN_2="93.8" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="2.6" SD_2="4.0" SE="1.1583687589961074" STUDY_ID="STD-Karadag-2005-_x002d_-IPR" TOTAL_1="11" TOTAL_2="22" WEIGHT="2.730428242134268"/>
<CONT_DATA CI_END="-2.296674426088554" CI_START="-6.703325573911446" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="92.2" MEAN_2="96.7" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" ORDER="133" SD_1="2.6" SD_2="4.1" SE="1.1241663577958558" STUDY_ID="STD-Karadag-2005-_x002d_-SAL" TOTAL_1="12" TOTAL_2="24" WEIGHT="2.826912827255435"/>
<CONT_DATA CI_END="0.8961074661341748" CI_START="-1.2961074661341805" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" MEAN_1="95.6" MEAN_2="95.8" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="2.0" SD_2="1.9" SE="0.5592487794572418" STUDY_ID="STD-Lines-1990" TOTAL_1="23" TOTAL_2="26" WEIGHT="4.963472597768008"/>
<CONT_DATA CI_END="-0.646091924004884" CI_START="-1.353908075995116" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="93.0" MEAN_2="94.0" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="0.4" SD_2="0.6" SE="0.18056866288702125" STUDY_ID="STD-Lines-1992" TOTAL_1="14" TOTAL_2="17" WEIGHT="6.385122315275484"/>
<CONT_DATA CI_END="1.9220895753456884" CI_START="-1.0020895753457009" EFFECT_SIZE="0.45999999999999375" ESTIMABLE="YES" MEAN_1="96.22" MEAN_2="95.76" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="3.3" SD_2="4.1" SE="0.745977776570626" STUDY_ID="STD-Patel-2002" TOTAL_1="48" TOTAL_2="51" WEIGHT="4.158065727975541"/>
<CONT_DATA CI_END="0.7390914756607522" CI_START="-1.139091475660758" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="97.2" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" ORDER="137" SD_1="1.3" SD_2="1.5" SE="0.47913710816534827" STUDY_ID="STD-Tinsa-2009" TOTAL_1="19" TOTAL_2="16" WEIGHT="5.314848325385604"/>
<CONT_DATA CI_END="1.4799547519927243" CI_START="-3.4799547519927243" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="95.0" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="2.4" SD_2="3.1" SE="1.2653062870309306" STUDY_ID="STD-Totapally-2002" TOTAL_1="9" TOTAL_2="10" WEIGHT="2.452527405890795"/>
<CONT_DATA CI_END="-0.700547930775687" CI_START="-3.49945206922433" EFFECT_SIZE="-2.1000000000000085" ESTIMABLE="YES" MEAN_1="95.1" MEAN_2="97.2" MODIFIED="2014-05-09 04:52:52 +1000" MODIFIED_BY="[Empty name]" ORDER="139" SD_1="2.7" SD_2="1.8" SE="0.7140192780393011" STUDY_ID="STD-Wang-1992" TOTAL_1="17" TOTAL_2="40" WEIGHT="4.291377056616085"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.889764387195507" CI_END="0.10746372443123459" CI_START="-0.6147537945166557" DF="12" EFFECT_SIZE="-0.2536450350427106" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" MODIFIED="2014-05-09 04:58:25 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6256311143067542" P_Z="0.16860784157818873" STUDIES="13" TAU2="0.0" TOTAL_1="357" TOTAL_2="390" WEIGHT="47.88998018216433" Z="1.376690873589795">
<NAME>Outpatient studies</NAME>
<CONT_DATA CI_END="0.6248450531794176" CI_START="-1.8248450531794347" EFFECT_SIZE="-0.6000000000000085" ESTIMABLE="YES" MEAN_1="94.8" MEAN_2="95.4" MODIFIED="2014-05-09 04:53:15 +1000" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="3.1" SD_2="2.2" SE="0.6249324287797365" STUDY_ID="STD-Alario-1992" TOTAL_1="37" TOTAL_2="37" WEIGHT="4.6745123733163085"/>
<CONT_DATA CI_END="0.43218366940213027" CI_START="-1.2321836694021133" EFFECT_SIZE="-0.3999999999999915" ESTIMABLE="YES" MEAN_1="98.7" MEAN_2="99.1" MODIFIED="2014-05-09 04:53:15 +1000" MODIFIED_BY="[Empty name]" ORDER="141" SD_1="1.2" SD_2="1.9" SE="0.4245913067618999" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_" TOTAL_1="18" TOTAL_2="36" WEIGHT="5.5475682001959585"/>
<CONT_DATA CI_END="0.5482729683174299" CI_START="-0.7482729683174185" EFFECT_SIZE="-0.09999999999999432" ESTIMABLE="YES" MEAN_1="98.7" MEAN_2="98.8" MODIFIED="2014-05-09 04:53:15 +1000" MODIFIED_BY="[Empty name]" ORDER="142" SD_1="1.2" SD_2="1.1" SE="0.3307575921960396" STUDY_ID="STD-Anil-2010-SAL-3_x0025_" TOTAL_1="19" TOTAL_2="36" WEIGHT="5.9202973551836555"/>
<CONT_DATA CI_END="5.560305397471131" CI_START="-3.3603053974711425" EFFECT_SIZE="1.0999999999999943" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="93.9" MODIFIED="2014-05-09 04:53:15 +1000" MODIFIED_BY="[Empty name]" ORDER="143" SD_1="1.9" SD_2="16.3" SE="2.2757078357834413" STUDY_ID="STD-Can-1998" TOTAL_1="52" TOTAL_2="52" WEIGHT="1.019762063349005"/>
<CONT_DATA CI_END="2.083758364894027" CI_START="-2.083758364894027" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="94.0" MODIFIED="2014-05-09 04:53:15 +1000" MODIFIED_BY="[Empty name]" ORDER="144" SD_1="4.4" SD_2="4.1" SE="1.063161558748246" STUDY_ID="STD-Gadomski-1994a-_x002d_-neb" TOTAL_1="32" TOTAL_2="32" WEIGHT="3.0086316960388526"/>
<CONT_DATA CI_END="3.094962219860549" CI_START="-1.094962219860549" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="93.0" MODIFIED="2014-05-09 04:53:15 +1000" MODIFIED_BY="[Empty name]" ORDER="145" SD_1="3.4" SD_2="5.0" SE="1.0688779163215976" STUDY_ID="STD-Gadomski-1994a-_x002d_-oral" TOTAL_1="32" TOTAL_2="32" WEIGHT="2.9910706246737444"/>
<CONT_DATA CI_END="1.2591123689912598" CI_START="-1.2591123689912598" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="97.0" MODIFIED="2014-05-09 04:53:15 +1000" MODIFIED_BY="[Empty name]" ORDER="146" SD_1="2.0" SD_2="2.0" SE="0.642416074439621" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb" TOTAL_1="18" TOTAL_2="21" WEIGHT="4.598252191309531"/>
<CONT_DATA CI_END="0.3125685037969599" CI_START="-2.31256850379696" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="98.0" MODIFIED="2014-05-09 04:53:15 +1000" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="2.0" SD_2="2.0" SE="0.6696901137726676" STUDY_ID="STD-Gadomski-1994b-_x002d_-oral" TOTAL_1="22" TOTAL_2="15" WEIGHT="4.480206550431768"/>
<CONT_DATA CI_END="1.8657031665808221" CI_START="-1.4057031665808142" EFFECT_SIZE="0.23000000000000398" ESTIMABLE="YES" MEAN_1="96.33" MEAN_2="96.1" MODIFIED="2014-05-09 04:53:15 +1000" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="3.35" SD_2="3.11" SE="0.8345577671238023" STUDY_ID="STD-Ipek-2011" TOTAL_1="30" TOTAL_2="30" WEIGHT="3.803530918272336"/>
<CONT_DATA CI_END="1.7211968990561308" CI_START="-1.7211968990561308" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="95.0" MODIFIED="2014-05-09 04:58:25 +1000" MODIFIED_BY="[Empty name]" ORDER="149" SD_1="4.0" SD_2="4.0" SE="0.8781778199154231" STUDY_ID="STD-Klassen-1991" TOTAL_1="41" TOTAL_2="42" WEIGHT="3.6380044786854047"/>
<CONT_DATA CI_END="4.158179664626616" CI_START="-2.558179664626621" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" MEAN_1="89.32" MEAN_2="88.52" MODIFIED="2014-05-09 04:58:25 +1000" MODIFIED_BY="[Empty name]" ORDER="150" SD_1="6.75" SD_2="5.06" SE="1.7133884556632217" STUDY_ID="STD-Ralston-2005" TOTAL_1="25" TOTAL_2="23" WEIGHT="1.6091337136896193"/>
<CONT_DATA CI_END="1.1981801755722672" CI_START="-1.5981801755722445" EFFECT_SIZE="-0.19999999999998863" ESTIMABLE="YES" MEAN_1="95.9" MEAN_2="96.1" MODIFIED="2014-05-09 04:58:25 +1000" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="2.3" SD_2="2.2" SE="0.7133703407822402" STUDY_ID="STD-Schuh-1990" TOTAL_1="19" TOTAL_2="21" WEIGHT="4.294110158263311"/>
<CONT_DATA CI_END="-0.696785188371706" CI_START="-5.903214811628288" EFFECT_SIZE="-3.299999999999997" ESTIMABLE="YES" MEAN_1="91.8" MEAN_2="95.1" MODIFIED="2014-05-09 04:58:25 +1000" MODIFIED_BY="[Empty name]" ORDER="152" SD_1="3.8" SD_2="2.7" SE="1.3281952281583322" STUDY_ID="STD-Schweich-1992" TOTAL_1="12" TOTAL_2="13" WEIGHT="2.3048998587548275"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.876110366879898" CI_END="0.2092608527719883" CI_START="-0.5943543028490981" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1925467250385549" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2014-05-09 06:39:57 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6500164539916157" P_Q="1.0" P_Z="0.3476191767342487" Q="0.0" RANDOM="YES" SCALE="11.76743367712133" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="266" TOTAL_2="306" UNITS="" WEIGHT="100.00000000000001" Z="0.9392173449616856">
<NAME>Sub-analysis - oxygen saturation (outpatients treated with albuterol/salbutamol)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.43218366940213027" CI_START="-1.2321836694021133" EFFECT_SIZE="-0.3999999999999915" ESTIMABLE="YES" MEAN_1="98.7" MEAN_2="99.1" MODIFIED="2013-09-19 06:27:18 +1000" MODIFIED_BY="[Empty name]" ORDER="165" SD_1="1.2" SD_2="1.9" SE="0.4245913067618999" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_" TOTAL_1="18" TOTAL_2="36" WEIGHT="23.312984121815525"/>
<CONT_DATA CI_END="0.5482729683174299" CI_START="-0.7482729683174185" EFFECT_SIZE="-0.09999999999999432" ESTIMABLE="YES" MEAN_1="98.7" MEAN_2="98.8" MODIFIED="2013-09-19 06:27:18 +1000" MODIFIED_BY="[Empty name]" ORDER="166" SD_1="1.2" SD_2="1.1" SE="0.3307575921960396" STUDY_ID="STD-Anil-2010-SAL-3_x0025_" TOTAL_1="19" TOTAL_2="36" WEIGHT="38.41673222051413"/>
<CONT_DATA CI_END="5.560305397471131" CI_START="-3.3603053974711425" EFFECT_SIZE="1.0999999999999943" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="93.9" MODIFIED="2013-09-19 06:27:18 +1000" MODIFIED_BY="[Empty name]" ORDER="167" SD_1="1.9" SD_2="16.3" SE="2.2757078357834413" STUDY_ID="STD-Can-1998" TOTAL_1="52" TOTAL_2="52" WEIGHT="0.8115346248948201"/>
<CONT_DATA CI_END="2.083758364894027" CI_START="-2.083758364894027" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="94.0" MODIFIED="2013-09-19 06:27:18 +1000" MODIFIED_BY="[Empty name]" ORDER="168" SD_1="4.4" SD_2="4.1" SE="1.063161558748246" STUDY_ID="STD-Gadomski-1994a-_x002d_-neb" TOTAL_1="32" TOTAL_2="32" WEIGHT="3.718275229947046"/>
<CONT_DATA CI_END="1.2591123689912598" CI_START="-1.2591123689912598" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="97.0" MODIFIED="2013-09-19 06:27:18 +1000" MODIFIED_BY="[Empty name]" ORDER="177" SD_1="2.0" SD_2="2.0" SE="0.642416074439621" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb" TOTAL_1="18" TOTAL_2="21" WEIGHT="10.18373912167384"/>
<CONT_DATA CI_END="1.8657031665808221" CI_START="-1.4057031665808142" EFFECT_SIZE="0.23000000000000398" ESTIMABLE="YES" MEAN_1="96.33" MEAN_2="96.1" MODIFIED="2013-09-19 06:27:18 +1000" MODIFIED_BY="[Empty name]" ORDER="178" SD_1="3.35" SD_2="3.11" SE="0.8345577671238023" STUDY_ID="STD-Ipek-2011" TOTAL_1="30" TOTAL_2="30" WEIGHT="6.0343049938972575"/>
<CONT_DATA CI_END="1.7211968990561308" CI_START="-1.7211968990561308" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="95.0" MODIFIED="2013-09-19 06:27:18 +1000" MODIFIED_BY="[Empty name]" ORDER="179" SD_1="4.0" SD_2="4.0" SE="0.8781778199154231" STUDY_ID="STD-Klassen-1991" TOTAL_1="41" TOTAL_2="42" WEIGHT="5.449731879369634"/>
<CONT_DATA CI_END="4.158179664626616" CI_START="-2.558179664626621" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" MEAN_1="89.32" MEAN_2="88.52" MODIFIED="2013-09-19 06:27:18 +1000" MODIFIED_BY="[Empty name]" ORDER="180" SD_1="6.75" SD_2="5.06" SE="1.7133884556632217" STUDY_ID="STD-Ralston-2005" TOTAL_1="25" TOTAL_2="23" WEIGHT="1.4316220904212014"/>
<CONT_DATA CI_END="1.1981801755722672" CI_START="-1.5981801755722445" EFFECT_SIZE="-0.19999999999998863" ESTIMABLE="YES" MEAN_1="95.9" MEAN_2="96.1" MODIFIED="2013-09-19 06:27:18 +1000" MODIFIED_BY="[Empty name]" ORDER="181" SD_1="2.3" SD_2="2.2" SE="0.7133703407822402" STUDY_ID="STD-Schuh-1990" TOTAL_1="19" TOTAL_2="21" WEIGHT="8.25866720201408"/>
<CONT_DATA CI_END="-0.696785188371706" CI_START="-5.903214811628288" EFFECT_SIZE="-3.299999999999997" ESTIMABLE="YES" MEAN_1="91.8" MEAN_2="95.1" MODIFIED="2013-09-19 06:27:18 +1000" MODIFIED_BY="[Empty name]" ORDER="182" SD_1="3.8" SD_2="2.7" SE="1.3281952281583322" STUDY_ID="STD-Schweich-1992" TOTAL_1="12" TOTAL_2="13" WEIGHT="2.38240851545249"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="22.865106340056286" CI_END="0.495190558494936" CI_START="0.062104631218131624" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.17536712068694246" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="124" I2="73.75914237718244" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.3052276443446424" LOG_CI_START="-1.20687601274638" LOG_EFFECT_SIZE="-0.7560518285455111" METHOD="MH" MODIFIED="2014-06-09 10:13:51 +1000" MODIFIED_BY="Liz Dooley" NO="3" P_CHI2="8.429414140572744E-4" P_Q="0.6857492433249484" P_Z="0.0010128056780811484" Q="0.16372597585040594" RANDOM="YES" SCALE="902.3470936079397" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.3728733647816063" TOTALS="YES" TOTAL_1="196" TOTAL_2="169" WEIGHT="100.0" Z="3.286945124786406">
<NAME>Improvement in clinical score (dichotomous)</NAME>
<GROUP_LABEL_1>Bronchodilator</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.626947863548132" CI_END="0.7915829427927847" CI_START="0.05058622038313669" DF="4" EFFECT_SIZE="0.20010794385942726" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="59" I2="77.30747245090654" ID="CMP-001.03.01" LOG_CI_END="-0.10150357263994998" LOG_CI_START="-1.2959677682701853" LOG_EFFECT_SIZE="-0.6987356704550677" MODIFIED="2013-09-18 00:30:24 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0014594228866628978" P_Z="0.021843807299334966" STUDIES="5" TAU2="1.8579051137244906" TOTAL_1="116" TOTAL_2="92" WEIGHT="71.19718274163479" Z="2.2930729172385">
<NAME>Inpatient</NAME>
<DICH_DATA CI_END="2.063292486295694" CI_START="0.2981390297682462" EFFECT_SIZE="0.7843137254901961" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.3145607966500628" LOG_CI_START="-0.5255811661900107" LOG_EFFECT_SIZE="-0.10551018476997398" MODIFIED="2010-05-12 06:06:42 +1000" MODIFIED_BY="Melissa A Brower" ORDER="356" O_E="0.0" SE="0.493503547742047" STUDY_ID="STD-Henry-1983" TOTAL_1="34" TOTAL_2="32" VAR="0.2435457516339869" WEIGHT="17.353841573022798"/>
<DICH_DATA CI_END="0.1742726220997846" CI_START="0.008407332742953081" EFFECT_SIZE="0.03827751196172249" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="19" LOG_CI_END="-0.7587708343753459" LOG_CI_START="-2.075341763862875" LOG_EFFECT_SIZE="-1.4170562991191105" MODIFIED="2010-05-25 02:25:26 +1000" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.0" SE="0.7733602811121825" STUDY_ID="STD-Lines-1990" TOTAL_1="26" TOTAL_2="23" VAR="0.5980861244019139" WEIGHT="14.232195748225147"/>
<DICH_DATA CI_END="1.8276571424212003" CI_START="0.09499107194750914" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.261894727984157" LOG_CI_START="-1.0223172114073689" LOG_EFFECT_SIZE="-0.38021124171160603" MODIFIED="2013-09-18 00:30:23 +1000" MODIFIED_BY="Melissa A Brower" ORDER="359" O_E="0.0" SE="0.754352450150206" STUDY_ID="STD-Lines-1992" TOTAL_1="17" TOTAL_2="14" VAR="0.569047619047619" WEIGHT="14.445016813489742"/>
<DICH_DATA CI_END="0.19172736070982216" CI_START="0.0071546497453692775" EFFECT_SIZE="0.037037037037037035" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.7173159061235294" LOG_CI_START="-2.1454116221944455" LOG_EFFECT_SIZE="-1.4313637641589874" MODIFIED="2013-09-18 00:30:24 +1000" MODIFIED_BY="Melissa A Brower" ORDER="360" O_E="0.0" SE="0.8388704928078611" STUDY_ID="STD-Mallol-1987" TOTAL_1="31" TOTAL_2="15" VAR="0.7037037037037037" WEIGHT="13.508326605158278"/>
<DICH_DATA CI_END="4.399701310085551" CI_START="0.08182373634654756" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.6434231938078273" LOG_CI_START="-1.08712069304054" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2010-05-12 06:06:44 +1000" MODIFIED_BY="Melissa A Brower" ORDER="361" O_E="0.0" SE="1.016530045465127" STUDY_ID="STD-Tal-1983" TOTAL_1="8" TOTAL_2="8" VAR="1.0333333333333332" WEIGHT="11.65780200173882"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.2751621496391525" CI_END="1.4647723592247002" CI_START="0.008123738980726086" DF="1" EFFECT_SIZE="0.10908450078963468" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="65" I2="81.04323674546374" ID="CMP-001.03.02" LOG_CI_END="0.16577013607965205" LOG_CI_START="-2.090244039114037" LOG_EFFECT_SIZE="-0.9622369515171925" MODIFIED="2013-09-18 00:30:38 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.02163182837872324" P_Z="0.09453797245260812" STUDIES="2" TAU2="2.8939084623314963" TOTAL_1="80" TOTAL_2="77" WEIGHT="28.802817258365202" Z="1.6719307797836813">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="0.20733133216120156" CI_START="0.0031892164242778905" EFFECT_SIZE="0.025714285714285714" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="35" LOG_CI_END="-0.6833350618401385" LOG_CI_START="-2.4963160079817626" LOG_EFFECT_SIZE="-1.5898255349109507" MODIFIED="2013-09-18 00:30:38 +1000" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="1.0649539821640108" STUDY_ID="STD-Alario-1992" TOTAL_1="38" TOTAL_2="36" VAR="1.134126984126984" WEIGHT="11.189101459077813"/>
<DICH_DATA CI_END="0.8353194599368611" CI_START="0.13301630865813854" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="30" LOG_CI_END="-0.07814740097801223" LOG_CI_START="-0.8760951084613127" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2010-08-27 03:20:35 +1000" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.468718433280546" STUDY_ID="STD-Klassen-1991" TOTAL_1="42" TOTAL_2="41" VAR="0.2196969696969697" WEIGHT="17.61371579928739"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="73.62361020155282" CI_END="-0.05490239718504411" CI_START="-0.5449047822654117" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.2999035897252279" ESTIMABLE="YES" I2="72.83480130185443" I2_Q="31.585613971195947" ID="CMP-001.04" MODIFIED="2014-05-09 06:40:05 +1000" MODIFIED_BY="Melissa A Brower" NO="4" P_CHI2="4.614272031133737E-8" P_Q="0.22666316845096335" P_Z="0.016432151271827993" Q="1.4616808803618828" RANDOM="YES" SCALE="4.5088036692514395" SORT_BY="STUDY" STUDIES="21" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.22945250511118775" TOTALS="YES" TOTAL_1="598" TOTAL_2="488" UNITS="" WEIGHT="100.00000000000001" Z="2.399172953410484">
<NAME>Average clinical score after treatment: by treatment setting (continuous)</NAME>
<GROUP_LABEL_1>Bronchodilator</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="12.492736247108612" CI_END="0.12102210673895814" CI_START="-0.40658580729182076" DF="8" EFFECT_SIZE="-0.1427818502764313" ESTIMABLE="YES" I2="35.96278796127178" ID="CMP-001.04.01" MODIFIED="2013-10-08 11:28:29 +1000" MODIFIED_BY="Melissa A Brower" NO="1" P_CHI2="0.1305359611206992" P_Z="0.2887738454429081" STUDIES="9" TAU2="0.05589992246308399" TOTAL_1="249" TOTAL_2="167" WEIGHT="40.50984770018967" Z="1.0608153393675988">
<NAME>Inpatient studies</NAME>
<CONT_DATA CI_END="0.5005641673682338" CI_START="-0.38614281814261675" EFFECT_SIZE="0.05721067461280852" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="3.1" MODIFIED="2013-09-19 06:05:45 +1000" MODIFIED_BY="Melissa A Brower" ORDER="362" SD_1="1.7" SD_2="1.8" SE="0.22620491817836505" STUDY_ID="STD-Goh-1997" TOTAL_1="60" TOTAL_2="29" WEIGHT="5.568263560068407"/>
<CONT_DATA CI_END="0.14075195739929636" CI_START="-1.3569681736155126" EFFECT_SIZE="-0.6081081081081081" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.7" MODIFIED="2013-10-08 11:28:28 +1000" MODIFIED_BY="Melissa A Brower" ORDER="363" SD_1="0.8" SD_2="0.8" SE="0.3820784827753556" STUDY_ID="STD-Gurkan-2004" TOTAL_1="18" TOTAL_2="12" WEIGHT="4.162016084831678"/>
<CONT_DATA CI_END="0.49412515830040604" CI_START="-0.9583151623791526" EFFECT_SIZE="-0.23209500203937325" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="5.3" MODIFIED="2013-10-08 11:23:25 +1000" MODIFIED_BY="Melissa A Brower" ORDER="364" SD_1="1.8" SD_2="1.4" SE="0.3705272984953352" STUDY_ID="STD-Karadag-2005-_x002d_-IPR" TOTAL_1="22" TOTAL_2="11" WEIGHT="4.260674924274277"/>
<CONT_DATA CI_END="-0.11541710889268209" CI_START="-1.5607733672977944" EFFECT_SIZE="-0.8380952380952382" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="5.3" MODIFIED="2013-10-08 11:21:50 +1000" MODIFIED_BY="Melissa A Brower" ORDER="365" SD_1="1.4" SD_2="1.4" SE="0.36872010654427784" STUDY_ID="STD-Karadag-2005-_x002d_-SAL" TOTAL_1="24" TOTAL_2="12" WEIGHT="4.276252346928353"/>
<CONT_DATA CI_END="0.11162308169033991" CI_START="-0.6808153144150191" EFFECT_SIZE="-0.2845961163623396" ESTIMABLE="YES" MEAN_1="5.33" MEAN_2="6.17" MODIFIED="2013-09-18 03:40:51 +1000" MODIFIED_BY="[Empty name]" ORDER="366" SD_1="2.86" SD_2="3.0" SE="0.20215636673837173" STUDY_ID="STD-Patel-2002" TOTAL_1="51" TOTAL_2="48" WEIGHT="5.780461526825809"/>
<CONT_DATA CI_END="1.6986397948851037" CI_START="-0.13582716226969693" EFFECT_SIZE="0.7814063163077034" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="2.8" MODIFIED="2013-10-08 11:27:59 +1000" MODIFIED_BY="[Empty name]" ORDER="101" SD_1="2.9" SD_2="2.2" SE="0.4679848639120009" STUDY_ID="STD-Scarlett-2012" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.4842895456062943"/>
<CONT_DATA CI_END="0.7170938711260141" CI_START="-0.6132293941154029" EFFECT_SIZE="0.05193223850530557" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="4.6" MODIFIED="2013-09-18 03:40:52 +1000" MODIFIED_BY="Melissa A Brower" ORDER="63" SD_1="2.4" SD_2="1.3" SE="0.3393744159930583" STUDY_ID="STD-Tinsa-2009" TOTAL_1="16" TOTAL_2="19" WEIGHT="4.534091558982211"/>
<CONT_DATA CI_END="1.3949621047632235" CI_START="-0.438241728548874" EFFECT_SIZE="0.47836018810717473" ESTIMABLE="YES" MEAN_1="0.95" MEAN_2="0.58" MODIFIED="2013-09-18 03:46:11 +1000" MODIFIED_BY="[Empty name]" ORDER="367" SD_1="0.71" SD_2="0.77" SE="0.4676626325208461" STUDY_ID="STD-Totapally-2002" TOTAL_1="10" TOTAL_2="9" WEIGHT="3.486633560871228"/>
<CONT_DATA CI_END="0.3217129007019345" CI_START="-0.8262471886129156" EFFECT_SIZE="-0.25226714395549055" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="3.2" MODIFIED="2013-10-08 11:28:29 +1000" MODIFIED_BY="Melissa A Brower" ORDER="368" SD_1="1.5" SD_2="1.7" SE="0.29285234279043204" STUDY_ID="STD-Wang-1992" TOTAL_1="38" TOTAL_2="17" WEIGHT="4.95716459180141"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="56.7950137029997" CI_END="-0.055567147358716984" CI_START="-0.7856226088586538" DF="11" EFFECT_SIZE="-0.4205948781086854" ESTIMABLE="YES" I2="80.63210256885804" ID="CMP-001.04.02" MODIFIED="2013-10-08 11:28:23 +1000" MODIFIED_BY="Melissa A Brower" NO="2" P_CHI2="3.6294170224770994E-8" P_Z="0.023925479334950917" STUDIES="12" TAU2="0.329717941578149" TOTAL_1="349" TOTAL_2="321" WEIGHT="59.49015229981035" Z="2.2583238031843935">
<NAME>Outpatient studies</NAME>
<CONT_DATA CI_END="-0.32634810064882747" CI_START="-1.7094422533019573" EFFECT_SIZE="-1.0178951769753923" ESTIMABLE="YES" MEAN_1="17.5" MEAN_2="22.4" MODIFIED="2013-10-08 11:28:19 +1000" MODIFIED_BY="Melissa A Brower" ORDER="369" SD_1="4.2" SD_2="5.1" SE="0.35283662443871416" STUDY_ID="STD-Alario-1992" TOTAL_1="17" TOTAL_2="20" WEIGHT="4.41471807251289"/>
<CONT_DATA CI_END="0.3561228743199225" CI_START="-0.7784831227671276" EFFECT_SIZE="-0.21118012422360255" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.8" MODIFIED="2013-09-18 03:40:59 +1000" MODIFIED_BY="Melissa A Brower" ORDER="56" SD_1="1.4" SD_2="1.4" SE="0.2894456240106138" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_" TOTAL_1="36" TOTAL_2="18" WEIGHT="4.988558817765776"/>
<CONT_DATA CI_END="1.012424237734891" CI_START="-0.1127446796421177" EFFECT_SIZE="0.44983977904638667" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="1.8" MODIFIED="2013-10-08 11:27:32 +1000" MODIFIED_BY="Melissa A Brower" ORDER="57" SD_1="0.9" SD_2="1.4" SE="0.28703816147954697" STUDY_ID="STD-Anil-2010-SAL-3_x0025_" TOTAL_1="36" TOTAL_2="19" WEIGHT="5.010760462956798"/>
<CONT_DATA CI_END="-1.3264431012231523" CI_START="-2.2403362588335702" EFFECT_SIZE="-1.7833896800283613" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="10.2" MODIFIED="2013-10-08 11:28:21 +1000" MODIFIED_BY="Melissa A Brower" ORDER="370" SD_1="1.8" SD_2="3.5" SE="0.2331402936020995" STUDY_ID="STD-Can-1998" TOTAL_1="52" TOTAL_2="52" WEIGHT="5.505759820791039"/>
<CONT_DATA CI_END="0.3341737984100366" CI_START="-0.6474078119039632" EFFECT_SIZE="-0.1566170067469633" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="9.5" MODIFIED="2013-09-18 03:46:14 +1000" MODIFIED_BY="Melissa A Brower" ORDER="371" SD_1="5.1" SD_2="6.2" SE="0.2504080733259872" STUDY_ID="STD-Gadomski-1994a-_x002d_-neb" TOTAL_1="32" TOTAL_2="32" WEIGHT="5.348405808861128"/>
<CONT_DATA CI_END="0.1482111121861518" CI_START="-0.8395384007860573" EFFECT_SIZE="-0.3456636442999528" ESTIMABLE="YES" MEAN_1="10.1" MEAN_2="12.4" MODIFIED="2013-09-18 03:46:14 +1000" MODIFIED_BY="Melissa A Brower" ORDER="372" SD_1="6.0" SD_2="7.1" SE="0.25198154679459706" STUDY_ID="STD-Gadomski-1994a-_x002d_-oral" TOTAL_1="32" TOTAL_2="32" WEIGHT="5.333973524566887"/>
<CONT_DATA CI_END="0.30764774553906366" CI_START="-0.9607089700288596" EFFECT_SIZE="-0.32653061224489793" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.0" MODIFIED="2013-09-18 03:46:15 +1000" MODIFIED_BY="Melissa A Brower" ORDER="373" SD_1="3.0" SD_2="3.0" SE="0.323566332231755" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb" TOTAL_1="21" TOTAL_2="18" WEIGHT="4.676293584588463"/>
<CONT_DATA CI_END="0.13040037463215004" CI_START="-1.2076023318780857" EFFECT_SIZE="-0.5386009786229679" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="6.0" MODIFIED="2013-09-18 03:46:16 +1000" MODIFIED_BY="Melissa A Brower" ORDER="374" SD_1="3.0" SD_2="4.0" SE="0.34133349313156525" STUDY_ID="STD-Gadomski-1994b-_x002d_-oral" TOTAL_1="15" TOTAL_2="22" WEIGHT="4.516614216295821"/>
<CONT_DATA CI_END="0.7790082070802199" CI_START="-0.2380538230424326" EFFECT_SIZE="0.27047719201889364" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="2.47" MODIFIED="2013-10-08 11:27:50 +1000" MODIFIED_BY="[Empty name]" ORDER="99" SD_1="2.43" SD_2="2.16" SE="0.2594593671478425" STUDY_ID="STD-Ipek-2011" TOTAL_1="30" TOTAL_2="30" WEIGHT="5.265235204717749"/>
<CONT_DATA CI_END="0.04500821061557514" CI_START="-0.8241158968701442" EFFECT_SIZE="-0.3895538431272845" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="6.2" MODIFIED="2013-10-08 11:28:21 +1000" MODIFIED_BY="Melissa A Brower" ORDER="375" SD_1="2.9" SD_2="3.2" SE="0.22171940768842166" STUDY_ID="STD-Klassen-1991" TOTAL_1="42" TOTAL_2="41" WEIGHT="5.608418269683539"/>
<CONT_DATA CI_END="0.34199315155338805" CI_START="-0.7945102230076315" EFFECT_SIZE="-0.22625853572712173" ESTIMABLE="YES" MEAN_1="6.39" MEAN_2="7.0" MODIFIED="2013-09-18 03:41:01 +1000" MODIFIED_BY="Melissa A Brower" ORDER="68" SD_1="2.43" SD_2="2.84" SE="0.28992965777065627" STUDY_ID="STD-Ralston-2005" TOTAL_1="23" TOTAL_2="25" WEIGHT="4.984096536466852"/>
<CONT_DATA CI_END="-0.03210054317540223" CI_START="-1.6847668182997528" EFFECT_SIZE="-0.8584336807375775" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="6.6" MODIFIED="2013-10-08 11:28:23 +1000" MODIFIED_BY="Melissa A Brower" ORDER="376" SD_1="2.8" SD_2="3.5" SE="0.421606286686993" STUDY_ID="STD-Schweich-1992" TOTAL_1="13" TOTAL_2="12" WEIGHT="3.8373179806033995"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="53.60277546636654" CI_END="0.11108738805713719" CI_START="-0.8250561882300769" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.3569844000864698" ESTIMABLE="YES" I2="85.07539967772814" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2014-05-09 06:40:09 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="8.242876825548251E-9" P_Q="1.0" P_Z="0.13496505217783913" Q="0.0" RANDOM="YES" SCALE="7.581983867389905" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.4305042919548381" TOTALS="YES" TOTAL_1="285" TOTAL_2="247" UNITS="" WEIGHT="99.99999999999999" Z="1.4948061065313634">
<NAME>Sub-analysis - average clinical score (outpatients treated with albuterol/salbutamol)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3561228743199225" CI_START="-0.7784831227671276" EFFECT_SIZE="-0.21118012422360255" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.8" MODIFIED="2013-09-18 02:52:18 +1000" MODIFIED_BY="[Empty name]" ORDER="116" SD_1="1.4" SD_2="1.4" SE="0.2894456240106138" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_" TOTAL_1="36" TOTAL_2="18" WEIGHT="11.089871895580178"/>
<CONT_DATA CI_END="1.012424237734891" CI_START="-0.1127446796421177" EFFECT_SIZE="0.44983977904638667" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="1.8" MODIFIED="2013-09-18 02:52:18 +1000" MODIFIED_BY="[Empty name]" ORDER="117" SD_1="0.9" SD_2="1.4" SE="0.28703816147954697" STUDY_ID="STD-Anil-2010-SAL-3_x0025_" TOTAL_1="36" TOTAL_2="19" WEIGHT="11.119880412315162"/>
<CONT_DATA CI_END="-1.3264431012231523" CI_START="-2.2403362588335702" EFFECT_SIZE="-1.7833896800283613" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="10.2" MODIFIED="2013-09-18 02:52:18 +1000" MODIFIED_BY="[Empty name]" ORDER="118" SD_1="1.8" SD_2="3.5" SE="0.2331402936020995" STUDY_ID="STD-Can-1998" TOTAL_1="52" TOTAL_2="52" WEIGHT="11.762877313990975"/>
<CONT_DATA CI_END="0.3341737984100366" CI_START="-0.6474078119039632" EFFECT_SIZE="-0.1566170067469633" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="9.5" MODIFIED="2013-09-18 02:52:18 +1000" MODIFIED_BY="[Empty name]" ORDER="119" SD_1="5.1" SD_2="6.2" SE="0.2504080733259872" STUDY_ID="STD-Gadomski-1994a-_x002d_-neb" TOTAL_1="32" TOTAL_2="32" WEIGHT="11.563736884314729"/>
<CONT_DATA CI_END="0.30764774553906366" CI_START="-0.9607089700288596" EFFECT_SIZE="-0.32653061224489793" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.0" MODIFIED="2013-09-18 02:52:18 +1000" MODIFIED_BY="[Empty name]" ORDER="120" SD_1="3.0" SD_2="3.0" SE="0.323566332231755" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb" TOTAL_1="21" TOTAL_2="18" WEIGHT="10.656462978620244"/>
<CONT_DATA CI_END="0.7790082070802199" CI_START="-0.2380538230424326" EFFECT_SIZE="0.27047719201889364" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="2.47" MODIFIED="2013-09-18 02:52:18 +1000" MODIFIED_BY="[Empty name]" ORDER="121" SD_1="2.43" SD_2="2.16" SE="0.2594593671478425" STUDY_ID="STD-Ipek-2011" TOTAL_1="30" TOTAL_2="30" WEIGHT="11.45653787072869"/>
<CONT_DATA CI_END="0.04500821061557514" CI_START="-0.8241158968701442" EFFECT_SIZE="-0.3895538431272845" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="6.2" MODIFIED="2013-09-18 02:52:18 +1000" MODIFIED_BY="[Empty name]" ORDER="122" SD_1="2.9" SD_2="3.2" SE="0.22171940768842166" STUDY_ID="STD-Klassen-1991" TOTAL_1="42" TOTAL_2="41" WEIGHT="11.890272755982432"/>
<CONT_DATA CI_END="0.34199315155338805" CI_START="-0.7945102230076315" EFFECT_SIZE="-0.22625853572712173" ESTIMABLE="YES" MEAN_1="6.39" MEAN_2="7.0" MODIFIED="2013-09-18 02:52:18 +1000" MODIFIED_BY="[Empty name]" ORDER="123" SD_1="2.43" SD_2="2.84" SE="0.28992965777065627" STUDY_ID="STD-Ralston-2005" TOTAL_1="23" TOTAL_2="25" WEIGHT="11.083827913468552"/>
<CONT_DATA CI_END="-0.03210054317540223" CI_START="-1.6847668182997528" EFFECT_SIZE="-0.8584336807375775" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="6.6" MODIFIED="2013-09-18 02:52:18 +1000" MODIFIED_BY="[Empty name]" ORDER="124" SD_1="2.8" SD_2="3.5" SE="0.421606286686993" STUDY_ID="STD-Schweich-1992" TOTAL_1="13" TOTAL_2="12" WEIGHT="9.37653197499903"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.637234373275738" CI_END="1.2109128235117421" CI_START="0.4640786333856432" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7496390920199398" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.08311287837790388" LOG_CI_START="-0.3334084264448464" LOG_EFFECT_SIZE="-0.12514777403347127" METHOD="MH" MODIFIED="2014-05-09 06:40:14 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9336281501109385" P_Q="0.7464487944686025" P_Z="0.23888453876904525" Q="0.5848565923146001" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="371" TOTAL_2="339" WEIGHT="100.00000000000001" Z="1.1777795133689077">
<NAME>Hospital admission after treatment (outpatients treated with albuterol or salbutamol)</NAME>
<GROUP_LABEL_1>Bronchodilator</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.021988964472604" CI_END="1.3320019344464555" CI_START="0.44450751858441406" DF="6" EFFECT_SIZE="0.7694705157642061" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="43" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.12450485555411044" LOG_CI_START="-0.3521208887947631" LOG_EFFECT_SIZE="-0.11380801662032633" MODIFIED="2013-10-08 11:55:52 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8060820396360996" P_Z="0.3492758662894627" STUDIES="8" TAU2="0.0" TOTAL_1="222" TOTAL_2="182" WEIGHT="75.10293519093403" Z="0.9359948192999983">
<NAME>Nebulized</NAME>
<DICH_DATA CI_END="40.303032527939116" CI_START="0.06064451610392316" EFFECT_SIZE="1.5633802816901408" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6053377250642094" LOG_CI_START="-1.2172084649290453" LOG_EFFECT_SIZE="0.19406463006758212" MODIFIED="2010-04-16 04:35:10 +1000" MODIFIED_BY="Melissa A Brower" ORDER="60" O_E="0.0" SE="1.657977603831013" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_" TOTAL_1="36" TOTAL_2="18" VAR="2.7488897348052275" WEIGHT="1.6404618740392531"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-02 00:53:02 +1000" MODIFIED_BY="Melissa A Brower" ORDER="61" O_E="0.0" SE="0.0" STUDY_ID="STD-Anil-2010-SAL-3_x0025_" TOTAL_1="36" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.019731760754187" CI_START="0.19709874139639916" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9551936221809109" LOG_CI_START="-0.705316148964311" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="397" O_E="0.0" SE="0.9753916592266354" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb" TOTAL_1="21" TOTAL_2="18" VAR="0.9513888888888888" WEIGHT="4.777423095793622"/>
<DICH_DATA CI_END="2.5688511869427124" CI_START="0.12014786098838545" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4097389463988714" LOG_CI_START="-0.9202839566054835" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2013-10-01 04:01:26 +1000" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.7812620369443087" STUDY_ID="STD-Ipek-2011" TOTAL_1="30" TOTAL_2="30" VAR="0.6103703703703705" WEIGHT="11.644968795996952"/>
<DICH_DATA CI_END="1.787852435918012" CI_START="0.24297353501841348" EFFECT_SIZE="0.6590909090909091" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.2523316705498274" LOG_CI_START="-0.6144410277242902" LOG_EFFECT_SIZE="-0.18105467858723137" MODIFIED="2013-10-08 11:55:52 +1000" MODIFIED_BY="Melissa A Brower" ORDER="398" O_E="0.0" SE="0.5091465735602709" STUDY_ID="STD-Klassen-1991" TOTAL_1="42" TOTAL_2="41" VAR="0.2592302333681644" WEIGHT="24.692945880668237"/>
<DICH_DATA CI_END="2.818326251263607" CI_START="0.27165946442741645" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.44999126589263144" LOG_CI_START="-0.5659751598480051" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2010-04-02 01:15:17 +1000" MODIFIED_BY="Melissa A Brower" ORDER="62" O_E="0.0" SE="0.5967837075949658" STUDY_ID="STD-Ralston-2005" TOTAL_1="23" TOTAL_2="25" VAR="0.3561507936507936" WEIGHT="15.52662506132927"/>
<DICH_DATA CI_END="12.413766870950864" CI_START="0.3222229031350909" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0939035851278134" LOG_CI_START="-0.491843593799851" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="399" O_E="0.0" SE="0.9314757424772421" STUDY_ID="STD-Schuh-1990" TOTAL_1="21" TOTAL_2="19" VAR="0.8676470588235294" WEIGHT="4.399210434043293"/>
<DICH_DATA CI_END="1.6688953338620802" CI_START="0.053927887611577255" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.22242910039913064" LOG_CI_START="-1.268186590959806" LOG_EFFECT_SIZE="-0.5228787452803376" MODIFIED="2013-10-08 11:55:47 +1000" MODIFIED_BY="Melissa A Brower" ORDER="400" O_E="0.0" SE="0.8755950357709131" STUDY_ID="STD-Schweich-1992" TOTAL_1="13" TOTAL_2="12" VAR="0.7666666666666666" WEIGHT="12.421300049063415"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.205727831695585" CI_START="0.03222866442656358" DF="0" EFFECT_SIZE="0.32142857142857145" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.5059266477092389" LOG_CI_START="-1.4917576915150275" LOG_EFFECT_SIZE="-0.49291552190289434" MODIFIED="2010-04-05 23:45:20 +1000" MODIFIED_BY="Melissa A Brower" NO="2" P_CHI2="1.0" P_Z="0.3334358061280285" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="22" WEIGHT="7.833252283193145" Z="0.9672165430556345">
<NAME>Oral in ED setting</NAME>
<DICH_DATA CI_END="3.205727831695585" CI_START="0.03222866442656358" EFFECT_SIZE="0.32142857142857145" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.5059266477092389" LOG_CI_START="-1.4917576915150275" LOG_EFFECT_SIZE="-0.49291552190289434" ORDER="401" O_E="0.0" SE="1.173449669557296" STUDY_ID="STD-Gadomski-1994b-_x002d_-oral" TOTAL_1="15" TOTAL_2="22" VAR="1.376984126984127" WEIGHT="7.833252283193145"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03291583818426724" CI_END="2.6394362809652914" CI_START="0.2795131141068084" DF="1" EFFECT_SIZE="0.8589278516727127" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.4215111820940561" LOG_CI_START="-0.5535978112100703" LOG_EFFECT_SIZE="-0.0660433145580071" MODIFIED="2010-04-05 23:46:30 +1000" MODIFIED_BY="Melissa A Brower" NO="3" P_CHI2="0.8560322990781012" P_Z="0.7906293670316319" STUDIES="2" TAU2="0.0" TOTAL_1="134" TOTAL_2="135" WEIGHT="17.063812525872834" Z="0.2654934347692392">
<NAME>Oral at home</NAME>
<DICH_DATA CI_END="7.305139277174508" CI_START="0.13688992941237685" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8636285004526189" LOG_CI_START="-0.8636285004526189" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-04-05 23:46:16 +1000" MODIFIED_BY="Melissa A Brower" ORDER="67" O_E="0.0" SE="1.0145993123917847" STUDY_ID="STD-Gupta-2008" TOTAL_1="70" TOTAL_2="70" VAR="1.0294117647058822" WEIGHT="5.027669067478049"/>
<DICH_DATA CI_END="3.1250994690407037" CI_START="0.20479348140443596" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4948638450938542" LOG_CI_START="-0.688683871109967" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-04-05 23:46:30 +1000" MODIFIED_BY="Melissa A Brower" ORDER="68" O_E="0.0" SE="0.695221787153807" STUDY_ID="STD-Patel-2003" TOTAL_1="64" TOTAL_2="65" VAR="0.48333333333333334" WEIGHT="12.036143458394783"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.0688639663112136" CI_END="0.39288231856717293" CI_START="-0.2652898163274132" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.06379625111987985" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2014-05-09 06:40:18 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6893697794476126" P_Q="1.0" P_Z="0.7039777874901201" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="220" TOTAL_2="129" UNITS="" WEIGHT="99.99999999999999" Z="0.3799563910850281">
<NAME>Duration of hospitalization (inpatients)</NAME>
<GROUP_LABEL_1>Bronchodilator</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7689088147014863" CI_START="-0.36890881470148595" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="4.3" MODIFIED="2010-05-12 05:34:40 +1000" MODIFIED_BY="Melissa A Brower" ORDER="402" SD_1="1.4" SD_2="1.1" SE="0.2902649330237526" STUDY_ID="STD-Chowdhury-1995" TOTAL_1="67" TOTAL_2="22" WEIGHT="33.46059552803884"/>
<CONT_DATA CI_END="1.4190714893488108" CI_START="-0.5590714893488105" EFFECT_SIZE="0.43000000000000016" ESTIMABLE="YES" MEAN_1="2.91" MEAN_2="2.48" MODIFIED="2010-05-12 05:34:40 +1000" MODIFIED_BY="Melissa A Brower" ORDER="403" SD_1="1.65" SD_2="1.2" SE="0.5046375837262727" STUDY_ID="STD-Karadag-2005-_x002d_-IPR" TOTAL_1="22" TOTAL_2="11" WEIGHT="11.070407956541638"/>
<CONT_DATA CI_END="0.5215422946098067" CI_START="-1.1415422946098068" EFFECT_SIZE="-0.31000000000000005" ESTIMABLE="YES" MEAN_1="2.17" MEAN_2="2.48" MODIFIED="2010-05-12 05:34:41 +1000" MODIFIED_BY="Melissa A Brower" ORDER="404" SD_1="1.2" SD_2="1.2" SE="0.4242640687119285" STUDY_ID="STD-Karadag-2005-_x002d_-SAL" TOTAL_1="24" TOTAL_2="12" WEIGHT="15.662111256698111"/>
<CONT_DATA CI_END="0.7499192938342012" CI_START="-0.9099192938342013" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="2.64" ORDER="405" SD_1="2.25" SD_2="1.96" SE="0.4234359918756154" STUDY_ID="STD-Patel-2002" TOTAL_1="51" TOTAL_2="48" WEIGHT="15.72342920501396"/>
<CONT_DATA CI_END="2.0413284434062415" CI_START="-0.5813284434062418" EFFECT_SIZE="0.73" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="2.57" MODIFIED="2010-04-13 04:28:19 +1000" MODIFIED_BY="Melissa A Brower" ORDER="65" SD_1="1.99" SD_2="1.95" SE="0.669057418273924" STUDY_ID="STD-Tinsa-2009" TOTAL_1="16" TOTAL_2="19" WEIGHT="6.297903894393895"/>
<CONT_DATA CI_END="0.5803255364954948" CI_START="-0.9803255364954943" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="2.9" MODIFIED="2013-10-08 11:56:14 +1000" MODIFIED_BY="Melissa A Brower" ORDER="406" SD_1="1.65" SD_2="1.24" SE="0.39813258950195146" STUDY_ID="STD-Wang-1992" TOTAL_1="40" TOTAL_2="17" WEIGHT="17.785552159313543"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1392170528140881" CI_END="0.9994820558456413" CI_START="-0.4269854980255182" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.28624827891006155" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2014-05-09 06:40:22 +1000" MODIFIED_BY="Melissa A Brower" NO="8" P_CHI2="0.7090607233553732" P_Q="1.0" P_Z="0.43151062419841935" Q="0.0" RANDOM="NO" SCALE="18.23406931874937" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="134" TOTAL_2="135" UNITS="" WEIGHT="100.0" Z="0.7866092933943741">
<NAME>Time to resolution of illness (outpatients)</NAME>
<GROUP_LABEL_1>Bronchodilator</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0449630529304699" CI_START="-0.6449630529304696" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="5.0" MODIFIED="2010-04-03 04:23:47 +1000" MODIFIED_BY="Melissa A Brower" ORDER="66" SD_1="2.6" SD_2="2.5" SE="0.4311115202092643" STUDY_ID="STD-Gupta-2008" TOTAL_1="70" TOTAL_2="70" WEIGHT="71.25057369664621"/>
<CONT_DATA CI_END="1.8302011247094128" CI_START="-0.8302011247094128" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="8.4" MODIFIED="2010-04-05 23:40:49 +1000" MODIFIED_BY="Melissa A Brower" ORDER="66" SD_1="4.0" SD_2="3.7" SE="0.6786865142430522" STUDY_ID="STD-Patel-2003" TOTAL_1="64" TOTAL_2="65" WEIGHT="28.749426303353793"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="16.82219531657939" CI_END="7.096809415959027E-4" CI_START="-0.7530324317908585" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.37616137542463135" ESTIMABLE="YES" I2="16.77661722187905" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2014-05-09 06:40:26 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.265777104792531" P_Q="0.5530574860918245" P_Z="0.050432979252931845" Q="0.3518685783324806" RANDOM="YES" SCALE="17.599991030804258" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.08808792349286514" TOTALS="YES" TOTAL_1="368" TOTAL_2="425" UNITS="" WEIGHT="99.99999999999997" Z="1.9562732020760096">
<NAME>Sensitivity analysis - oxygen saturation low risk of bias studies</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.205581550633044" CI_END="0.4778510952332954" CI_START="-1.770488616148051" DF="3" EFFECT_SIZE="-0.6463187604573778" ESTIMABLE="YES" I2="58.36560895301454" ID="CMP-001.09.01" MODIFIED="2013-09-19 05:28:39 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06562611605540636" P_Z="0.2598094265085701" STUDIES="4" TAU2="0.7360919081213135" TOTAL_1="93" TOTAL_2="117" WEIGHT="25.748131407932085" Z="1.1268417193509888">
<NAME>Inpatient</NAME>
<CONT_DATA CI_END="1.9220895753456884" CI_START="-1.0020895753457009" EFFECT_SIZE="0.45999999999999375" ESTIMABLE="YES" MEAN_1="96.22" MEAN_2="95.76" MODIFIED="2013-09-19 05:17:57 +1000" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="3.3" SD_2="4.1" SE="0.745977776570626" STUDY_ID="STD-Patel-2002" TOTAL_1="48" TOTAL_2="51" WEIGHT="5.736127327058897"/>
<CONT_DATA CI_END="0.7390914756607522" CI_START="-1.139091475660758" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="97.2" MODIFIED="2013-09-19 05:18:37 +1000" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="1.3" SD_2="1.5" SE="0.47913710816534827" STUDY_ID="STD-Tinsa-2009" TOTAL_1="19" TOTAL_2="16" WEIGHT="11.639289148837872"/>
<CONT_DATA CI_END="1.4799547519927243" CI_START="-3.4799547519927243" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="95.0" MODIFIED="2013-09-19 05:28:39 +1000" MODIFIED_BY="[Empty name]" ORDER="133" SD_1="2.4" SD_2="3.1" SE="1.2653062870309306" STUDY_ID="STD-Totapally-2002" TOTAL_1="9" TOTAL_2="10" WEIGHT="2.1889564996975435"/>
<CONT_DATA CI_END="-0.700547930775687" CI_START="-3.49945206922433" EFFECT_SIZE="-2.1000000000000085" ESTIMABLE="YES" MEAN_1="95.1" MEAN_2="97.2" MODIFIED="2013-09-19 05:18:47 +1000" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="2.7" SD_2="1.8" SE="0.7140192780393011" STUDY_ID="STD-Wang-1992" TOTAL_1="17" TOTAL_2="40" WEIGHT="6.183758432337773"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.167277779338068" CI_END="0.08353767747339463" CI_START="-0.6595145595161345" DF="10" EFFECT_SIZE="-0.2879884410213699" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" MODIFIED="2013-09-19 05:23:05 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5163055023862042" P_Z="0.12869557292490144" STUDIES="11" TAU2="0.0" TOTAL_1="275" TOTAL_2="308" WEIGHT="74.2518685920679" Z="1.5192659257781809">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="0.6248450531794176" CI_START="-1.8248450531794347" EFFECT_SIZE="-0.6000000000000085" ESTIMABLE="YES" MEAN_1="94.8" MEAN_2="95.4" MODIFIED="2013-09-19 05:22:49 +1000" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="3.1" SD_2="2.2" SE="0.6249324287797365" STUDY_ID="STD-Alario-1992" TOTAL_1="37" TOTAL_2="37" WEIGHT="7.724864412644459"/>
<CONT_DATA CI_END="0.43218366940213027" CI_START="-1.2321836694021133" EFFECT_SIZE="-0.3999999999999915" ESTIMABLE="YES" MEAN_1="98.7" MEAN_2="99.1" MODIFIED="2013-09-19 05:22:49 +1000" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="1.2" SD_2="1.9" SE="0.4245913067618999" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_" TOTAL_1="18" TOTAL_2="36" WEIGHT="13.77724489822796"/>
<CONT_DATA CI_END="0.5482729683174299" CI_START="-0.7482729683174185" EFFECT_SIZE="-0.09999999999999432" ESTIMABLE="YES" MEAN_1="98.7" MEAN_2="98.8" MODIFIED="2013-09-19 05:22:49 +1000" MODIFIED_BY="[Empty name]" ORDER="137" SD_1="1.2" SD_2="1.1" SE="0.3307575921960396" STUDY_ID="STD-Anil-2010-SAL-3_x0025_" TOTAL_1="19" TOTAL_2="36" WEIGHT="18.721798147844428"/>
<CONT_DATA CI_END="2.083758364894027" CI_START="-2.083758364894027" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="94.0" MODIFIED="2013-09-19 05:22:49 +1000" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="4.4" SD_2="4.1" SE="1.063161558748246" STUDY_ID="STD-Gadomski-1994a-_x002d_-neb" TOTAL_1="32" TOTAL_2="32" WEIGHT="3.03458527869757"/>
<CONT_DATA CI_END="3.094962219860549" CI_START="-1.094962219860549" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="93.0" MODIFIED="2013-09-19 05:22:49 +1000" MODIFIED_BY="[Empty name]" ORDER="139" SD_1="3.4" SD_2="5.0" SE="1.0688779163215976" STUDY_ID="STD-Gadomski-1994a-_x002d_-oral" TOTAL_1="32" TOTAL_2="32" WEIGHT="3.00453134481924"/>
<CONT_DATA CI_END="1.2591123689912598" CI_START="-1.2591123689912598" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="97.0" MODIFIED="2013-09-19 05:22:49 +1000" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="2.0" SD_2="2.0" SE="0.642416074439621" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb" TOTAL_1="18" TOTAL_2="21" WEIGHT="7.383068828934895"/>
<CONT_DATA CI_END="0.3125685037969599" CI_START="-2.31256850379696" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="97.0" MEAN_2="98.0" MODIFIED="2013-09-19 05:22:49 +1000" MODIFIED_BY="[Empty name]" ORDER="141" SD_1="2.0" SD_2="2.0" SE="0.6696901137726676" STUDY_ID="STD-Gadomski-1994b-_x002d_-oral" TOTAL_1="22" TOTAL_2="15" WEIGHT="6.890658978208276"/>
<CONT_DATA CI_END="1.7211968990561308" CI_START="-1.7211968990561308" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="95.0" MODIFIED="2013-09-19 05:22:49 +1000" MODIFIED_BY="[Empty name]" ORDER="142" SD_1="4.0" SD_2="4.0" SE="0.8781778199154231" STUDY_ID="STD-Klassen-1991" TOTAL_1="41" TOTAL_2="42" WEIGHT="4.3028138525863735"/>
<CONT_DATA CI_END="4.158179664626616" CI_START="-2.558179664626621" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" MEAN_1="89.32" MEAN_2="88.52" MODIFIED="2013-09-19 05:23:05 +1000" MODIFIED_BY="[Empty name]" ORDER="144" SD_1="6.75" SD_2="5.06" SE="1.7133884556632217" STUDY_ID="STD-Ralston-2005" TOTAL_1="25" TOTAL_2="23" WEIGHT="1.222751093079117"/>
<CONT_DATA CI_END="1.1981801755722672" CI_START="-1.5981801755722445" EFFECT_SIZE="-0.19999999999998863" ESTIMABLE="YES" MEAN_1="95.9" MEAN_2="96.1" MODIFIED="2013-09-19 05:23:05 +1000" MODIFIED_BY="[Empty name]" ORDER="145" SD_1="2.3" SD_2="2.2" SE="0.7133703407822402" STUDY_ID="STD-Schuh-1990" TOTAL_1="19" TOTAL_2="21" WEIGHT="6.19335319459243"/>
<CONT_DATA CI_END="-0.696785188371706" CI_START="-5.903214811628288" EFFECT_SIZE="-3.299999999999997" ESTIMABLE="YES" MEAN_1="91.8" MEAN_2="95.1" MODIFIED="2013-09-19 05:23:05 +1000" MODIFIED_BY="[Empty name]" ORDER="143" SD_1="3.8" SD_2="2.7" SE="1.3281952281583322" STUDY_ID="STD-Schweich-1992" TOTAL_1="12" TOTAL_2="13" WEIGHT="1.9961985624331409"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="22.276896017492618" CI_END="-0.028166402099378818" CI_START="-0.41393932072519646" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.22105286141228764" ESTIMABLE="YES" I2="37.1546197952951" I2_Q="55.77049327500174" ID="CMP-001.10" MODIFIED="2014-05-09 06:40:29 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.07310117800454596" P_Q="0.1326741219925709" P_Z="0.024693164602393555" Q="2.2609341004357297" RANDOM="YES" SCALE="6.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.05186288013998117" TOTALS="YES" TOTAL_1="392" TOTAL_2="342" UNITS="" WEIGHT="100.00000000000001" Z="2.2461693194583527">
<NAME>Sensitivity analysis - average clinical score low risk of bias studies</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.327946041549102" CI_END="0.3707602256589877" CI_START="-0.35154081686588234" DF="4" EFFECT_SIZE="0.009609704396552676" ESTIMABLE="YES" I2="36.78833584015854" ID="CMP-001.10.01" MODIFIED="2013-09-19 06:02:27 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.17595941085527156" P_Z="0.9584076840194243" STUDIES="5" TAU2="0.06100364422154194" TOTAL_1="125" TOTAL_2="103" WEIGHT="30.435080180467633" Z="0.05215186857125698">
<NAME>Inpatient</NAME>
<CONT_DATA CI_END="0.11162308169033991" CI_START="-0.6808153144150191" EFFECT_SIZE="-0.2845961163623396" ESTIMABLE="YES" MEAN_1="5.33" MEAN_2="6.17" MODIFIED="2013-09-19 06:02:27 +1000" MODIFIED_BY="[Empty name]" ORDER="150" SD_1="2.86" SD_2="3.0" SE="0.20215636673837173" STUDY_ID="STD-Patel-2002" TOTAL_1="51" TOTAL_2="48" WEIGHT="10.444476592845184"/>
<CONT_DATA CI_END="1.6986397948851037" CI_START="-0.13582716226969693" EFFECT_SIZE="0.7814063163077034" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="2.8" MODIFIED="2013-09-19 06:02:27 +1000" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="2.9" SD_2="2.2" SE="0.4679848639120009" STUDY_ID="STD-Scarlett-2012" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.575543307424161"/>
<CONT_DATA CI_END="0.7170938711260141" CI_START="-0.6132293941154029" EFFECT_SIZE="0.05193223850530557" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="4.6" MODIFIED="2013-09-19 06:02:27 +1000" MODIFIED_BY="[Empty name]" ORDER="152" SD_1="2.4" SD_2="1.3" SE="0.3393744159930583" STUDY_ID="STD-Tinsa-2009" TOTAL_1="16" TOTAL_2="19" WEIGHT="5.798188702694499"/>
<CONT_DATA CI_END="1.3949621047632235" CI_START="-0.438241728548874" EFFECT_SIZE="0.47836018810717473" ESTIMABLE="YES" MEAN_1="0.95" MEAN_2="0.58" MODIFIED="2013-09-19 06:02:27 +1000" MODIFIED_BY="[Empty name]" ORDER="153" SD_1="0.71" SD_2="0.77" SE="0.4676626325208461" STUDY_ID="STD-Totapally-2002" TOTAL_1="10" TOTAL_2="9" WEIGHT="3.579527502112175"/>
<CONT_DATA CI_END="0.3217129007019345" CI_START="-0.8262471886129156" EFFECT_SIZE="-0.25226714395549055" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="3.2" MODIFIED="2013-09-19 06:02:27 +1000" MODIFIED_BY="[Empty name]" ORDER="154" SD_1="1.5" SD_2="1.7" SE="0.29285234279043204" STUDY_ID="STD-Wang-1992" TOTAL_1="38" TOTAL_2="17" WEIGHT="7.037344075391614"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="13.895004051992252" CI_END="-0.0911698943038253" CI_START="-0.5433883241361104" DF="9" EFFECT_SIZE="-0.3172791092199678" ESTIMABLE="YES" I2="35.22851834858164" ID="CMP-001.10.02" MODIFIED="2013-09-19 06:08:15 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12610951063990095" P_Z="0.00595508101993648" STUDIES="10" TAU2="0.0460163991210737" TOTAL_1="267" TOTAL_2="239" WEIGHT="69.56491981953238" Z="2.7502445105950937">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="-0.32634810064882747" CI_START="-1.7094422533019573" EFFECT_SIZE="-1.0178951769753923" ESTIMABLE="YES" MEAN_1="17.5" MEAN_2="22.4" MODIFIED="2013-09-19 06:08:15 +1000" MODIFIED_BY="[Empty name]" ORDER="155" SD_1="4.2" SD_2="5.1" SE="0.35283662443871416" STUDY_ID="STD-Alario-1992" TOTAL_1="17" TOTAL_2="20" WEIGHT="5.491812132527824"/>
<CONT_DATA CI_END="0.3561228743199225" CI_START="-0.7784831227671276" EFFECT_SIZE="-0.21118012422360255" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.8" MODIFIED="2013-09-19 06:08:15 +1000" MODIFIED_BY="[Empty name]" ORDER="156" SD_1="1.4" SD_2="1.4" SE="0.2894456240106138" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_" TOTAL_1="36" TOTAL_2="18" WEIGHT="7.140263483892812"/>
<CONT_DATA CI_END="1.012424237734891" CI_START="-0.1127446796421177" EFFECT_SIZE="0.44983977904638667" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="1.8" MODIFIED="2013-09-19 06:08:15 +1000" MODIFIED_BY="[Empty name]" ORDER="157" SD_1="0.9" SD_2="1.4" SE="0.28703816147954697" STUDY_ID="STD-Anil-2010-SAL-3_x0025_" TOTAL_1="36" TOTAL_2="19" WEIGHT="7.214076734028732"/>
<CONT_DATA CI_END="0.3341737984100366" CI_START="-0.6474078119039632" EFFECT_SIZE="-0.1566170067469633" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="9.5" MODIFIED="2013-09-19 06:08:15 +1000" MODIFIED_BY="[Empty name]" ORDER="158" SD_1="5.1" SD_2="6.2" SE="0.2504080733259872" STUDY_ID="STD-Gadomski-1994a-_x002d_-neb" TOTAL_1="32" TOTAL_2="32" WEIGHT="8.45371190374974"/>
<CONT_DATA CI_END="0.1482111121861518" CI_START="-0.8395384007860573" EFFECT_SIZE="-0.3456636442999528" ESTIMABLE="YES" MEAN_1="10.1" MEAN_2="12.4" MODIFIED="2013-09-19 06:08:15 +1000" MODIFIED_BY="[Empty name]" ORDER="159" SD_1="6.0" SD_2="7.1" SE="0.25198154679459706" STUDY_ID="STD-Gadomski-1994a-_x002d_-oral" TOTAL_1="32" TOTAL_2="32" WEIGHT="8.395782189191458"/>
<CONT_DATA CI_END="0.30764774553906366" CI_START="-0.9607089700288596" EFFECT_SIZE="-0.32653061224489793" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.0" MODIFIED="2013-09-19 06:08:15 +1000" MODIFIED_BY="[Empty name]" ORDER="160" SD_1="3.0" SD_2="3.0" SE="0.323566332231755" STUDY_ID="STD-Gadomski-1994b-_x002d_-neb" TOTAL_1="21" TOTAL_2="18" WEIGHT="6.186313043986532"/>
<CONT_DATA CI_END="0.13040037463215004" CI_START="-1.2076023318780857" EFFECT_SIZE="-0.5386009786229679" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="6.0" MODIFIED="2013-09-19 06:08:15 +1000" MODIFIED_BY="[Empty name]" ORDER="161" SD_1="3.0" SD_2="4.0" SE="0.34133349313156525" STUDY_ID="STD-Gadomski-1994b-_x002d_-oral" TOTAL_1="15" TOTAL_2="22" WEIGHT="5.752265066392416"/>
<CONT_DATA CI_END="0.04500821061557514" CI_START="-0.8241158968701442" EFFECT_SIZE="-0.3895538431272845" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="6.2" MODIFIED="2013-09-19 06:08:15 +1000" MODIFIED_BY="[Empty name]" ORDER="162" SD_1="2.9" SD_2="3.2" SE="0.22171940768842166" STUDY_ID="STD-Klassen-1991" TOTAL_1="42" TOTAL_2="41" WEIGHT="9.587154406205276"/>
<CONT_DATA CI_END="0.34199315155338805" CI_START="-0.7945102230076315" EFFECT_SIZE="-0.22625853572712173" ESTIMABLE="YES" MEAN_1="6.39" MEAN_2="7.0" MODIFIED="2013-09-19 06:08:15 +1000" MODIFIED_BY="[Empty name]" ORDER="163" SD_1="2.43" SD_2="2.84" SE="0.28992965777065627" STUDY_ID="STD-Ralston-2005" TOTAL_1="23" TOTAL_2="25" WEIGHT="7.125531547964544"/>
<CONT_DATA CI_END="-0.03210054317540223" CI_START="-1.6847668182997528" EFFECT_SIZE="-0.8584336807375775" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="6.6" MODIFIED="2013-09-19 06:08:15 +1000" MODIFIED_BY="[Empty name]" ORDER="164" SD_1="2.8" SD_2="3.5" SE="0.421606286686993" STUDY_ID="STD-Schweich-1992" TOTAL_1="13" TOTAL_2="12" WEIGHT="4.218009311593043"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.637756235544863" CI_END="0.24859138454713903" CI_START="-0.476588429314282" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.11399852238357149" ESTIMABLE="YES" I2="46.78734101546226" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2014-05-09 06:40:33 +1000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.13062767116006246" P_Q="1.0" P_Z="0.5377532543934702" Q="0.0" RANDOM="YES" SCALE="3.605423362101026" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.06386171258110426" TOTALS="YES" TOTAL_1="137" TOTAL_2="103" UNITS="" WEIGHT="100.0" Z="0.6162140586149313">
<NAME>Sensitivity analysis - average clinical score using RDAI (outpatients)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3561228743199225" CI_START="-0.7784831227671276" EFFECT_SIZE="-0.21118012422360255" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.8" MODIFIED="2013-09-19 05:38:05 +1000" MODIFIED_BY="[Empty name]" ORDER="146" SD_1="1.4" SD_2="1.4" SE="0.2894456240106138" STUDY_ID="STD-Anil-2010-SAL-0.9_x0025_" TOTAL_1="36" TOTAL_2="18" WEIGHT="23.180872905008677"/>
<CONT_DATA CI_END="1.012424237734891" CI_START="-0.1127446796421177" EFFECT_SIZE="0.44983977904638667" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="1.8" MODIFIED="2013-09-19 05:38:05 +1000" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="0.9" SD_2="1.4" SE="0.28703816147954697" STUDY_ID="STD-Anil-2010-SAL-3_x0025_" TOTAL_1="36" TOTAL_2="19" WEIGHT="23.400847622178695"/>
<CONT_DATA CI_END="0.04500821061557514" CI_START="-0.8241158968701442" EFFECT_SIZE="-0.3895538431272845" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="6.2" MODIFIED="2013-09-19 05:38:05 +1000" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="2.9" SD_2="3.2" SE="0.22171940768842166" STUDY_ID="STD-Klassen-1991" TOTAL_1="42" TOTAL_2="41" WEIGHT="30.28135423283584"/>
<CONT_DATA CI_END="0.34199315155338805" CI_START="-0.7945102230076315" EFFECT_SIZE="-0.22625853572712173" ESTIMABLE="YES" MEAN_1="6.39" MEAN_2="7.0" MODIFIED="2013-09-19 05:38:05 +1000" MODIFIED_BY="[Empty name]" ORDER="149" SD_1="2.43" SD_2="2.84" SE="0.28992965777065627" STUDY_ID="STD-Ralston-2005" TOTAL_1="23" TOTAL_2="25" WEIGHT="23.136925239976797"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-06-02 18:12:48 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-06-02 18:12:48 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADOCAMAAADbsfL2AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-06-02 18:12:48 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAS0AAAU0CAIAAAACF9b5AAA5zElEQVR42u3dv27l1vX2cQEBjBQq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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2015-02-27 07:29:49 +1000" MODIFIED_BY="Liz  Dooley">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2015-02-27 07:29:49 +1000" MODIFIED_BY="Liz  Dooley" NO="1">
<TITLE MODIFIED="2015-02-27 07:28:32 +1000" MODIFIED_BY="Liz  Dooley">Bronchodilators for bronchiolitis</TITLE>
<DATE_SUBMITTED>
<DATE DAY="16" MONTH="11" YEAR="2014"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2015-02-27 07:29:49 +1000" MODIFIED_BY="Liz  Dooley">
<P>It's not clear to me if bronchiolitis is affecting infants less than 12 months old, why the studies inclusion criteria was infants less than 24 months old? Older infants may have more bronchospasm than younger and they should be analyzed separately.</P>
<P>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
<P>Renato Cutrera MD, PhD<BR/>Chief Pediatric Respiratory Unit<BR/>Ospedale Pediatrico Bambino Gesù</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY/>
<FEEDBACK_CONTRIBUTORS/>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-07-06 14:16:06 +1000" MODIFIED_BY="[Empty name]">Details of previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-02 18:12:44 +1000" MODIFIED_BY="[Empty name]">
<P>In 1998, three computerized bibliographic databases were searched for all publications in all languages examining bronchodilator therapy of bronchiolitis: the National Library of Medicine MEDLINE database (1966 to September 1994); the Excerpta Medica database (1974 to November 1994); and Reference Update® (Research Information Systems, Carlsbad, California) (November 8, 1993, June 29, 1994 and April 26, 1995). The MEDLINE search was repeated June 2, 1998. The search terms "explode bronchiolitis" and "albuterol" or "ipratropium" or "adrenergic agents" or "bronchodilator agents" were used. In addition, the bibliographies of all articles selected were searched for relevant studies.</P>
<P>For the 2010 updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effects (DARE) (<I>The Cochrane Library</I> 2010, Issue 1) which contains the Acute Respiratory Infections Group's Specialized Register, MEDLINE (1966 to Week 2, March 2010), EMBASE (1998 to March 2010) and reference lists of articles. In addition, we reviewed the files of one author (AG) and conducted a handsearch of reference lists of new studies. We searched presentations given at the Pediatric Academic Societies meetings in 2009 and 2010 for pending studies and found no clinical trials.</P>
<P>We searched MEDLINE and CENTRAL using the following keywords and MeSH terms. The MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-maximizing version (2008 revision); Ovid format (Lefebvre 2009) These search terms were adapted to search EMBASE.com.</P>
<SUBSECTION>
<HEADING LEVEL="5">MEDLINE (OVID)</HEADING>
<P>1 exp BRONCHIOLITIS/<BR/>2 bronchiolit$<BR/>3 or/1-2 (2208)<BR/>4 exp Bronchodilator Agents/<BR/>5 bronchodilator$<BR/>6 exp ALBUTEROL/<BR/>7 albuterol<BR/>8 salbutamol<BR/>9 exp IPRATROPIUM/<BR/>10 ipratropium<BR/>11 exp Adrenergic Agents/<BR/>12 adrenergic agent$<BR/>13 or/4-12<BR/>14 3 and 13</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Embase.com</HEADING>
<P>17. #13 AND #16<BR/>16. #14 OR #15<BR/>15. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR volunteer*:ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((doubl* OR singl*) NEAR/2 (mask* OR blind*)):ab,ti<BR/>14. 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp<BR/>13. #3 AND #12<BR/>12. #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11<BR/>11. 'adrenergic agent':ab,ti OR 'adrenergic agents':ab,ti<BR/>10. 'adrenergic receptor stimulating agent'/exp<BR/>9. ipratropium:ab,ti<BR/>8. 'ipratropium bromide'/de<BR/>7. albuterol:ab,ti OR salbutamol:ab,ti<BR/>6. 'salbutamol'/exp<BR/>5. bronchodilat*:ab,ti<BR/>4. 'bronchodilating agent'/exp<BR/>3. #1 OR #2<BR/>2.</P>
<P>*:ab,ti<BR/>1. 'bronchiolitis'/exp</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-07-06 14:20:12 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-04-07 17:31:47 +1000" MODIFIED_BY="[Empty name]">Embase.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-06 14:20:12 +1000" MODIFIED_BY="[Empty name]">
<P>#17 #3 AND #8 AND #16 <BR/>#16 #11 NOT #15 <BR/>#15 #12 NOT #14 <BR/>#14 #12 AND #13 <BR/>#13 'human'/de <BR/>#12 'animal'/de OR 'nonhuman'/de OR 'animal experiment'/de <BR/>#11 #9 OR #10 <BR/>#10 random*:ab,ti OR placebo*:ab,ti OR trial:ti OR allocat*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR (doubl* NEXT/1 blind*):ab,ti <BR/>#9 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp <BR/>#8 #4 OR #5 OR #6 OR #7 <BR/>#7 albuterol:ab,ti OR salbutamol:ab,ti OR terbutaline:ab,ti OR ipratropium:ab,ti OR 'adrenergic agent':ab,ti OR 'adrenergic agents':ab,ti <BR/>#6 'salbutamol'/de OR 'terbutaline'/de OR 'ipratropium bromide'/de OR 'adrenergic receptor stimulating agent'/exp <BR/>#5 bronchodilator*:ab,ti <BR/>#4 'bronchodilating agent'/exp <BR/>#3 #1 OR #2 <BR/>#2 bronchiolit*:ab,ti <BR/>#1 'bronchiolitis'/exp <BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>